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Abstract  
Cytochrome P450 is a superfamily of heme-dependent monooxygenases. These enzymes 
play a very important role in drug metabolism and detoxification since they catalyse a broad 
range of reactions including hydroxylation, dehalogenation, deamination, epoxidation, 
peroxidation, desulphurisation and dealkylation involving various substrates, such as 
alkanes, phenols, steroids and fatty acids. This thesis presents results from two P450 
hemoprotein investigations: I) targeting study of the most common cytochrome P450 BM-3 
from Bacillus megaterium, and II) discovery study of four novel putative cytochrome P450s 
from Cupriavidus necator H16. In Part II of this project, P450 BM-3 WT and W5F5 variants 
were expressed and purified, and their activities in three green solvents, 1-butanol, 2-butanol 
and dimethyl carbonate, were examined to check the tolerance of the wild type and the mutant 
W5F5 variants towards green solvents used for the first time with this enzyme. The results 
revealed a new green solvent with lower denaturation effect on P450 BM-3, the wild type 
and the mutant, with potential application in industrial biosynthesis. Part III focuses on the 
characterisation of four novel cytochrome P450 proteins of unknown structure and function. 
The proteins were analysed structurally and the first predicted models were discussed. 
Optimisations of the expression and purification of these proteins as well as optical properties 
were analysed. Scanning the changes in light absorbance of the substrate-protein complex 
with eleven substrates resulting in Type I changes when lauric acid and 3-phenoxytoluene 
were added to the purified P450-H16-B1743, as well as the evaluation of the catalytic activity 
of P450-H16-B1279 showed possible catalytic activity towards indol, malonic acid, adipic 
acid, 3-phenoxytoluene and S-Ethyl-N,N-dipropylthiocarbama (EPTC).     
  
1 Introduction 
 
1.1 Objectives 
In recent years, biocatalysts have been the subject of intensive investigations by 
pharmaceutical and industrial researchers, and that interest is continuously growing. This is 
not surprising given the potential advantages of enzymes: (I) the ability to display regio- 
chemo- and enantioselectivity; (II) the enhancement in reactions rate up to 1012 folds. (III) 
the ability to catalyse reactions in moderate conditions (pH and temperature), while these 
reactions require harsh conditions by using chemical catalysts (Carrea & Riva, 2000). 
Cytochrome P450 (CYP) is a superfamily of multifunction monooxygenases. More than 
6,000 enzymes have been classified as members of this family. They are found in nearly 
every organism including both prokaryotes and eukaryotes and play a crucial role in the 
metabolism of endogenous fatty acids and steroids as well as foreign compounds such as 
chemical carcinogens and drugs. Indeed, no other enzyme group can accept as many 
substrates (alkanes, phenols, steroids and fatty acids) or catalyse as many reaction types 
(hydroxylation, dehalogenation, deamination, epoxidation, peroxidation, desulphurisation 
and dealkylation (Bernhardt, 2006; Urlacher & Eiben, 2006; Urlacher et al., 2004). One of 
the main reasons that P450s attract so much attention is their ability to introduce one oxygen 
atom into the substrate, while the second one is reduced to water, a reaction which is difficult 
to catalyse by chemical catalysts (Whitehouse et al., 2012).  
This thesis is dedicated to the study of cytochrome P450s from two organisms: Bacillus 
megaterium (Part II) and Cupriavidus necator H16 (Part III). 
  
2 
 
1.1.1 Part II: Cytochrome P450 BM-3  
Despite the potential of using P450s, commercial application of the catalysed reactions of 
these enzymes has been hampered by the solubility of nonpolar substrates in aqueous 
solution. Therefore, organic co-solvents need to be added as supplements to increase 
substrate solubility (Wong et al., 2004).  
Traditional co-solvents, further to their negative effect on enzyme activity, could cause 
serious problems such as environmental pollution, human health and safety issues, as well as 
the risk of explosion. In addition, using hazardous solvents increases the final products’ cost 
as they require complicated separation processes, more accurate transformation and storage 
process as well as additional units for waste treatment. In contrast, using green solvents 
instead of hazardous solvents can result in potential savings of time, effort and costs by 
decreasing waste treatment costs, minimising safety requirements, reducing energy 
consumption and increasing the solvent recovery rate (Sheldon et al., 2007). For example, a 
comparison of ethers shows that t-amyl ethyl ether would be a highly desirable solvent for 
use instead of t-butyl methyl ether, which has a very low flash point and a low boiling point 
of 55°C, both of which lead to handling difficulties, especially on the commercial scale 
(Henderson et al., 2011). In addition, the removal of residual solvents from the reaction 
medium should be performed by either evaporation or distillation, both of which are 
associated with major environmental issues of global proportion and high insurance costs 
because of the high volatility of traditional solvents. Some of these solvents, which were 
classified as red solvents by GSK, such as chlorinated hydrocarbon solvents have already 
been banned or are likely to be in the near future. These issues of the non-green solvents have 
stimulated the chemical and pharmaceutical industries to seek more benign alternatives. The 
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intent of Part II of this project is to provide the pharmaceutical industry with the best green 
solvents which can be used as a replacement to the traditional organic solvents in reactions 
catalysed by cytochrome P450 BM-3. The behaviour of this protein will be investigated in 
the presence of different green solvents which are used for the first with the wild type and 
the W5F5 variant of P450 BM-3.  
1.1.2 Part III: Putative cytochrome P450s from Cupriavidus necator H16  
Although more than 6000 P450 cytochromes have been identified in animals, plants and 
microbes (Whitehouse et al., 2012), there are no general rules that can be applied to all P450s 
regarding their structure, substrates and reactions that can be catalysed by these superior 
enzymes. Due to this structural and functional diversity, identification of new P450 proteins 
can provide essential knowledge for industrially important biosynthetic processes. Each 
newly discovered cytochrome P450 represents a start point for unlimited expectations in 
biosynthesis applications.      
Although the full sequencing of the Cupriavidus necator H16 genome published by 
Pohlmann and co-workers showed the presence of four cytochromes P450 genes, P450 H16-
B2406, P450 H16-B1743, P450 H16-B1279 and P450 H16-B1009 (Pohlmann et al., 2006), 
the lack of structural data, spectroscopic information, relative substrates and catalytic 
activities of these novel P450s has motivated the investigation of the sequences of these four 
proteins and to align them with the other closest known P450s. In addition, it is of great 
interest to analyse the model and structure of the four P450s and try to express, purify, find 
proper substrates and discover what activities these proteins may exhibit. In this part of thesis, 
the main focus was to identify and characterise four novel cytochromes P450 from 
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Cupriavidus necator H16, the most excellent platform organism for the production of 
bioplastic and value-added compounds.        
 
1.2 Organisation of this thesis  
This thesis is organised in such a way that serves the diversity of its content, with a focus on 
the interconnections between its components to ensure that the reader understands the 
practical aspects of the thesis, linking it with the theoretical basis and moves from one topic 
to another easily. My thesis consists of three main parts, Part I, Part II and Part III, in addition 
to a general introduction (chapter 1) and comprehensive conclusions (chapter 12).  
Part I consists of two chapters (chapters 2 and 3), providing general information about heme 
proteins as well as the cytochrome P450 superfamily, which is essential to understand the 
subsequent Part II and Part III. In chapter 2, I tried to familiarise the reader with a background 
about hemoproteins by including information about heme structure and heme function, as 
well as explaining the differences in structures and reactions between seven types of 
hemoproteins. Chapter 3 provides detailed information about the discovery, nomenclature, 
evolution, structure, optical properties and catalytic cycle of cytochromes P450 superfamily 
in general, as well as explaining the usual and unusual catalytic reactions and the industrial 
applications of different P450s.  
The second part of the thesis (Part II) comprises four chapters (chapters 4-7) and is devoted 
to the P450 BM-3 and its tolerance towards non-conventional solvents and green solvents in 
particular. Chapter 4 provides detailed information about cytochrome P450 BM-3 
(CYP102A1) from Bacillus megaterium, such as protein, domains, expression, structure and 
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dimerisation. In addition, it provides information about the mechanism of electron 
transformation, protein engineering and immobilisation approaches that have been reported 
and industrial applications of this enzyme. Chapter 5 highlights solvent classification and the 
biocatalysis in different known solvent systems, as well as the methods of stabilising 
enzymes in these solvents and the tolerance of P450 BM-3 against these solvents. Chapters 
6 and 7 are the experimental chapters. All materials and protocols used for protein expression, 
purification, optical characterisation and activity evaluation in the presence of three green 
solvents are presented in chapter 6, while the results from these experiments are discussed in 
chapter 7.   
The study of four novel cytochrome P450s from Cupriavidus necator H16 (Ralstonia 
eutropha H16) is presented in Part III. This part consists of one theoretical chapter (chapter 
8) and three experimental chapters (chapters 9-11). Chapter 8 gives a brief overview of the 
history, genome, metabolism and industrial applications of Cupriavidus necator H16, as well 
as summarising the known P450s from this bacterium. Chapter 9 details the methodology 
that has been followed in the identification, sequence alignment and modelling of the four 
P450s, as well as the cloning, expression, purification, optical characterisation, substrate 
selectivity and activity investigation of these proteins. Chapter 10 presents the novel results 
from the sequence analysation and 3D structure modelling of P450s from Cupriavidus 
necator H16, while chapter 11 focuses on the results from expression, purification, optical 
characterisation, substrate binding and activity measurement of these proteins.  
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Part I: Heme proteins and cytochrome 
P450 superfamily 
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2 Heme proteins 
 
2.1 Heme structure & function 
Heme is an important molecule which apparently plays a pivotal role in biocatalysis and 
exhibits diverse biological activities, such as storing and transferring dioxygen and electron 
transformation (Ting et al., 2011). Although marking the active role of heme in biology as a 
superior biocatalyst for the organic substrate hydroxylation dates to the mid-1960s, the 
discovery of the enzymatic role of heme dates back earlier, to when the action of horseradish 
peroxidase (HRP) was indicated in 1903 (Bach & Chodat, 1903). HRP was the subject of 
study due to its stability and ease of purification until Mason clarified the ability to insert a 
single atom of oxygen from molecular dioxygen into an organic substrate enzymatically 
(Mason, 1957). It was not too long before P450 was distinguished as one of the most 
attractive oxidases in biotechnology (Garfinkel, 1958; Klingenberg, 1958; Omura & Sato, 
1964).   
Both the reductive and the oxidative reactions can be catalysed by heme enzymes, but this 
project will focus on the oxidant enzymes. Depending on the oxygen source that heme 
enzymes use to catalyse oxidation reactions, they are classified into two groups, oxygenases 
and peroxidases. The former normally use O₂, while the later use H₂O₂ to oxidise organic 
substrates. There are issues associated with each oxidant, by using O₂, a large kinetic barrier 
usually forms since O₂ is not a reactive molecule, however, H₂O₂ can lead to the creation of 
toxic hydroxyl radicals which negatively affect enzyme activity. In general, before heme 
oxygenases can bind to O₂, the iron should be reduced to ferrous (Fe²⁺) to enable the 
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formation of the ferric-superoxide (Fe³⁺-OOˉ). After the arrival of the second electron the 
superoxide will be reduced to peroxide and from this point and on, both the oxidase and the 
peroxidase mechanism will be similar. Directly after the peroxide level, the O-O bond 
cleavage will take place either homolytically leaving behind two hydroxyl radicals or 
heterolytically to yield a water molecule and O atom with six valence electrons. In nature, 
the heterolytical pathway dominates the O-O bond cleavage because it is preferred to avoid 
the formation of hydroxyl radicals in the protein active site in most cases. The O-O cleavage 
leads to the most important step in the heme catalytic cycle, the formation of the active 
oxidant (compound I) by the oxidising equivalents rearrangement (Poulos, 2014).   
 
2.2 Structural analysis of heme proteins 
Heme as a prosthetic group can be found in many forms, but the most common forms are 
heme b which links to the host protein non-covalently and heme c which binds to two cysteine 
residues of the protein covalently by its vinyl groups (Figure 2-1). Heme proteins functional 
proficiency depends on several interrelated factors: I) heme protein diversity, II) protein’s 
microenvironment variability, III) axial ligands type and V) heme accessibility to solvents. 
Due to the heme complexity, a good structure analysis is required for a thorough 
understanding of the heme binding surroundings (Bowman & Bren, 2008; Schneider et al., 
2007).   
A recent study on dataset of 125 heme binding proteins (heme b and heme c) identified five 
amino acids as axial ligands to the iron (the residue is counted as axial ligand when the 
distance between the heme iron and the residue’s nitrogen, sulphur or oxygen is 3 Å or less). 
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These axial ligands are histidine (H), cysteine(C), methionine (M), lysine (K), and 
tyrosine(Y), with histidine domination for both heme b and heme c proteins. After histidine, 
cysteine represented the more utilising axial ligands in heme b against methionine in heme 
c. The relative frequency of heme proteins to all investigated proteins was also calculated 
and it was found that heme proteins have fewer cysteine (C), aspartic acid (D), isoleucine (I), 
lysine (K), asparagine (N), and serine residues (S) and higher number of alanine, 
phenylalanine (F), histidine, methionine, and tryptophan residues, while the highest relative 
frequencies were shown by C, F, M and Y (the axial ligands were excluded from the 
calculations) (Ting et al., 2011). Cysteine showed a dramatically high frequency with eight 
fold improvement compared to the background values in heme c proteins, which is expected 
owing to the classic binding motif in heme c (CXXCH) when histidine and the cysteine 
dominate because H works as a ligand and C binds to the vinyl groups covalently (Bowman 
& Bren, 2008). As well as the aromatic residues like phenylalanine and tyrosine in heme b 
and heme c and tryptophan in heme b which play a crucial role in heme interacting also 
showed higher relative frequency while the negatively charged residues such as glutamic 
acid, aspartic acid and lysine recorded fewer relative frequencies, which supports the idea 
that the heme binding pocket is fundamentally hydrophobic (Smith et al., 2010; Ting et al., 
2011). In contrast, arginine which holds a positive charge showed a higher level of 
occurrences compared to other charged amino acids. A secondary structure analysis of heme 
b illustrated fewer coil types and was more helical in comparison to both heme proteins and 
all investigated proteins. In contrast, coil types and helices in heme c showed similar levels 
to the background. When relative heme accessibility against solvents was checked, it is found 
that the heme interacting residues are mostly buried residues (Ting et al., 2011). The 
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investigation of the sequence motifs that play a pivotal role in heme binding, marked three 
types of motifs, heme c classic motif (CXXCH), binding motif came from heme b 
(GX[HR]XC[PLAV]G) and the binding motif which represents a traditional signature of 
P450s (FXXGXXCXG) (Nelson, 1999; Otyepka et al., 2007; Ting et al., 2011).  
 
 
 
 
2.3 Heme enzymes 
There are many types of hemoproteins were reported previously. In this section seven types 
of heme enzymes will be discussed in detail. These enzymes were chosen due to their 
biological functions variations. Figure 2-2 shows different types of heme enzymes.     
Figure 2-1: Chemical structures of of the natural occurring heme groups; heme b which 
links to the host protein non-covalently and heme c which binds to two cysteine residues 
of the protein covalently by its vinyl groups. The image was acquired with permission 
from (Ting et al., 2011) 
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Figure 2-2:  Seven types of hemoproteins. Each one of these enzymes has a biological 
diffrent function.  
 
 
 
2.3.1 Cytochrome P450s 
The discovery, structure, catalytic cycle, optical properties, catalysed reactions and 
applications of cytochrome P450s will be discussed in detail in chapter 3 of this thesis.  
  
12 
 
2.3.2 Nitric oxide synthases 
The importance of nitric oxide synthases comes from their ability to produce nitric oxide 
(NO), an essential signalling molecule in the nervous, immune and cardiovascular systems 
by catalysing the oxidation of L-arginine to L-citrulline (Bredt & Snyder, 1994). However, 
there is no sequence similarity with P450s; the C-terminal part of the molecule is similar to 
P450 reductase and the N-terminal portion which binds heme gives 450 nm absorption bands 
when it is reduced in the presence of CO, a specific characteristic of P450, and these two 
halves provide a self-sufficient oxygenase (Griffith & Stuehr, 1995; McMillan et al., 1992; 
Stuehr & Ikeda-Saito, 1992; White & Marletta, 1992). Nitric oxide synthase is normally 
activated when Ca²⁺-calmodulin binds to the linker region which connects the heme to the 
reductase domains (Abu-Soud & Stuehr, 1993). An unusual feature of nitric oxide synthase 
(NOS) is its ability to catalyse the reaction to produce NO using two different mechanisms, 
the first one in the presence of the cofactor tetrahydrobiopterin (BH4), while the second one 
is in the absence of BH4 (Poulos, 2014).  
Despite the similarity in heme ligation and optical properties between NOS and P450s, these 
two proteins have completely different architecture. The heme in NOS is encompassed by a 
beta structure instead of the helices in P450. Also, both the movement of the substrates into 
the active site and the exit of the product (NO) are much easier than P450 because the heme 
is more exposed to substrates. The cystine (Cys) in both proteins, NOS and P450s, accepts 
an H-bond from the NH group, indole NH in NOS rather than peptide NH in P450s, and 
unlike other proteins, the cofactor BH4 is permanently linked to NOS, donating the one 
required electron for the oxygen molecule activation (Poulos, 2014). This reaction can be 
catalysed by NOS in two steps. The first step is similar to the traditional reaction of P450s, 
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except it requires just one electron and this electron is donated by BH4, forming N-hydroxy-
L-arginine from L-arginine (Hurshman et al., 1999; Poulos, 2014; Wei et al., 2001). The 
second step is the oxidation of L-NHA to produce L-citrulline and NO. In the BH4 
mechanism, the peroxy intermediate is created by the reduction of the oxy complex by BH4. 
After this step, the cyclic intermediate is formed, yielding L-citrulline and NOˉ, while in the 
absence of BH4, the reactive H atom will form hydroperoxyl, followed by the formation of 
a cyclic intermediate which yields the products (Huang et al., 2001; Poulos, 2014).          
2.3.3 Peroxidases 
Peroxidases are ubiquitous enzymes owing to their ability to catalyse a variety of substrates. 
Except for cytochrome c peroxidase (Ccp) which uses cytochrome c as its redox partner, the 
most traditional substrates of these enzymes are small aromatic molecules (Hiner et al., 
2002). Non-mammalian peroxidases are classified into three classes: class I are intercellular 
peroxidases such as the cytochrome c peroxidase, pea cytosolic ascorbate peroxidase and the 
gene-duplicated bacterial and fungal catalase-peroxidases; class II are the fungal extracellular 
peroxidases such as manganese peroxidases and class III are the plant extracellular 
peroxidase such as HRP. Class II and class III need extra stabilisation represented by four or 
five disulphide bonds and the binding sites of two Ca ions, while class I does not contain any 
disulphide bonds. Peroxidases are single polypeptide chains with a single heme group 
connected to the enzyme by a histidine residue, varying in size between 30–40 kDa 
(Welinder, 1992). 
All three classes share the same catalytic cycle. In the first step, a porphyrin π cation radical 
(compound I) is formed by the removal of two electrons by the peroxide; one from the iron 
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and the second from the porphyrin (Dolphin et al., 1971). Compound I has a green colour 
and different spectral properties from other heme oxidative enzymes. In the second step, 
compound I will be reduced to compound II (red colour) by gaining an electron from the 
substrate molecule. At the final step, the Fe4⁺ is reduced to Fe³⁺ by the second substrate 
(Poulos, 2014). The O-O bond in peroxidase cleaves heterolytically leaving the oxygen atom 
with only six valence electrons, this oxygen atom is called oxenoid. The mechanism of the 
formation of compound I was described following the structural details of peroxide activation 
in cytochrome c peroxidase. This mechanism demonstrated the role of the distal His residue 
in the formation of compound I. This residue is essential for the acid-base catalysis of the 
peroxidases. The distal His52 residue transfers the peroxide proton of O1 “an oxygen atom 
bound to the heme iron” to the other oxygen atom O2 “an oxygen atom not bound to the 
heme iron” and that leads to heterolytic cleavage of the O−O bond (HAMILTON, 1974). The 
other residue which plays a crucial role in the peroxidases catalytic cycle is the distal Arg48. 
In order to stabilise the developed negative charge of the O2 atom, the anionic peroxide 
ligand interacts with the guanidinium side chain of Arg48 which is positively charged. So, 
the heterolytic cleavage of O-O bond in Ccp is achieved as a result of proton transformation 
from the His52 residue to the O2. The only problem with this mechanism is that the distance 
between O2 and the His52 is too far to form a H-bond. A functional study suggested that a 
water atom could play a vital role in proton transformation between O1 and O2 instead of 
His52 (Hiner et al., 2002; Poulos, 2014).   
2.3.4 Chloroperoxidases 
The main function of chloroperoxidase (CPO)  is the production of chlorinate compounds by 
converting Clˉ into a chlorinating agent like HOCl. This step comes after the formation of 
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compound I. Compound I is created using the same traditional steps of the heme peroxidases, 
but the distal His in the heme peroxidases is replaced by the active site Glu in CPO. In 
addition to chlorination, CPO has the ability to behave as a peroxidase and as a P450 in 
oxidising different organic molecules (Morris & Hager, 1966; Piontek et al., 2010).   
Chloroperoxidase has similar spectral properties to both P450s and NOS owing to the H-
bond acceptance by CYS ligand from a nearby NH group. CPO has been known as a 
peroxide-P450 hybrid, despite the fact that the overall structure of chloroperoxidase is not 
similar to either P450 or peroxidases. CPO exhibits peroxidase-like distal pocket properties 
owing to the distal pocket polarity and acid-base catalytic group which is responsible for the 
heterolysis of the peroxide O-O bond, except this group is Glu instead of His in other heme 
peroxidases which drops the optimal pH to about 3 (Poulos, 2014).  
2.3.5 Heme oxygenases 
Heme oxygenases are the enzymes responsible for the degradation of heme to produce 
biliverdin which is converted to bilirubin. These enzymes play a crucial role in getting rid of 
the toxic free heme which accumulates in the mammals’ bodies due to haemoglobin 
degradation, approximately 300 mg/day of heme is produced from the degradation of 6–8 g 
of haemoglobin (Kikuchi et al., 2005; Maines, 1988). Two isoforms of heme oxygenases 
have been identified, HO-1 and HO-2, which have completely different functions. HO-1 is 
responsible for heme degradation, while HO-2 is used mainly for CO formation, an important 
messenger molecule (Farombi & Surh, 2006; Maines, 2005). The structure of the human HO-
1 and those which are structurally related to human are not similar to any known heme protein 
structures. The heme lies between the proximal helices and the distal helices, with the axial 
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heme ligand served by a histidine residue. Different from the rest of the heme enzymes, the 
heme itself is a substrate for HO-1 and as a result, has active site flexibility important for the 
functionally active enzyme. The mechanism of the α-meso heme carbon oxidation by HO-1 
will be discussed in more detail because α-meso heme carbon is considered as the main 
substrate of most heme oxygenases. The first step of the catalytic cycle is the formation of α-
meso-hydroxyheme. Initially, it was thought that Fe(IV)=O acts as oxidant in HO just like 
P450, but this is unlikely as His serves as an axial ligand in HO and the role that the distal 
ligand plays in heme proteins is different from that in P450s, also the distance between the 
ferryl O atom and α-meso heme carbon is too far to enable the transformation of proton to an 
oxygen molecule (Montellano, 1998; Poulos, 2014).    
Like P450s and peroxidases, the dioxygen molecule must be cleaved into O1 and O2 by 
accepting a proton. From a structural point of view, it was suggested that the Asp residue 
plays an essential role in the O activation process until it was found recently that the most 
important residue in the HO catalytic cycle is the water molecule in the active site. This water 
molecule is the key catalytic group which transfers a proton to the iron-linked dioxygen 
(Matsui et al., 2010; Unno et al., 2007).    
2.3.6 Dioxygenases 
There are two types of dioxygenase enzymes, the human dioxygenase called indoleamine 2,3 
(IDO) and the bacterial enzyme tryptophan 2,3 (TDO). Both enzymes are soluble and have a 
similar function, which is the conversion of L-Trp to N-formylkynurenine. These enzymes 
have different names since they were discovered in 1930s, they were called tryptophan 
pyrrolase, then tryptophan peroxidase−oxidase and eventually named as dioxygenases 
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(Poulos, 2014). Tryptophan apparently plays a pivotal role in building a strong immune 
system during the conversion into N-formylkynurenine. As a result, IDO and TDO are 
considered as possible therapeutic targets to fight cancer cells (Platten et al., 2012). The 
structures of IDO and TDO are homologous, except IDO has extra domain. The active sites 
of these two enzymes are also very similar, but Ser 167 in human dioxygenase is His55 in 
the bacterial type. Based on the crystal structure of the L-Trp binding to the TDO, it is reported 
that the substrate carboxylate is linked to Arg117 by H-bonds, while the α-amino group bonds 
to the heme propionate. There are two possible mechanisms for the TDO catalytic cycle. The 
first one depends on the role of the N1 substrate proton abstracts in activating the substrate. 
Products using this mechanism were achieved either by dioxetane intermediate or by Criegee 
rearrangement. The second mechanism showed that the N1 proton transformation is not 
essential for O₂ cleavage. Based on the later mechanism, the first step in this reaction would 
be the insertion of dioxygen complex to the L-Trp so the O-O bond will cleave homolytically. 
In the second step, two actions are combined, the oxygen atom of epoxide will receive a 
proton from the α-amino N atom of L-Trp and the indol ring will be opened by ferryl O atom 
attack (Efimov et al., 2012; Poulos, 2014).    
2.3.7 Diheme proteins 
Diheme proteins or MauGs are involved in tryptophan tryptophylquinone (TTQ) post 
translational synthesis from the bacterial methyl amine dehydrogenase (MADH) (McIntire 
et al., 1991). Diheme proteins have two c-type hemes similar to peroxidase, low spin and 
high spin heme. Unlike peroxidase, these enzymes can use either H₂O₂ or O₂ to oxidise both 
hemes into Fe4⁺ and form the oxyferryl species (Fu et al., 2009; Poulos, 2014). The two 
hemes are kept close, sharing spin and charge via the Trp93 residue which lies between the 
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two hemes (Geng et al., 2013). The O-O cleavage in these enzymes occurs under the control 
of the general local acid-base mechanism. The challenging question about how the electron 
is transferred between MADH and MauG has been answered by studying the mutant Trp199 
in MauG. Trp199 is located between TTQ and the low spin heme in the midway. It was found 
that the Trp199 mutant has a negligible effect on heme properties, while it stopped TTQ 
production which supported the belief that Trp199 plays a pivotal role in electron 
transformation (Tarboush et al., 2011).        
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3 Cytochrome P450 superfamily 
3.1  Discovery 
The discovery of P450 hemoproteins dates back to 1958 when a study of heme proteins in 
rats and pig chromosomes highlighted a unique spectral feature of the CO-bound ferrous 
complex of a membrane-bound protein. This complex showed a Soret peak at 450 nm when 
it was pre-treated with a proper reduced agent (Garfinkel, 1958). The protein from this 
experiment was later identified as a member of P450 hemoprotein family, which takes its 
name from the distinctive Soret peak at 450 nm (Omura & Sato, 1962, 1964). The unique 
absorption band is a characteristic feature, not only for P450s, but also for the other three 
hemoprotein classes which are chloroperoxidases, protein H450 and NOSs (Danielson, 
2002). Cytochrome P450s belong to a superfamily which is classified into 265 different 
families, with more than 2000 identified protein, genomic and DNA sequences. A member 
of this family can be found in almost every living organism, prokaryotic and eukaryotic. 
P450s are also found in archaea, which supports the concept that P450s originally date back 
to ancient times, approximately 3.5 billion years ago (Danielson, 2002; Whitehouse et al., 
2012).   
 
3.2 Nomenclature 
In order to name and locate P450 genes into a certain family and subfamily, a standard 
nomenclature system was created due to the genetic diversity and sequence conservation 
shortage of these proteins. According to the P450 Nomenclature Committee, three factors 
need to be considered: “amino acid sequence identity, gene organisation and phylogenetic 
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association”(Nelson, 2009). Based on this system, P450’s name usually starts with three italic 
letters (CYP), which represent a root for all P450s genomic and cDNA sequence names. Next, 
the family name is written using Arabic numerals, followed by a letter for the subfamily. 
Subfamily members are allocated their numbers depending on the sequence reported to the 
nomenclature committee. The pseudogenes in P450s nomenclature system can be 
distinguished by the letter (P) directly after the family Arabic numeral. A pseudogene is a 
defective gene responsible for the production of a non-functional protein due to either the 
denaturation of one copy during the gene duplication or the shortage in the “requisite 
regulator elements” which are required for mRNA transcription (Danielson, 2002). P450 
sequences are placed in families and subfamilies depending on the similarity between their 
amino acids; 40% similarity qualifies P450 to be classified in the same family, while 55% 
similarity places it in the same subfamily and 97% similarity is considered as alleles (Nelson 
et al., 1993). P450 families are classified depending on the cytochrome type. For example, 
animal P450s are represented by CYP (1-49) and (301-499), CYP (51-69) and (501-699) 
represent lower eukaryotes, CYP (71-99) and (701-999) are for plants, with CYP (101-299) 
for bacteria (Danielson, 2002).            
 
3.3  Evolution 
Many mechanisms have been reported to be responsible for the functional diversity of the 
P450 superfamily, but the most recognised is the gene duplication process. It is believed that 
the first CYP member existed 3.5 billon years ago. At that time, due to the lack of oxygen, 
the P450 protein acted as nitro reductase or endo reductase. Directly after the formation of a 
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high amount of oxygen, the earlier CYP started to work as oxygen detoxify to protect living 
organisms (Danielson, 2002; Loomis, 1988; Schlezinger et al., 1999).    
By looking at the evolutionary history of P450 multigene family, enormous expansion has 
taken place because of genome duplication. Indeed, the first expansion related to the 
endogenous fatty acid metabolism occurred 1.5 billon years ago. Examples of these enzymes 
are CYP11 and CYP4, which are important to maintain eukaryotic membrane integrity 
(Nebert & Gonzalez, 1985).  
The second expansion is believed to have accorded the “endogenous steroid-synthesised 
P450 lineages” 900 million years ago. CYP19, CYP21 and CYP27 evolved dramatically to 
give rise to the CYP1 and CYP2, which are the focus of attention in the study of major drugs 
and carcinogen metabolism in mammals. The last evolutionary event was the largest to have 
occurred to many P450s about 400 million years ago. This expansion was motivated by two 
events. Firstly, the appearance of aquatic organisms and the use of toxic plants in their food. 
Secondly, the effect of hydrocarbon combustion products on terrestrial organisms (Gonzalez 
& Nebert, 1990; Nelson & Strobel, 1987).    
The phylogenetic analysis of the evolution of P450s revealed that the changes in the CYP 
genes were very fast in comparison to other proteins. The unit evolutionary period, which is 
defined as the time required for a protein to show a 1% change in amino acid sequence, has 
been estimated to be 2–4 million years for P450s, which is a relatively short period in 
comparison, for example, to 400 million years for the highly conserved histone proteins 
(Gonzalez & Nebert, 1990; Nelson & Strobel, 1987).  
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As mentioned previously, the mechanism responsible for the diversity of the P450s is mainly 
gene duplication. This continuous process produces new genes, which may be functionally 
inactive in some cases, causing continuous expansion in the family’s genes. As a result, the 
sequence diversity due to gene duplication in a single species is not only responsible for the 
evolutionary history of this particular species, but also the evolutionary history of the whole 
gene family (Gonzalez & Nebert, 1990).             
 
3.4  Structure 
Cytochrome P450 superfamily members were classified into three basic groups depending 
on the subcellular localisation: I) the microsomal type from the endoplasmic reticulum, II) 
the mitochondrial type from mitochondria and III) the cytosolic form. The majority of 
eukaryotic P450s are insoluble proteins found either as the microsomal type or mitochondrial 
type, the only exception being nitric oxide reductase (CYP55), which is thought to be 
acquired from bacteria and did not arise originally in eukaryotes, while the majority of 
prokaryotic P450s are soluble cytosolic forms (Nelson et al., 1996).  
Microsomal P450 can be distinguished by the presence of 20–25 hydrophobic residues 
consisting of an amino-terminal signal anchor sequence with less known hydrophobic 
connectors. These residues link the P450 protein to the endoplasmic reticulum membrane. 
The other characterisation of this P450 type is the presence of the charged residues, a 
negatively charged residue close to the amino-terminus and polar positively charged amino 
acids at the carboxy-terminus. These charged residues ensure a proper protein attachment to 
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the endoplasmic reticulum as well as providing suitable folding to the P450s (Kusano et al., 
2001). 
Like the microsomal P450, the mitochondrial type can be characterised by the amino-
terminus residue, but in this type, the residue is cleaved after protein synthesis and imported 
to the mitochondria so that the protein is connected to the mitochondria inner membrane by 
a string of hydrophobic amino acids, like the hydrophobic core residues in the microsomal 
P450. Similar to microsomal P450, the carboxy-terminus serves to provide the proper folding 
to the mitochondrial P450s (Kusano et al., 2001).  
Nevertheless, even though the sequence identity between eukaryotic and prokaryotic is very 
low, about 20% or less, the secondary structure of these two types is very highly conserved. 
The crystal structures of many bacterial cytochromes, such as CYP175A1, CYP121A1, 
CYP152, CYP101A1, CYP102A1, CYP107A1, CYP108 and CYP111A1, have been 
determined and analysis of their three dimensional structures have shown that even with a 
very low sequence homology between different bacterial cytochromes or between the 
eukaryotic and prokaryotic P450s, the overall protein topography showed a very high 
similarity (Graham‐Lorence et al., 1995; Hasemann et al., 1995). To date, there is a lack of 
understanding of eukaryotic cytochromes due to crystallisation difficulties of the membrane-
bound P450s. The only crystallised eukaryotic P450 is the cytosolic CYP55A1 from the 
Fusarium oxysporum, but as was mentioned previously in this section, this protein was 
originally a bacterial P450, so the crystal structure of this protein is not applicable for 
membrane-bound P450 structures. However, two key studies apparently played a pivotal role 
towards a better perception of the eukaryotic P450s. The first study succeeded in solving the 
crystal structure of prokaryotic CYP51 from Mycobacterium tuberculosis, which showed a 
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high conservation with the eukaryotic CYP51 family. The similarity between these two 
proteins is not limited to their structures, but extends to their catalytic activity (Podust et al., 
2001). The second important study was performed on the crystallisation of a modified 
mammalian cytochrome P450 (CYP2C5). In order to crystallise this protein, they created a 
more water-soluble protein through the replacement of the hydrophobic amino-terminal 
signal residue with a more water-soluble sequence. The CYP2C5 structure showed high 
similarity to bacterial P450s structures (Williams et al., 2000).  
In general, all P450s have a triangular structural framework with two portions, the rich 
carboxy-terminal (alpha helix) and the rich amino-terminal (beta sheet), with both the alpha 
helices and beta sheets located in the same heme plane. Sequence alignments of P450s 
established a number of sequence motifs, one of which is located in helix I close to the protein 
centre and has a sequence (G/A)GX(D/E)T with terminal threonine which plays an important 
role in the creation of the oxygen binding pocket in the enzymes (Poulos et al., 1987). A key 
sequence in helix K is EXXR, the mutation of any residue in this sequence caused complete 
functional inactivation of the mutants. Another important residue is cysteine, the fifth ligand 
of the heme. The heme is buried deep inside the protein and it is surrounded by helices L and 
I (Danielson, 2002; Nebert et al., 1988).  
The regions responsible for substrate-P450 binding gain special attention due to their 
importance in the catalytic activity of P450s. Many approaches have been applied for 
identifying the binding sites, including X-ray crystallography, which was used to identify the 
residues responsible for drug metabolism in eukaryotic P450s. Another predictive approach 
performed is site-directed mutation to determine differences in location of the amino acids 
which are closely related but different in their functions. The homology-based approach is 
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completely unbiased, providing supportive information about residues involved in substrate 
binding. In general, the experimental purpose of these approaches is to diagnose the amino 
acid changes responsible for a shift in either catalytic activity or substrate performance. 
CYP2A4 and CYP2A5 are the best examples of such an approach. Despite those proteins 
being highly identical (97.8%), they display completely different catalytic activity, but each 
protein starts to catalyse the reaction of the other protein by reciprocal substitutions of some 
amino acids. The residues that have the ability to shift the substrate specificity are called 
“substrate recognition sites (SRS)”. The homology-based analysis of P450s proved the 
significance of the SRSs, not only for substrate selectivity, but also for kinetic differences 
between P450 isoforms that catalyse the same reaction and metabolise the same substrate. 
For example, CYP2C4 and CYP2C5 show more than 95% sequence identity and they 
catalyse the hydroxylation of progesterone 21, but the Km of CYP2C4 is about 10-fold 
greater than the Km of CYP2C5. It was found that this Km difference is due to one amino acid 
located in SRS1. Only 6 SRSs were reported in eukaryotic P450s and the positions of these 
sites are compatible with the substrate contact site in the prokaryotic P450s-substrate 
complex (Danielson, 2002; Hanioka et al., 1992).   
 
3.5 Biochemistry 
3.5.1 Optical properties 
Hemoproteins are characterised by the ability of its heme group to absorb light at certain 
wavelengths. This chromatography phenomenon is affected by several factors, such as the 
surrounding environment of the heme, ligands that bind to heme and the heme oxidation 
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state. The spectroscopic properties of all P450s are dominated by the spin state of the heme 
iron. A hexacoordinated iron is represented spectroscopically by a low spin state, while a 
pentacoordinated iron, when the heme loses the distal ligand, is displayed as a high spin state. 
For a low spin state, the Soret peak is normally between 416–419 nm, while for the high spin 
state, the absorption maximum is shifted towards the blue region between 390–416 nm, with 
a trough at about 420 nm. The differences in the spectrum between the bound and unbound 
proteins yield a Type I difference spectrum. Many substrates, like saturated and unsaturated 
fatty acids and aromatic compounds, show a Type I difference spectrum when they are bound 
to P450s. The dissociation constant Kd can also be calculated depending on the differences 
between the substrate-free protein and substrate-bound protein in the spectrum. Another type 
(Type II) of difference spectrum is obtained when inhibitors, such as imidazole, nicotine, 
methylenedioxyphenyl compounds or 1,1-dialkylhydrazines, bind to a P450. The Soret peak 
of Type II can be seen at 426–435 nm with a trough at approximately 390–405 nm. A shift 
in the spin state also occurred when CO bound to the reduced P450 protein, due to the 
nitrogen atom of a histidine imidazole linked to the iron causing a shift in the absorption 
maximum to 447–452 nm (Danielson, 2002).   Type I and Type II changes are shown in 
Figure 3-1.  
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3.5.2  Catalytic cycle 
The hydroxylation of organic compounds represents a signature reaction of all P450s. To 
enable this reaction, the protein needs to activate the inert molecular oxygen splitting it into 
two oxygen atoms, one is introduced into the H-C bond of the organic substrates like fatty 
acids and aromatic compounds, while the other is released as a water molecule. In addition 
Figure 3-1: Scheme of the changes in cytochrome P450 spectra due to the substrate binding 
and inhibition are presented in as orange and green curves. Proposed structures for the high 
spin heme (Type I) and the metabolic intermediate complex of methylenedioxyphenyl 
compounds to carbene-iron complex (Type II) are also displayed as examples for the both 
types.  
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to atomic oxygen, this reaction requires a transfer of two electrons from a suitable donor via 
protein domains. NADPH and NADH are the preferred coenzymes for the chromosomal 
P450s, while in mitochondrial P450s, the required electrons are obtained from adrenodoxin 
and adrenodoxin reductase. In this protein system, a hydride ion transfers from NADPH to 
FAD, which is caused by the generation of the reduced form of two adrenodoxin molecules 
and two electrons. After that, each electron will be used to reoxide one adrenodoxin molecule. 
Finally, every adrenodoxin molecule will transfer a single electron to the heme iron of the 
hemoprotein (Danielson, 2002; Sligar & Murray, 1986).  
The catalytic cycle is shown in (Figure 3-2). From this figure, the P450 heme converts from 
a low spin state (hexacoordinate) to the high spin state (pentacoordinate) immediately after 
substrate binding. Receiving one electron reduces the iron from the ferric form (Fe+3) into a 
ferrous form (Fe+2). In the next step, an oxygen molecule will bind to the ferrous iron to 
produce ferrous dioxygen-bound complex, then a second electron will be accepted to form 
the ferric peroxy complex. The oxygen molecule will then be cleaved into two oxygen atoms 
by receiving two protons, forming the oxyferryl intermediate with (FeIV). This intermediate 
represents the catalytically reactive heme. Finally, the oxygen atom of the oxyferryl will be 
transferred to the substrate to produce the hydroxyl form of that substrate.  
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3.6 Cytochrome P450-catalysed reactions 
In general, cytochrome P450 catalysed reactions can be classified into four basic categories: 
I) the most common reaction is the hydroxylation of organic substrates, when a hydrogen 
atom is replaced by hydroxyl group; II) epoxidation reactions, in this reaction the C-C bond 
is cleaved when an oxygen atom is introduced to it; III) heteroatom oxidation reactions 
Figure 3-2: : Scheme of cytochrome P450 enzyme catalytic cycle. This figure shows 
the basic steps of substrate hydroxylation by P450; substrate binding, receiving the 
first electron, binding of molecular oxygen, accepting the second electron, oxygen 
cleavage, forming the oxyferryl intermediate with (FeIV) and finally produce the 
substrate hydroxyl. Image was acquired and modified with permission from (Erdogan, 
2014)  
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(heteroatom such as sulphur or nitrogen); IV) reduction reactions occurring under limited 
oxygen conditions (Danielson, 2002; Goeptar et al., 1995).  
 
3.6.1 Hydroxylation 
The most common substrate for the hydroxylation reactions of P450s are the aliphatic and 
the aromatic hydrocarbons. One of the important issues in the hydroxylation is the site of the 
oxygen atom insertion in the C-H bond, which depends mainly on the required energy to 
cleave this bond. For example, the hydroxylation of hydrocarbon chains is more likely to 
occur at the site not at the terminal methyl group due to the differences in the C-H bond 
strength in these two sites. An exception to this can be seen in mammalian P450 (CYP4A), 
which prefers to hydroxylate fatty acids at the ω position instead of the ω-1, regardless of the 
fact that the later position has a weaker carbon bond than the first position. The explanation 
of this behaviour is still unknown, but it could be an access limitation stands behind the 
hydroxylation of the terminal methyl group in this case (CaJacob et al., 1988; Danielson, 
2002). However, the presence of an adjacent heteroatom, such as a methyl group, on an 
aromatic ring gives this site the preference. Another possible hydroxylation reaction is the 
hydroxylation of a methyl group linked to N or O atom, but the hydroxylation of a methyl 
group with more than one halogen atom could cause protein acylation, which seriously 
affects both protein structure and function (Danielson, 2002; Mehendale et al., 1994; Raucy 
et al., 1993).   
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3.6.2 Epoxidation 
The majority of P450 epoxidation studies focused on the olefins epoxidation reactions to 
their epoxides, such as the production of the corresponding epoxide and 
trichloroacetaldehyde from the epoxidation of trichloroethylene. However, the epoxidation 
of the terminal olefin group like octane or ethylene causes protein inactivation. Surprisingly, 
in limited cases (1 out of 100), the reaction diverts from its path when the olefin terminal 
carbon alkylates one of the heme associated nitrogen atoms. This rare reaction is known as a 
“suicide inactivation” because it inactivates the catalysed protein (Danielson, 2002). 
 
3.6.3 Oxidation of aromatic rings 
The discovery of ability of the P450s to hydroxylate different aromatic substrates dates back 
to 1950s, when acetanilide hydroxylation was studied by a number of researchers in the 
National Institutes of Health in Bethesda, Maryland. The objective of this study was to 
identify the role of microsomal hydroxylases in drug metabolism. An example of the 
aromatic compounds hydroxylation is the conversion of “5-nitrobenzo[b] naphtho[2,1-
d]thiophene”, an environmental pollutant with a high risk to human health, into DNA adducts 
by cytochrome P450 (Danielson, 2002). 
 
3.6.4 Dealkylation 
The ability of cytochrome P450 to catalyse heteroatom oxidation has attracted much 
biomedical research attention. The molecules bearing atoms with high electronegative 
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charge, such as nitrogen or sulphur, are more likely be oxidised by P450s than molecules 
with low electronegative atoms like oxygen. This reaction requires free electron pairs on the 
heteroatoms and two different mechanisms have been reported. The first mechanism is when 
ferryl oxygen (the electron deficient molecule) moves from iron to the electron pairs of 
sulphur or nitrogen to produce sulphoxide or N-oxide metabolites, the sulphoxide bearing 
electron pairs can also oxidise again to produce a sulphone. However, the oxidation of 
oxygen heteroatoms by P450s is unlikely to accur; the oxidation of bromide and iodide 
substituents by breaking the carbon-halogen bond was reported. The second mechanism 
involves the alkyl-substituted heteroatoms dealkylation; this reaction requires two successive 
steps. Firstly, the carbon atom neighbouring the heteroatom is hydroxylated, then the 
heteroatom atom is extruded to produce a carbonyl group. This mechanism is normally 
applied for sulphur and oxygen dealkylation, but it takes a different path for nitrogen 
dealkylation. The transformation of one electron from nitrogen to ferryl oxygen will give the 
nitrogen atom a positive charge. This positively charged nitrogen will cause acidification of 
the proton on the carbon adjacent to the heteroatom atom, and produce either N-hydroxyl 
derivative of the substrate or N-dealkylated product when it is transferred to the ferryl oxygen 
group (Danielson, 2002; Seto & Guengerich, 1993).  
 
3.6.5 Unusual P450 reactions 
Cytochrome P450s were extensively studied due to their ability to catalyse a wide range of 
reactions. In addition to the four traditional types of reactions that were described in sections 
(3.6.1–3.6.4), many P450s are also involved in different unusual reactions.  
  
33 
 
Although, reduction reactions catalysed by P450s are not common, the variety of these 
reactions needs to be taken in consideration. The mechanism of this reaction remains 
uncertain, but the reduction could happen when the Fe2+O2 complex works as a reduced agent 
during the waiting of an electron. A classic example of this type of reaction is the reduction 
of alkyl halides in the presence of CCl4 and halothane (Mico et al., 1983; Van Dyke & 
Gandolf, 1976). Another example is the reduction of nitrogen oxides, such as nitroxides, C- 
and N-nitroso compounds, hydroxylamines and nitro groups by P450s (Guengerich, 2001; 
Wislocki et al., 1980). Additional unusual reduction reactions are the reduction of glyceryl 
trinitrate to produce nitric oxide and the reduction of benzamidoximine to produce 
benzamidoxime as a final product (Clement et al., 1997; Delaforge et al., 1993). Cytochrome 
P450s can also reduce inorganic substrates in addition to organic compounds, for example, 
the reduction of SO2 or HSO3
- to SO2˙ˉ, which is in equilibrium with dithionite, S2O4 2- 
(Lambeth & Palmer, 1973).  
A second unusual type of reaction catalysed by P450s is dehydrogenation, also known as 
alkane desaturation. Many organic compounds have been reported as dehydrogenation 
substrates, such as valproic acid, testosterone, warfarin, lovastatin, ethyl carbamate and 
bufuralol. It is believed that this reaction shares the same starting point with classic C-
hydroxylation, that is, abstraction of a hydrogen atom. During the reaction, there is 
competition between oxygen rebound and a hydrogen atom abstract, but the C-hydroxylation 
represents a key step in this reaction. To date, there is no clear explanation why some C-
hydroxylations are accompanied by dehydrogenation and others are not (Fisher et al., 1998; 
Guengerich, 2001; Rettie et al., 1988). 
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Another uncommon reaction catalysed by P450s is the oxidative cleavage of a carboxylic 
acid ester. This reaction was first discovered in rat P450 2C11 (Guengerich, 1987; 
Guengerich et al., 1988). The product of this reaction is normally carbonyl instead of alcohol. 
It is suggested that this reaction is a C-hydroxylation similar to the classic O-dealkylation 
reaction (Guengerich et al., 1988). Ring expansion, when stable five or six membered rings 
are formed from unstable membered rings as in the production of pyrroline from 
cyclobutylamine (Bondon et al., 1989), is also one of the unusual P450s reactions. P450s can 
catalyse, not only the ring expansion reaction, but also the formation of non-existing rings 
such as the oxidation of dihydropyridines which results in the production of a very stable five 
membered lactone ring (Guengerich et al., 1988). Cytochrome P450 catalytic reactions are 
not limited to the reactions described above, but also include numerous other reactions such 
as aldehyde scissions, dehydration, one electron oxidation, coupling reactions, isomerisation, 
phospholipase D activity and rearrangement of fatty acids and prostaglandin hydroperoxides. 
It is expected that new P450s catalytic reactions will be discovered in the near future due to 
the intensive research focussing on the study and improvement of reactions of this P450 
superfamily (Guengerich, 2001).  
 
3.7 Industrial applications of cytochrome P450s  
CYP proteins apparently play a pivotal role in the biodegradation and modification of 
chemical compounds due to their substrate diversity. The adaptation of some organisms to a 
new diet in some circumstances leads to the further expansion of the variety of P450 
substrates. Recent studies have shown that there are no similar enzymes to the cytochrome 
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P450 superfamily in terms of substrate acceptability and diversity of catalysed reactions, 
making the members of this family outstanding biocatalysts in many practical applications. 
In spite of the broad applicability of these enzymes, their applications have been hampered 
by many limitations including: I) electron transfer requirement and transformation limitation; 
II) the need for NAD(P)H and uncoupling between the NAD(P)H oxidation and the product 
formation; III) limited 3D structures for the substrate-protein complex; IV) low activity 
(Bernhardt, 2006; Bernhardt & Urlacher, 2014; Julsing et al., 2008; O'Reilly et al., 2011; 
Urlacher & Eiben, 2006). 
P450 enzymes were described by many researchers as biological manufacturer enzymes of 
many pharmaceutical compounds and fine chemicals. CYP71AV1 is reported as a biocatalyst 
of the three step reaction to produce artemisinic acid, which is used as anti-malarial drug by 
the oxidation of amorpha-4,11-diene into intermediates, artemisinic aldehyde and artemisinic 
alcohol, using the engineered S. cerevisiae strain (Paddon et al., 2013; Ro et al., 2006). In 
2010, more than 655,000 people died because of malaria and more than 200 million malaria 
cases were reported, therefore there is a need for a stable and relatively inexpensive source 
of artemisinin. The yield of artemisinic acid was very low, approximately 100 mg/l in 2008, 
which hindered the industrial application of this reaction until 2013, when a combination of 
improvements was applied, methods of synthetic biology, recombinant protein expression, 
downstream processing and protein engineering. These efforts successfully increased the 
artemisinic acid yield up to 25 g/L. Currently, CYP71AV1 is used by Sanofi (France) for the 
industrial manufacture of artemisinin (Bernhardt & Urlacher, 2014).     
In addition to anti-malarial drugs, CYPs enzymes are involved in the production of anticancer 
agents, anti-inflammatory materials and antibiotics. Taxol, a chemotherapeutic agent, is 
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synthesised in E. coli at a concentration of 1 g/L from geranylgeranyl pyrophosphate (GGPP) 
in a series of reactions ending in taxol production. Taxadiene-5α-hydroxylase produces 
taxadien-5α-ol in the first step of this reaction, which is later converted to taxol (Ajikumar et 
al., 2010). 
Another remarkable example of a multi-enzyme system application was reported in 
hydrocortisone production. In the first step, engineered S. cervisiae serves to produce ergosta-
5-ene-ol and ergosta-5,22-diene-ol (CYP11A1 substrates to produce pregnenolone). The 
yelled pregnenolone in a multi-step reaction using 3-β-hydroxysteroid dehydrogenase, 
CYP17A1, CYP21A1, and CYP11B1 to produce hydrocortisone as a final industrial product 
(Szczebara et al., 2003).  
Parvastin, which is used widely around the world to reduce the cholesterol levels, is produced 
in a two-step reaction. The first step is the compactin biosynthesis by Penicillium citrinum 
and the second step is the sodium compactin hydroxylation to produce parvastin using 
CYP105A3 (Arai, 1988; Bernhardt & Urlacher, 2014).  CYPs also participate in the 
biosynthesis of vitamin D3 metabolites. CYP105A1 from Streptomyces griseolus converts 
vitamin D3 directly into its active form 1α,25-dihydroxyvitamin D3 through two oxidation 
steps (Sakaki et al., 2011; Sasaki et al., 1992).  
An available industrial application of plants CYPs is their ability to biosynthesise 
anthocyanin, which results in the delphinidin-derived pigments in violet or blue flowers. Two 
CYPs are involved in anthocyanin biosynthesis, CYP75B and CYP75A. Suntory Ltd (Japan) 
and Florigene Pty Ltd (Australia) have successfully used these CYPs to develop genetically 
engineered blue roses, which is impossible to achieve by traditional plant hybridisation 
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methods (Bernhardt & Urlacher, 2014; Holton et al., 1993; Katsumoto et al., 2007). These 
P450s’ products and other products are listed in Table 3-1  
Table 3-1: Some of the CYP’s commercial products. The table was produced depending on 
the data from (Bernhardt & Urlacher, 2014; Girvan & Munro, 2016) 
Substrates P450s involved Products 
Amorpha-4,11-diene CYP71AV1 Artemisinic acid 
Taxadien-5α-o Taxadiene-5α-hydroxylase Taxol 
Ergosta-5-ene-ol and 
ergosta-5,22-diene-ol 
CYP17A1, CYP21A1 and 
CYP11B1 
Hydrocortisone 
vitamin D3 CYP105A1 1α,25-dihydroxyvitamin D3 
Roses CYP75B and CYP75A Blue roses 
Sugar CYP82Y2 and CYP719B1 Morphine 
Tyrosine CYP from Petunia hybrida Fisetin 
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Part II: Tolerance of cytochrome P450 
BM-3 to non-conventional solvents 
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4 Introduction to cytochrome P450 BM-3 
 
4.1 Domain architecture 
Cytochrome P450s are widely known heme-dependent monooxygenases found in many 
eukaryotes such as fungi, plants and mammals as well as prokaryotes, but the bacterial types 
are more preferred because of their purification and crystallisation simplicity (Munro et al., 
2002; Nelson et al., 1996). A bacterial type P450 BM-3 from Bacillus megaterium (118 kDa) 
is more thermostable, highly active and easier to handle in comparison to other P450s 
(Bernhardt, 2006). P450 BM-3 protein has two distinct domains, the heme domain (BMP) at 
about 55 kDa and the reductase domain (BMR) at approximately 65 kDa. The latter consists 
of two prosthetic flavin groups in an equimolar ratio: flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN) (Narhi & Fulco, 1986), with both domains matching the 
chromosomal P450s domains well (Govindaraj & Poulos, 1995). BMR aligned well with the 
mammalian P450 reductases (CPR), while BMP shows similarity to the eukaryotic 
cytochromes such as CYP2A and CYP2A subfamilies (Porter, 1991). When BMP and BMR 
were expressed and purified separately, P450 BM-3 appeared to have lost its activity. This 
discovery showed the role of the linker region on enzyme activity. This was further supported 
in latter research when a number of residues were deleted from the linking region resulting 
in P450 BM-3 inactivity (Govindaraj & Poulos, 1995; Munro et al., 1994). BMR is less stable 
than BMP and undergoes proteolysis easily to the FMN binding region and an FAD/NADPH-
binding region, both subdomains are inactive individually (Oster et al., 1991). P450 BM-3 
BMP has remarkable homology with eukaryotic P540 sequences, making it a potential 
template for eukaryotic P450 sequence analysis because the crystal structure of BMP has 
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been fully elucidated (Amarneh et al., 1993; Loughran et al., 2000). Comparing BMP with 
prokaryotic heme showed some minor differences, such as CO-binding behaviour, and a 
major variation regarding electron transformation because in contrast to P450 BM-3, which 
receives two electrons vie integrated flavin domain, other bacterial P540s required an 
external partner to transfer electrons to the heme during catalytic reactions (Boddupalli et al., 
1990; Tuck et al., 1992).   
 
4.2 Protein expression 
The expression of P450 BM-3 cannot be induced by monounsaturated acids or saturated 
straight-chain fatty acids in B. megaterium (Narhi & Fulco, 1982). It is found that 
polyunsaturated analogues, like arachidonic and linoleic acids, in spite of their toxic effects 
when they added exogenously to B. megaterium, bind more strongly than other straight-chain 
analogues to the BM-3 repressor Bm3R1 and induce the expression of BM3 (English et al., 
1994; Liang et al., 1998; Ruettinger & Fulco, 1981). Other inducers of BM-3 expression in 
B. megaterium are branched-chain saturated fatty acids. These fatty acids apparently play a 
pivotal role in the membrane fluidity regulation and it is thought that they could be the 
original BM-3 substrates owing to their high ratio (about 90%) in the total fatty acid content 
in B. megaterium (English et al., 1997; Kaneda, 1991). Although, P450 BM-3 is not able to 
metabolise barbiturates, it is reported that barbiturate members are strong inducers for BM-
3 expression (Fulco et al., 1983; Narhi & Fulco, 1982).  
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4.3 Protein structure 
The crystal structure of P450BM-3 has been extensively studied by many researchers. The 
resolved structure of the substrate-free protein has a long hydrophobic substrate access 
channel. This channel starts from the protein surface charged residues and extends to the 
buried heme iron (the active site for the substrate hydroxylation) (Huang et al., 2007; Li & 
Poulos, 1995).  
An open confirmation was distinguished in the substrate-free structure. It was found that this 
open conformation is too wide to serve in substrate binding. In order to enhance substrate 
binding, it was suggested that the protein will reshape the access channel during the binding 
process, resulting in more closed conformation (Whitehouse et al., 2012). A substrate-free 
(SF) form differs from a substrate-bound (SB) by F/G loop, F helix and G helix positions. 
Palmitoleiate-BMP complex was the first solved structure. From the analysis of the substrate-
protein complex crystal structure, it was observed that F and G helices turn around their axes 
180º resulting in locking the access channel and preventing contact with the I helix and salt 
bridge. Fatty acid bound to P450 BM-3 in the hydroxylation position near the heme iron with 
(ω-1), (ω-2) or (ω-3) carbon positions, while the (ω) end is confined between Phe 81 and 87 
residues due to the 90º rotation of Phe 87 and rearrangement of the methyl groups of the close 
side-chains which are in contact with the Ala 82 residue (Huang et al., 2007). The binding of 
N-palmitoyl glycine (NPG) to P450 BM-3 is the most studied complex structure because 
NPG is more soluble than the equivalent chain fatty acids and it binds to the protein more 
tightly (Haines et al., 2001). The P450 substrate-free structure (PDB code 1BU7) and the 
structural changes in P450 BM-3 during NPG binding (PDB code 1JPZ) are shown in Figure 
4-1. The changes in water molecules are the most significant phenomena in the substrate 
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binding process, highlighting the crucial role of water in this process. The access channel and 
active site of the SF contain approximately 17–21 water molecules, while the number is 
reduced to only three molecules in SB. One of the important water molecules that will be 
removed during the substrate binding is Wat202 (Figure 4-1 C). This molecule plays an 
important role in dioxygen binding in the SF form by stopping the formation of a hydrogen 
bond as a result of creating a kink in the I helix. The removal of Wat202 will allow the 
formation of a traditional hydrogen bond, reducing the kink angle of the I helix from 13º to 
5º, the whole hydrogen bond network will be widely rearranged due to the Gly265 
repositioning and His266 rotation. Wat23, the axial water molecule will be displaced to an 
alternative position, Wat502, due to the I helix movement during the replacement of this 
water molecule to stay connected to Ala264 by hydrogen bonds. As a result of Wat23 ligand 
replacement, the heme iron centre will change from hexacoordinate to pentacoordinate . The 
proteolysed FMN-BMP complex has also been determined. In this structure (PDB code 
1BVY), the two asymmetric molecules of the BMP were observed together with the FMN 
domain situated close to the centre, interrupting the Pro382–Gln387 reign. (Whitehouse et 
al., 2012). In an attempt to understand the enzyme inactivity in the presence of organic 
solvents, a structural study on the DMSO-BMP complex was performed at 14% v/v and 28% 
v/v DMSO (Kuper et al., 2007). In the low solvent concentration, Wat23 was off-axial at 
3.75 A˚ instead of 2.6 A˚ in the DMSO-free protein. At the high solvent concentration, 
DMSO was linked to the heme as a sixth ligand by the sulphur atom instead of oxygen. The 
DMSO-protein complex behaviour was represented well spectroscopically through the 
partial high spin at 14% (v/v) solvent against the typical low spin state at 28% v/v DMSO 
(Kuper et al., 2007). 
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Figure 4-1: Structural changes induced in P450 BM-3 by substrate binding. The substrate-
free BMP structure (PDB code 1BU7) first time crystilised by Sevrioukova et al. 
(Sevrioukova et al., 1999) has been shown in grey  and the structural changes in P450 
BM-3 during NPG binding (PDB code 1JPZ) (Haines et al., 2001) in green. The water and 
hydrogen bonds in black, and the haem iron in orange, and NPG in plum. A. Complete 
overlay B. Regions of the G-, H- and I-helices. C. The kink region of the I-helix. D. The 
active site. This figure acquired with permission from (Whitehouse et al., 2012).   
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4.4 Dimerisation  
The discovery that fatty acid oxidation activity of P450 BM-3 is directly proportional to the 
enzyme concentration supported the belief that enzyme dilution may cause a dissociation of 
the function of this enzyme (Matson et al., 1977), which was further supported when it was 
found that electron transfer could be intermolecular. During a sedimentation velocity study, 
the P450 BM-3 enzyme mixture consisted of monomers, dimers, trimers and tetramers, but 
the overwhelming majority in the mixture was dimers. Not only P450 BM-3, but also other 
P450s such as eukaryotic soluble NOS and cyctochrome c reductase, lost their activity when 
monomeric (Black & Martin, 1994). When enzymes lose their activity due to the deletion of 
some residues from their linker region, it may be because this linker region becomes too short 
to form the proper functional dimer (Urlacher & Eiben, 2006). Aiming to prove that 
intermolecular electron transfer occurs in P450 BM-3, two mutants of this enzyme were 
mixed. The BMP of the first one was inactivated, while the BMR of the second mutant was 
FMN-deficient. Surprisingly, the P450 BM-3 mutant mixture showed distinguished 
hydroxylation activity, providing strong evidence that the electrons in P450 BM-3 transfer 
by intermolecularly instead of intramolecularly (Neeli et al., 2005). Despite the evidence 
supporting the dimerisation theory, there is experimental evidence to show that enzyme 
inactivity could be due to FMN depletion after a long preincubation time instead of 
monomerisation (Haines et al., 2001).  
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4.5 Electron transfer and redox partners 
One of the catalytic activity requirements of P50 BM-3 enzymes is the transfer of two 
electrons from a cofactor such as NADH or NADPH through FAD and FMN domains to the 
iron heme centre. Flavin reduction and semiquinone formation play a crucial role in electron 
transfer and BMR function. In P450BM3, the FMN domain receives the first electron from 
the FADH2 and as a result of this transformation, three components are formed, anionic 
FMNH semiquinone (red colour), FADH semiquinone (blue colour) and heme-reducing 
species (Sevrioukova & Peterson, 1995; Sevrioukova et al., 1996). The transformation rate 
of the first FMN-to-heme electron is known as kf and is calculated by measuring the increase 
in the rate at 450 nm absorbance when the FeII(CO) complex is formed. Stopped-flow 
techniques are usually used for kf estimation, these measurements are normally taken in CO-
saturated buffer after adding NADPH to the SB enzyme (Govindaraj & Poulos, 1995). In a 
study regarding the relationship between the catalytic reaction rate and the electron transfer 
speed, it was found that the electrons were transferred to the heme much slower when laurate 
bound to the enzyme instead of myristate. This indicated that the kf value is directly 
proportional to Kcat and both of them are dramatically decreased when some residues were 
deleted from the linker region (Munro et al., 1996).  
All P450s require a cofactor to reduce oxygen and donate the required electrons for enzyme 
catalytic activity. In P450 BM-3, either NADH or NADPH is used as a cofactor. Using these 
cofactors is usually associated with uncoupling problems. Coupling efficiency is “the 
percentage of reducing equivalents from NAD(P)H that are utilised for the oxidation of 
substrate”. The coupling efficiency varies from enzyme to enzyme and from catalytic 
reaction to another for the same enzyme. In the oxidation reaction of P450cam (the cytochrome 
  
46 
 
from Pseudomonas putida that catalyses the hydroxylation of camphor), the coupling 
efficiency was 100%, that is, all electrons that have been donated by NADH were used by 
P450cam in the oxidation forming 5-exo-hydroxycamphor. However, the coupling efficiency 
of the NADH when the same enzyme was used in the styrene epoxidation was no more 7%. 
There are many uncoupling mechanisms which could cause untargeted consumption of the 
electros such as: I) ferrous-oxy intermediate auto-oxidation; II) two electron reduction 
resulting in water molecule formation; III) intermediate decomposition resulting in H2O2 
formation. Uncoupling due to peroxide formation may occur either by the promotion of H2O2 
dissociation or by the inhibition of the cleavage of the O-O bond. The peroxide dissociation 
happens when the substrate is unable to remove a water molecule from the active site, so 
when the H2O molecule accesses the active site, the polarity is raised and a charge is 
separated from iron producing a hydrogen peroxide anion (Cirino, 2004).  
 
4.6 Protein engineering 
Protein engineering using a biological approach has emerged as a superior tool to improve 
enzyme catalytic activity, producing tailor made enzymes able to work with new 
environments and substrates. This technique has already been successfully performed with 
many P450s, however, eukaryotic P450s catalyse a wide range of reactions and use a variety 
of substrates, hence their catalytic ability was hindered by solubility and isolation issues. As 
a result, the majority of P450s protein engineering research has focused on the soluble 
bacterial membranes of this family, in particular on P450BM3, a soluble self-sufficient 
highly active enzyme (Whitehouse et al., 2012).  
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Two different strategies of genetic approaches have been used to improve this enzyme: site-
directed mutagenesis and the random mutagenesis/directed evolution approach (both 
approaches are shown in Figure 4-2). Recently, a combination of these two types were also 
utilised and have become increasingly important for novel enzyme expression (Urlacher et 
al., 2006).  
Site-directed mutagenesis is the earliest engineering approach successfully used to improve 
protein specifications (activity, selectivity and stability). This method requires a wide 
knowledge of enzyme structures and the relationship between these structures and protein 
activity, which is a major limitation in rational approach application. The first site 
mutagenesis was applied at Ala328, Thr268 and Phe87 to enhance the ability of P450 BM-3 
to catalyse chemical substrates, such as 1,1,2,2-tetrachloroethane and 2-phenylpropanal 
(Alworth et al., 1997). Other mutations, such as F87G and F87V, increased enzyme activity 
when used with propylbenzene and 3-chlorostyrene, while the F87A variant showed lower 
activity, but higher selectivity giving 54% β-hydroxylation versus 1% by the WT (Appel et 
al., 2001). This engineering approach was also used to produce the high-value primary-
alcohols from n-alkanes. For example, the mutant A328V catalysed the oxidation of octane 
to produce 5% 1-octanol and 82% 2-octanol in comparison to zero and 17% in the WT 
respectively (Peters et al., 2003). Other mutants also achieved high production of either 1-
octanol or 2-octanol from octane such as A82L, F87V/A328F, V78T and A82G (Peters et 
al., 2003). Site mutagenesis was also used to improve enzyme accessibility towards short 
chain fatty acids by applying a double mutation at L75T/L181K. By using this mutant, the 
enzyme was able to oxidise hexanoic acid giving Kcat (43 s
-1) instead of (3.8 s-1) for WT (Ost 
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et al., 2000). Although a site mutagenesis approach succeeded in improving P450 BM-3 
activity, selectivity and stability, good structural knowledge is required.  
In recent years, directed evolution has won protein engineering researchers’ attention because 
it does not require accurate information about protein structure. It is also able to be applied 
with a wide variety of design problems, in particular, obtaining new functional proteins. It is 
a random mutagenesis method using one or many start points, which are chosen depending 
on the specific goal of engineering (selectivity, stability or activity) (Arnold, 1998). In this 
process, the protein of interest should be encoded first, then screened before the improved 
protein variant can be isolated. The choice of suitable screening method is essential to the 
success of directed evolution experiments. Directed evolution applications have contributed 
to the development of protein properties knowledge and a wide range of molecule synthesis 
from building blocks to drug analogues, as well as the massive enhancement in activity, 
selectivity and stability not previously encountered in nature (Denard et al., 2015; Johannes 
& Zhao, 2006). 
Random mutagenesis followed by site-saturating to produce a second-generation variant, 
A74G/F87V/L188Q, also known as GVQ variant, was used to generate indigo-producing 
mutants. This variant was also able to oxidise a number of chemical substrates such as 
chlorinated dioxins, organophosphorus pesticides and polyaromatic hydrocarbons (PAHs) 
(Li et al., 2000). Furthermore, when the GVQ mutation was applied to CYP102A3, GVQA3 
showed a great improvement in enzyme activity with capric acid against WTA3 (35 s
-1 vs. 0.8 
s-1) (Lentz et al., 2004). Further investigation lead to the discovery that when A330VA3 was 
used instead of Glu in GVQA3, the ability of the enzyme to produce 1-octanol from octane 
increased to form half of the product mixture (Lentz et al., 2006). A similar role was applied 
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on CYP102A1 (P450 BM-3) to generate A328VA1. Starting from F87A as a platform, eight 
random generations were screened and the most active mutations were combined to produce 
the V26T/R47F/A74G/F87A/L188K variant, which showed impressive enhancement in 
protein activity (Li et al., 2001). Furthermore, when the F87V mutant was used instead of 
F87A as a platform, even more enhancement in activity was observed (Lentz et al., 2001). 
One of the most interesting directed evolutions, is that identified during indigo screening in 
an experiment aiming to improve selectively towards small non-natural substrates. The 
variant from this study gave 30% propylphenol from propylbenzene in comparison to 1% for 
the WT. In addition, F87A and A330P were shown in the same screening to yield 78% 2-
phenyl-1-propanol from propylbenzene against zero for the WT (Whitehouse et al., 2012). 
Directed evolution was also used by Wong in 2004 to enhance P450 BM-3 tolerance towards 
co-solvents (Wong et al., 2004). The engineered P450 BM-3 was significantly more resistant 
in the media containing DMSO and tetrahydrofuran (THF), showing high tolerance in the 
present of acetone, acetonitrile, dimethylformamide and ethanol (Wong et al., 2004). There 
have been numerous attempts to improve P450 BM-3 performance through applying a 
successful protein engineering approach, many of which are ongoing, giving hope for 
tremendous developments in this area.   
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Figure 4-2: Biological approaches for enzymes engineering. Two approches are shown 
in the figure; random mutagenesis on the right hand when no accurate information about 
protein structure is required and three techniques of rational mutagenesis on the left hand,  
these techniques vary depending on the information available on the protein structure     
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4.7 Immobilisation 
Enzyme immobilisation, a process which can be defined as linking the purified enzyme or 
the whole cell to a carrier, is required for the effective application of enzymes in industrial 
manufacturing by achieving a continuous operation process, recycling the enzyme and the 
cofactor as well as ease of product separation (Tan et al., 2016). Immobilization methods are 
classified into four groups: I) binding to a solid support, II) carrier-free insolubilisation by 
cross-linking, and III) entrapment in a polymer network and IV) encapsulation in a 
membrane. Types of immobilisation are presented in Figure 4-3. Although the difficulties of 
immobilising P450s due to their need for electron transformation could negatively affect their 
function as shuttle molecules, many researchers have succeeded in applying an 
immobilisation technique with P450 BM-3.   
The first attempt to immobilise P450 BM-3 on a carrier was applied in 2003 by Maurer 
(Maurer et al., 2003). The enzyme was immobilised in a sol-gel matrix combined with a FDH 
(formate dehydrogenase), nicotinamide-adenine-dinucleotide phosphate (NADP+) 
dependent system. This approach succeeded in achieving continuous production of hydroxyl-
compounds from –ionone, naphthalene and octane using a cheap cofactor recycling system 
with the ability of FDH to convert NADP+ into NADPH which could be used by P450 BM-
3 as a source of the required electrons for hydroxylation (Maurer et al., 2003). The next step 
in P450 BM-3 immobilisation was achieved three years later by Waibel (Waibel et al., 2006). 
A triple mutant of P450 BM-3 together with Nippostrongylus brasilliensis AchE (NbAchE) 
were immobilised on a sol-gel matrix to produce an active bienzymatic biosensor used for 
insecticide detection in food (Waibel et al., 2006). In 2007, the continuous production of 
indigo from indole using whole cell immobilisation in calcium-alginate capsules was 
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investigated (Yan & Lehe, 2007). The immobilised E. coli strain showed very high thermal 
stability and the indigo yield was maintained at 94% of the original yield after five repeated 
runs Purified mutant P450 BM-3 M9 (R47F F87A M238K V281G M354S D363H W575C 
A595T) was entrapped on DEAE (anion matrix) combined with k-carrageenan, catalase (for 
immediate elimination of the hydrogen peroxide) and zinc dust as an alternative electron 
source. The immobilised enzyme was able to hydroxylate 3-phenoxytoluene in a plug flow 
reactor (Zhao et al., 2011).     
 
 
 
 
(A)                                 (B)                                  (C)                                        (D) 
Figure 4-3: Enzyme immobilisation strategies: (A) entrapment in a polymer network  (B) 
encapsulation in a membrane (C) binding to a solid support (D) crosslinking (carrier-free 
insolubilisation).  
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4.8 Industrial applications of cytochrome P450 BM-3 
By using P450 BM-3, a vast range of substrates can be utilised, including alkanes, phenols, 
steroids and fatty acids, and a broad range of reactions can be catalysed. Indeed, this natural 
soluble self-sufficient enzyme recorded the highest activity level among all other 
monooxygenases (Bernhardt, 2006; Urlacher & Eiben, 2006; Urlacher et al., 2004). Applying 
protein engineering approaches, both the rational and the random designs, made this protein 
more applicable, overcoming the barriers which hindered its industrial application for a long 
time. Examples of the applications of BM-3 variants are enormous. Multiple mutation 
variants of BM-3 were used to produce 4- and 5-hydroxy diclofenac products (nonsteroidal 
anti-inflammatory agents) used as painkillers from the conversion of diclofenac (Ren et al., 
2015). Another application of BM-3 is the manufacture of (ــــ)-perillyl alcohol (a possible 
anticancer drug) from terpene (ــــ)-limonene using a triple BM-3 variant 
A264V/A238V/L437F (Seifert et al., 2011). The production of antibacterial and antifungal 
agents 9 and 10-hydroxy-β-cembrenediol (tobacco diterpene b-cembrenediol) from β-
cembrenediol using two BM-3 mutants (F78A/I263L and L75A/V78A/F87G) was also 
reported (Venkataraman et al., 2014). In 2014, a BM-3 variant from a directed evolution 
approach was used to hydroxylate 1-tetralone; the hydroxylated products are of great 
biological importance in the synthesis of numerous biologically active compounds (Roiban 
et al., 2014). Another example of the application of P450 BM-3 variants is the conversion of 
omeprazole and esomeprazole (the potent antiulcer drugs) to their human type metabolites 
(CYP2C19) by a double BM3 mutant (F87V/A82F) (Butler et al., 2014). The BM3 mutant 
from a saturation mutagenesis of the active site was used to transfer 1-hexene into 1,2-
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epoxyhexane, which was recently used to produce aluminium core-shell nanoparticles (the 
new energetic material in the nanoparticle field) (Kubo et al., 2006).  
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5 Biocatalysis in non-conventional solvents 
 
5.1 Tolerance vs stability 
In general, proteins are barely stable molecules and denaturation can easily occur by a 
number of physical elements, such as heating, agitation and freezing. Furthermore, chemical 
changes, such as hydrolysis, play a significant role in protein instability. Potency and safety 
during manufacturing, transportation, and storage processes are affected in both biochemical 
and pharmaceutical industries. However, a general strategy for stabilising proteins is still 
lacking (Klibanov, 2001). 
According to Matthews (1993), protein stability is defined as the difference between folded 
and unfolded protein in their free energy, so protein stability depends mainly on the protein 
structure and could be improved either by stimulating the conversion from unfolded to folded 
protein or by decreasing the formation of the denatured form, or a combination of both 
(Matthews, 1993).  
The protein in its native state (folded condition) is an ensemble of compact conformations 
with low energy, which is mainly characterised by low entropy due to the retention of all 
protein atoms in a well-known geometry. When a protein is denatured (unfolding state) by 
changing temperature, pH or adding denaturants, the protein conformations ensemble 
becomes highly heterogeneous and complex. In other words, the entropy will increase due to 
the loss of the native interactions and as a result, a large set of arrangements will be offered 
to the residues (Matthews et al., 1987).  
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Finding the most stable protein is a great challenge in protein science because enhancing 
protein stability will not provide an outstanding protein unless it is combined with improving 
the tolerance of this protein. Tolerance in general can be defined as the ability to bear 
something potentially difficult, while protein tolerance specifically is the ability of the protein 
to stay catalytically active in the presence of denaturants, such as organic solvents. In 
summary, a stable folded protein must also be kinetically accessible and the protein activity 
should be kept within satisfied limits in the presence of denaturants (Matthews, 1993; 
Pietrzykowski & Treistman, 2008).      
 
5.2 Solvent classification 
Green chemistry is the design of chemical processes that reduce or eliminate the use of 
hazardous substances. Solvents form an interesting part of the green chemistry philosophy 
because of the volume in which they are used in the chemical and pharmaceutical industries. 
According to the American Chemical Society Green Chemistry Institute Pharmaceutical 
Roundtable (ACS GCIPR), 22000 kg of solvents are used annually (Henderson et al., 2011). 
This quantity constitutes 80–90% of the non-aqueous mass of materials used to make an 
active pharmaceutical ingredient (API) (Breeden et al., 2012; Henderson et al., 2011; Sheldon 
et al., 2007).  
There are many classifications used to sort solvents such as Pfizer results and tools, ACS 
GCI Solvent Selection Guide, Sanofi’s Solvent Selection Guide and GSK Solvent Selection 
Guide (Henderson et al., 2011). The one suggested by GSK is the most common classification 
because it gives reliable information to researchers to help them to switch to a more 
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sustainable biosynthesis process. Solvents, according to GSK, are classified depending on 
lifecycle assessment information. They are scored from 1 (red) to 10 (green), 1–3 red, 4–7 
orange and 8–10 green to give a relative ranking for every solvent in the guide in each 
category, where the score depends on the following categories: environmental impact (effects 
of solvents on the environment), health (acute and chronic effects on human health and the 
potential for exposure), flammability and explosion (issues affecting storage and handling of 
solvents), reactivity and stability (factors affecting the stability of the solvent), melting and 
boiling points (covering high boiling point solvents that have high energy. The GSK solvents 
classification and the solvents selection guide are shown in (Table 5-1 and Figure 5-1) 
respectively.  
Table 5-1: The ranking of green  solvents  in each category depending on the GSK guide, 
2010 (Henderson et al., 2011).  
 
 
 
Solvent M. P. 
˚C 
B. P. 
˚C 
Recycling Environment Health Explosion 
 
Stability Life 
cycle 
Water 0 100 4 10 10 10 10 10 
1-Butanol 
-89 
 
118 5 7 5 8 9 5 
2-Butanol 
-115 
 
100 4 6 8 7 9 6 
t-Butyl 
acetate 
-78 95 6 9 8 6 10 8 
Isopropyl 
acetate 
-73 89 5 7 7 6 9 7 
Propyl 
acetate 
-92 102 5 7 8 6 10 4 
Dimethyl 
carbonate 
-1 91 4 8 7 6 10 8 
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Figure 5-1: Solvents classification depending on GSK in 2010 (Henderson et al., 2011), 
the green region represents solvents with few issues, the orang region indicates solvents 
with some issues and the red area is sets solvents with major issues such as: environmental 
impact, health, flammability and explosion, reactivity and stability and melting and boiling 
points 
N-Methyl pyrrolidne 
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5.3 Biocatalysis in organic media 
In recent years, biocatalysts have been the subject of intensive investigations by 
pharmaceutical and industrial researchers, with the interest continuously growing. This is not 
surprising given the potential advantages of enzymes: (I) the ability to display regio-, chemo- 
and enantioselectivity; (II) the enhancement in reaction rate up to 1012 fold; (III) the ability 
to catalyse reactions in moderate conditions (pH and temperature), while these reactions 
require harsh conditions using chemical catalysts (Carrea & Riva, 2000). These superior 
properties of enzymes are restricted by their orientation to the aqueous reaction media (their 
natural media). The importance of water in enzymatic catalyst systems is an assumptive 
matter, since it helps to maintain proteins in their active structures as well as playing an 
essential role in enzyme dynamics. In spite of these advantages, using aqueous enzymatic 
media is faced with a variety of limitations. The insolubility of many substrates in water, the 
unwanted side reactions and the difficulties of products recovery are major issues indicated 
in biocatalytic systems using water as a solvent (Zaks & Russell, 1988). 
In an effort to resolve this problem, many types of solvents were investigated to find a 
suitable active solvent as a replacement of water. In this chapter, different types of solvents 
that have been with enzymes and their impact on enzyme stability and activity will be 
highlighted. 
 
5.3.1 Neat solvent 
The fact that enzymatic activity and structural stability decrease in a media containing 
organic solvents made the later a way of study for years. In fact, the phenomenon of using 
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organic solvents in enzymatic media dates back to the 1930s of the last century, but this field 
did not command attention until a report by Zaks and Klibanov in the early 1980s (Halling 
& Kvittingen, 1999; Zaks & Klibanov, 1984). They indicated that the enzymatic deactivation 
theory is actually based on studying the enzymes in hydrous solvents not in neat solvents. 
Accordingly, anhydrous enzymology became a material of study and analysis by many 
researchers and industrial laboratories (Carrea et al., 1995; Klibanov, 1997). The 
hydrophobicity of organic solvents is considered valuable to provide an effective enzyme 
medium. It was measured and studied depending on the partition coefficient value, log P (a 
ratio of a compound concentration in a mixture of two immiscible phases at equilibrium). It 
was reported that the activity of biocatalysts in organic solvents is highly dependent on the 
log P value as follows: I) strongly inactivating when it is used with a solvent log P < 2; II) 
slightly denatured at log P value between 2 and 4; and III) keep its native structure in a log P 
> 4 (Laane et al., 1987). The reason behind this observed trend is that a highly hydrophobic 
solvent does not strip off the enzymes’ water which is essential to their activity, so these 
solvents should not affect enzyme structures. 
It was shown that protein stability and activity for numerous enzymes, such as ribonuclease, 
porcine pancreatic lipase (PPL) and α-chymotrypsin, can be improved by using neat organic 
solvents (Volkin et al., 1991; Zaks & Klibanov, 1984; Zaks & Russell, 1988). Chymotrypsin 
showed no appreciable effect on its crystal structure when it was introduced into neat hexane. 
In addition to enhancement in activity and structure stability of enzymes achieved by using 
neat solvents, new enzymatic reactions have come to light. Examples of these reactions, 
which would not have been possible with aqueous media, are the production of esters from 
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their constituent acids and alcohols, transesterification, aminolysis and thio-
transesterification (Klibanov, 2001; Schmitke et al., 1996; Zaks & Klibanov, 1985). 
 
5.3.2 Water-solvent mixture (co-solvent) 
Water-solvent mixture or water-miscible solvents are homogeneous systems in which the 
enzymes are either suspended or dissolved. At high concentrations, most co-solvents cause a 
significant drop in enzymatic activity. These solvents form a layer around the enzyme and 
strip the water, which is an essential molecule for biocatalyst, from the active site of the 
enzyme, thereby changing the enzyme structure. As a result, most enzymes are unstable and 
inactive in water-solvent mixtures. However, there are some exceptions, such as polyols and 
glymes, when enzymes showed stability and activity very similar to their activity and stability 
in aqueous medium.   
The dynamic and catalytic properties of enzymes greatly depend on the amount of water 
present in the reaction media. By using water-miscible solvents, a relationship between 
thermodynamic water activity and water concentration was examined using a variety of 
common polar solvents. This study showed that a solvent’s hydrophilic nature has a 
significant impact on the enzyme activity. Five alcoholic solvents were investigated, 
methanol, 2-propanol, 1, 2-butanol, ethanol and acetonitrile (Bell et al., 1997) and the effect 
of water on the enzyme’s secondary structure was assessed using three types of conditions, 
a neat organic solvent, a water-solvent mixture (co-solvent) and pure water. The secondary 
structures of lysozyme and subtilisin in pure solvents were very close to those of the native 
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enzymes, while a significant deviation was recorded in the water-solvent mixture (Griebenow 
& Klibanov, 1996). 
 
5.3.3 Biphasic system 
The biphasic solvent system is used to improve catalysts’ recyclability, activity, stability and 
product separation. The prosperity of such schemes depends on the differences between the 
two liquids in various properties, and usually polarity. One of solvents should be polar to 
dissolve and retain the catalyst, and the other solvent should be nonpolar to dissolve the 
products (Lee et al., 2003). The first biphasic used was a mixture of water and carbon dioxide 
(Bhanage et al., 1999), which showed a good result when it was used with water-soluble 
catalysts and substrates. However, another combination needs to be applied for water-
insoluble reaction media, such as ionic liquids mixed with supercritical CO2 (Heldebrant & 
Jessop, 2003). 
The activity, selectivity, product and catalyst recovery of two enzymes, Wilkinson’s catalyst 
and a cationic rhodium complex were examined using two different biphasic solvents 
(polyethylene oxide, heptane and CH2Cl2 and polyethylene oxide, heptane and methanol), 
respectively. The results showed that using both enzymes led to high yields and selectivity 
(da Rosa et al., 2000). Three years later, an encouraging result was achieved using 
polyethylene glycol together with supercritical fluid CO2 as a biphasic solvent in a reaction 
catalysed by RhCl(PPh3)3. The biphasic solvent and the catalyst were not replaced for five 
cycles and the catalyst activity was about 99% combined with an increase in product mass 
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recovery for five cycles (Heldebrant & Jessop, 2003). The effects of some solvents used with 
proteins are shown in Table 5-2. 
Table 5-2: Some solvents used with native enzymes and their effects on enzymes properties 
Solvents Enzymes Reaction 
Effect on 
enzyme 
References 
99% ethanol 
porcine 
pancreatic lipase 
(PPL) 
transesterification 
high activity at 
high temperature 
(Zaks & 
Klibanov, 
1984) 
1-butanol & DMF 
ribonuclease, 
chymotrypsin 
and lysozyme 
hydrolysis of N-
benzoylL-tyrosine 
ethyl ester (BTEE) 
high thermal 
stability 
(Volkin et al., 
1991) 
hexane 
uncrosslinked 
chymotrypsin 
crystallisation stable structure 
(Klibanov, 
1997) 
hexane, dodecane, 
hexadecane, ethyl ether, 
isopropyl, ether butyl, ether 
acetonitrile tetrahydrofuran, 
dioxane, toluene, pyridine, 
dimethyl sulphoxide, 
formamide & carbon 
tetrachloride 
PPL, Candida 
cylindracea 
lipase, Mucor 
and 
Pseudomonas 
lipoprotein 
lipase 
 
transesterification 
reaction between 
tributyrin and 
heptanol 
enzymatic 
activity similar 
to that in water 
(Zaks & 
Klibanov, 
1985) 
supercritical carbon dioxide 
(SC-CO2) 
amberlyst & 
zeolite 
carbonatation 
Stability 
improvement 
(Vieville et 
al., 1998) 
Supercritical CO2/toluene 
mixture 
commercial 0.5 
wt.% Pd/Al2O3 
oxidation of 
benzyl alcohol to 
benzaldehyde 
high reaction 
rate 
(Caravati et 
al., 2006) 
Supercritical CO2/n-hexane 
mixture 
lipase B esterification 
high conversion 
rate 99% 
(Knez et al., 
2012) 
ionic liquid 1-butyl-3-
methylimidazolium 
hexafluorophosphate 
chymotrypsin 
transesterification 
and hydrolysis 
slight 
enhancement in 
activity 
(Berberich et 
al., 2003) 
[C4mpy][Tf2N] monellin ------------ 
improved 
thermostability 
(Baker et al., 
2004) 
1-Butyl-3-
methylimidazolium 
(bmim) dihydrogen 
phosphate (dhp), 
N-butyl-N-methyl 
pyrrolidinium 
dihydrogen phosphate (p1,4 
dhp),choline dihydrogen 
phosphate 
cytochrome c & 
P1,4dhp 
----------- 
improved 
thermostability 
(Fujita et al., 
2005) 
polyethylene oxide, heptane 
CH2Cl2 
Wilkinson’s 
catalyst 
hydrogenation of 
hex-1-ene 
high selectivity 
and yield 
(da Rosa et 
al., 2000) 
polyethylene oxide, heptane, 
methanol 
cationic rhodium 
complex 
hydrogenation of 
hex-1-ene 
high selectivity, 
yield, separation 
and recycling 
efficiency 
(da Rosa et 
al., 2000) 
  
64 
 
5.4 Biocatalysis in micellar systems  
A mixture of water-in-oil (w/o) or oil-in-water (o/w) is called an emulsion. The stability of 
emulsions is controlled by the effect of amphiphilic compounds. Amphiphilic molecules have 
the ability to interact with polar as well as nonpolar molecules at the same time because of 
the differences in polarity between the head and the tail of these components; hydrophilic 
head and hydrophobic tail. The presence of these amphiphiles encourages the formation of 
monophasic (emulsion) inside the biphasic (microemulsion) by decreasing the interfacial 
water-oil tension. The ratio of water to oil is responsible for the variation in the 
microemulsion microstructure from tiny droplets of water-in-oil phase to the reverse 
microemulsions, tiny droplets of oil-in-water phase. The structure and stability of emulsions 
differ from those for microemulsions; emulsions are less stable and they separated into two 
layers once the agitation stops. In addition, the size of emulsion droplets is in micrometres 
range, while they are in nanometres in microemulsions. Another important difference 
between these two systems is the formation of spherical aggregates, these aggregates are in 
colloidal size and they called micelles. The micelle system is homogeneous monophasic 
system. Different micelles systems have different structures based on their composition, 
temperature and presence of amphiphilic compounds (Braga & Belo, 2015).  
Microemulsions have been used successfully for enzymatic catalysis in many reactions such 
as hydrolysis, transesterifications, peptide and sugar acetals, and ester syntheses (Krishna et 
al., 2002). Microemulsions were used to overcome the heterogeneous nature of the reaction 
mixture when lipase was applied to hydrolyse long-chain aliphatic esters to glycerol and free 
fatty acids (Carvalho & Cabral, 2000). When reverse micellar system (sodium lauryl 
sulphate/benzene) was applied, hydrogen production by Rhodopseudomonas sphaeroides 
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increased by 25-fold. In addition, a 12-fold increase in alcohol dehydrogenases (ADH) 
catalysed reduction rate was recorded when Marlipal O 13/60/cyclohexane was used to 
reduce 2-heptanone to S-2-heptanol (Braga & Belo, 2015).   
 
5.5 Biocatalysis in ionic liquids 
Salts which have the ability to stay in a liquid state and do not crystallise at room temperature 
are called ionic liquids. For the names and physical properties of some ionic liquids, see Table 
5-3. Imidazolium is a widely used ionic liquid and the first one discovered was EtNH3NO3. 
Over the past twenty years, ionic liquids have become increasingly important as green 
solvents for various reactions because of their remarkable results in biochemical reactions 
such as redox, hydrolysis and esterification. They provide an ideal solvent for engineering 
media for biocatalytic reactions because of the unique advantages for biocatalysis, such as 
their non-volatile nature which maintains a stable system pressure, ability to dissolve several 
compounds, as well as forming multiphase systems with many solvents (Seongsoon & Romas, 
2003a). 
Neat ionic liquids represent a new class of solvents, which are polar and non-aqueous at the 
same time depending on the cation and anion properties. Unlike organic solvents, they do not 
inactivate enzyme activity (Seongsoon & Romas, 2003b). Much attention has been given to 
improve protein stability, activity and solubility in neat ionic liquids (Weingärtner et al., 
2012). 
The first kinetics study to compare pure ionic liquids, aqueous ionic liquids and pure organic 
solvents was conducted in 2000. In this study, they highly recommended using anhydrous 
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ionic liquids due to the high product yield (80%) (Lau et al., 2000). Subsequently, numerous 
studies reported the excellence of pure ionic liquids as alternative to organic solvents 
(Eckstein et al., 2002; Lozano et al., 2001; Summers & Flowers, 2000).  
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Table 5-3: Names and physical properties of some common ionic liquids used with enzymes 
IL IL name 
M. P. 
°C 
Viscosity 
cP at 25 
°C 
Density 
g/ml at 
25 °C 
Enzyme References 
[C2mim] 
[BF4] 
1-Ethyl-3-
midazolium 
tetrafluoroborate 
- 43 - 
Lysozyme, 
Catalase, 
Myoglobin, 
Trypsin 
Glucose isomerase, 
Xylanase 
(Huddleston et al., 
2001; Judge et al., 
2009; Noritomi et al., 
2011) 
 
[C2mim] 
[Br] 
1-Ethyl-3-
methylmidazolium 
bromide 
 
58–60 - - 
Trypsin 
 
(Ge et al., 2010; 
Huddleston et al., 2001) 
[C4mim] 
[BF4] 
1-Butyl-3-
methylmidazolium 
tetrafluoroborate 
−81 233 1.12 
Horseradish 
Peroxidase, 
Glucose Oxidase 
(HRP), Esterase 
(Huddleston et al., 
2001; Patel et al., 2014; 
Persson & 
Bornscheuer, 2003) 
[C4mim] 
[PF6] 
1-Butyl-3-
methylmidazolium 
hexafluorophosphate 
10 450 1.36 
Candida rugose, 
Esterase, 
Thermolysin, 
Lipase 
Chymotrypsin 
(Erbeldinger et al., 
2000; Huddleston et al., 
2001; Lau et al., 2004; 
Meng et al., 2011; 
Pavlidis et al., 2009; 
Persson & 
Bornscheuer, 2003) 
[C8mim] 
[PF6] 
1-Octyl-3-
methylmidazolium 
hexafluorophosphate 
 
- 682 1.22 
Candida rugosa 
enzyme 
(Huddleston et al., 
2001; Lau et al., 2004) 
5.6 Biocatalysis in supercritical fluids 
Supercritical fluids (SCFs) are solvents used at a combination of high pressure and 
temperature, usually above their critical value. From the time they were discovered in 1822 
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to date, their applications have witnessed considerable developments. The superior 
specifications by mixing gas properties (diffusivity and viscosity) with liquid properties 
(density and solvating ability) has opened new prospects for the use of SCFs as solvents for 
many applications. Furthermore, they are considered safe, cost efficient, nontoxic, easy to 
recover and environmentally friendly, which makes them a good alternative for traditional 
solvents (Knez et al., 2014). The stability of heterogeneous catalysts in a glycerol 
carbonatation process was investigated using supercritical solvents. The catalysts appeared 
to be more stable in a media containing supercritical carbon dioxide (SC-CO2) (Vieville et 
al., 1998). A comparative study between neat CO2, neat toluene and CO2/toluene mixture 
was published by Caravati et al. in 2005 and it elucidated that the highest reaction rate can 
be achieved by adding a small amount of toluene to the SC-CO2 (Caravati et al., 2006). The 
same supercritical solvent (SC-CO2) was tested alone and as a mixture (SC-CO2/n-hexane) 
in the esterification process catalysed by lipase B, showing that the SC-CO2/n-hexane 
mixture was the best, with a 99% conversion rate and 11.2 (w/w) yield (Knez et al., 2012).  
5.7 Stabilisation of enzymes in non-conventional solvents 
Despite enzyme inactivation by organic solvents, the numerous advantages of using these 
solvents motivated industry and academia to find effective strategies for enzyme stabilisation 
in non-conventional solvents. These strategies can be classified into three categories: I) 
isolation of stable biocatalysts; II) enzyme structure modification, and III) solvent 
environment modification (Stepankova et al., 2013).  
Microorganisms that have the ability to live and survive under harsh conditions, such as high 
and low temperature, extreme pH and organic solvents medium, offer a very effective source 
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of extremozymes which are highly stable enzymes. This strategy succeeded in improving the 
tolerance of some enzymes against organic solvents by enhancing the hydration 
characteristics of these enzymes, which are responsible for enzyme inactivation due to the 
loss of crucial water molecules (Karan et al., 2012). The tolerance of protease towards many 
co-solvents was investigated. This enzyme was isolated from P. aeruginosa PST-01 grown 
in soil saturated with a high concentration of different organic solvents. This enzyme showed 
stability in a media containing co-solvents rather than in aqueous media (Ogino et al., 1999). 
In addition, α-amylase and alkaline phosphatase also showed very good tolerance against 
organic solvents when they isolated from Haloarcula sp. strain S-1 and Streptomyces 
clavuligerus strain Mit-1 respectively (Fukushima et al., 2005; Thumar & Singh, 2009).    
Modification of biocatalysts was also applied to improve enzyme activity using different 
strategies including enzyme immobilisation, ionic liquid coating, chemical modification and 
genetic engineering. Stabilising enzymes in solvents by using immobilisation is one of the 
most common strategies. All immobilisation types were reported as effective methods to 
enhance enzyme stability. Candida antarctica lipase B showed outstanding activity in neat 
solvents when it is adsorbed on Lewatit ion exchange resin (Hanefeld et al., 2009). In 
addition, when α-chymotrypsin was bound covalently to a nanoporous silica glass, it showed 
impressive improvement in activity and stability in the presence of organic solvents (Wang 
et al., 2001). Moreover, not only the enzyme, but also its cofactor NADPH were entrapped 
in the polymer network (polyvinyl alcohol gel beads), protected from the negative effect of 
pure hexane in this experiment, the entrapped dehydrogenase from Lactobacillus kefir 
successfully transformed some hydrophobic ketones to the “corresponding enantiomerically 
pure (R)-alcohols” (De Temiño et al., 2005). In addition to their importance as green solvents, 
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ionic liquids play a crucial role in enhancing enzyme tolerance towards organic solvents by 
acting as enzyme-coating agents. These coating agents offer a stable microenvironment for 
the reaction by binding to the enzymes. It was reported that when lipase B from C. Antarctica 
was coated with [BTMA][Tf2N] or [TOMA][Tf2N], it remained active at high temperatures, 
95°C, in hexane (Lozano et al., 2007).  
Numerous techniques and strategies have been applied to identify a suitable solution for loss 
of enzyme activity in a media containing solvents, but one which has been successfully used 
to overcome stability and activity problems, properly helping to maintain a satisfactory 
physical and chemical stability of enzymes in non-conventional solvents is protein 
engineering.  
Genetic mutagenesis, both rational and directed evolution approaches were used to stabilise 
enzymes towards organic solvents. By applying the B-FIT method, protein rigidity was 
increased as a result of replacing the high B-factors residues with the lowest ones and a 
considerable enhancement was reported in proteins’ tolerance in a high solvent media (Reetz 
et al., 2010). Reetz and co-workers highly recommended using the B-FIT method at sites 
showing high B-factors to increase thermostability and tolerance against solvents. By using 
this approach, lipase from Bacillus subtilis (BSL) showed high tolerance towards three 
different solvents, DMSO, ACN, and DMF (Reetz et al., 2010).  
Surface loop engineering has been successfully used to overcome stability problems towards 
solvents and maintain protein activity through insertion, deletion and substitution of residues 
from the enzyme surfaces (Reich, 2014). The stability and activity of a lipase from Bacillus 
subtilis was examined in the presence of 60% DMSO by applying site saturation mutagenesis 
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for 91 amino acids of the lipase loops. The protein showed improvement in DMSO tolerance 
and a massive increase in protein activity (8-fold) (Yedavalli & Rao, 2013). A year later, two 
loop mutants of reductase NCR from Zymomonas mobilis were generated using a rational 
approach dependent on surface structure information, one of them showed a considerable 
increase in tolerance towards organic solvents (Reich et al., 2014).  
In 2013, protein engineering of residues located in the access tunnels was used to enhance 
enzyme stability against solvents. A unique improvement in enzyme stability against 42% 
(v/v) DMSO for four variants generated using access tunnel mutagenesis was reported by 
Koudelakova and co-workers (Koudelakova et al., 2013). 
Directed evolution applications contributed to the expansion of the knowledge regarding 
protein properties and a wide range of molecule synthesis from building blocks to drug 
analogues as well as the massive enhancement in activity, selectivity and stability not 
previously encountered in nature (Denard et al., 2015; Johannes & Zhao, 2006). An 
impressive example about the role of this approach in activity and stability improvement is a 
500-fold enhancement in the protease subtillisin E specific activity after multiple generations 
of random mutagenesis were applied in the presence of 60% DMF. In addition, a 20-fold 
increase in p-nitrobenzyl (pNB) activity was recorded by using just four generations of 
random mutagenesis in approximately 15–20% DMF (Moore & Arnold, 1996). Wong et al. 
(2004) used directed evolution to enhance P450 BM-3 tolerance towards co-solvents. The 
engineered P450 BM-3 was significantly more resistant in the media containing DMSO and 
THF, showing a high tolerance in the presence of acetone, acetonitrile, dimethylformamide 
and ethanol (Wong et al., 2004). Likewise, the activity as well as tolerance of laccase in a 
  
72 
 
high concentration of acetonitrite and ethanol (20–60%) was increased significantly by the 
fifth generation (Zumárraga et al., 2007).  
Before genetic engineering, chemical enzyme modification approach was widely applied to 
enhance enzyme stability and it was used successfully to improve enzyme resistance towards 
organic solvents. However, chemical modification has been overshadowed in recent years by 
protein engineering, it remained a useful technique for enzyme stabilization taking into 
consideration the advantages can be gained by using this technique such as the simplicity of 
the procedure and no structure details are required, in Figure 5-2 the advantages and 
disadvantages of both chemical and biological proteins engineering are summarised. 
PEG was an investigated polymer for chemical modification since 1985, being used to shield 
and surface modify polypeptides (Veronese et al., 1985). This method was applied for the 
first time to improve enzyme resistance against organic solvents in 1986 by Inada and co-
workers (Inada et al., 1986). When lysozyme was conjugated with methoxy polyethylene 
glycol, protein tolerance was enhanced against dichloromethane (Diwan & Park, 2001). The 
improvement in protein stability by using this approach may be very well due to a decrease 
in residue mobility resulting by the polymer (Nischan & Hackenberger, 2014). 
The easiest method that has been used extensively for enzyme stabilisation is reaction 
environment modification. This technique can be applied by adding different additives to the 
enzyme aqueous solution or directly before enzyme lyophilisation. These agents could be 
sugars, inorganic salts or polyols. It was found that these additives increase protein rigidity 
by increasing the hydrophobicity around nonpolar amino acid residues (Stepankova et al., 
2013). Three additives (glycerol, trehalose and sorbitol) were examined for thermolysin 
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stabilisation in the presence of different co-solvents, with trehalose improving the stability 
of thermolysin effectively in the presence of dimethylformamide, while both glycerol and 
sorbitol significantly stabilised the same enzyme in n-propanol and isopropanol. Also, a 60-
fold enhancement in the fungal protease activity in neat organic solvents was reported when 
the enzyme was stabilised using sorbitol and PEG (Debulis & Klibanov, 1993; Pazhang et 
al., 2006).  
 
 
5.8 Tolerance of cytochrome P450 BM-3 to organic co-solvents 
Using P450 BM-3 in industry as a biocatalyst is hindered by some limitations, one of which 
is enzyme inactivation in a medium containing organic solvents. Increased P450 BM-3 
 
Figure 5-2: The advantages and disadvantages of chemical and biological approaches used 
for enzyme engineering 
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applicability requires a better understanding of the mechanism responsible for a loss in 
activity in the presence of co-solvents and enhancing BM-3’s tolerance in such mediums. 
Many experimental studies were focused on investigating this phenomenon (Bailey, 1995; 
Kuper et al., 2007; Roccatano et al., 2005; Wong et al., 2004). The behaviour of cytochrome 
P450 BM-3 in water as well as changes that have been noticed in the wildtype and its mutants 
structures (mainly F87A variant was selected for this purpose) by adding different cosolvents 
and in particular dimethylsulphoxide (DMSO) were extensively analysed (Roccatano et al., 
2005, 2006).   
A 15 ns long molecular dynamic study (MD) simulations in pure water and in 14%  
DMSO/water mixture was reported by Roccata(Roccatano et al., 2005)no and co-worker 
(Roccatano et al., 2005). In general, no major changes were noticed in protein structure in 
both cases. However, the significant variations were found in helices E, F, and G helices as 
well as in EF and FG loops when DMSO was used instead of water.  A higher mobility was 
recorded at the mouth of the active site around Phe42, Arg47, and Tyr51 residues in both 
simulations with more overall average deviations from the original crystal structure when 
DMSO was used (Roccatano et al., 2005). At the same study it was also observed that DMSO 
molecules accumulated on the protein surface increasing the solvent concentration to about 
30-40 % (v/v) and allowing to only one molecule of DMSO to form a hydrogen bond with 
the side chain of Arg47 as can be seen from the density distribution of the DMSO molecules 
around the heme domain at the last 5 ns of the simulation (Figure 5-3). It was found 
previously that both Arg47 and Tyr51 play an essential role in facilitating the access of fatty 
acids substrates to the substrate access channel (SAC) since the mutation of Arg47 and Tyr51 
hamper the binding of fatty acids (Denard et al., 2015; Ost et al., 2000).  
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Figure 5-3: Density distribution of the DMSO molecules around the heme domain. The 
last 5 ns of the trajectory from (Roccatano et al., 2005)was performed to calculate the 
solvent distribution by using a cubic grid with 0.1 nm grid spacing in the GROMACS 
package. The VMD program was used to visualise the averaged volumetric density data  
(Humphrey et al., 1996). The protein is shown in cartoon with the amino acids coloured 
according to their chemical nature (red: acid, blue: basic and green: polar, gray: unpolar). 
Residues Pro45, Ala191 and Arg47 are shown as sticks in the figure. The DMSO high 
density molecules are represented in yellow. This image was acquired with permission 
from (Roccatano, 2015) 
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Generally, mutant Phe87Ala, showed lower tolerance than the WT when the catalytic activity 
was observed in all the considered cosolvents (Wong et al., 2004). The activity of this mutant 
dramatically reduced as the concentration of DMSO increased. At about 14% (v/v) DMSO, 
the WT retained its full activity while the activity of F87A variant decreased to only about 
30% from its original activity (Wong et al., 2004). The low tolerance of this mutant against 
DMSO highlighted the vital role of Phe87 residues in protection the active site from the 
inhibitory effect of DMSO and other solvents because this residue lays in the active site 
cavity and likely prevents solvents from access to the heme cofactor region (Lau et al., 2000). 
The inhibitory effect of the cosolvent on the enzymatic activity is usually caused by the 
elimination of the functional water around the active site of the enzyme causing protein 
denaturation (Lau et al., 2000; Sørensen & Mortensen, 2005). 
The changes in opening of the SAC mouth in the water and in the DMSO were also studied 
and analysed (Roccatano et al., 2005). The entrance opening expanding is usually checked 
by the distance between the Cα of the residues Pro45 and Ala191 (Humphrey et al., 1996). 
A study to measure the SAC opining distance of P450 MB-3 substrate-free structure (PDB 
ID: 1BU7) reported that this distance showed a bimodal distribution with two peaks at about 
0.8 and 1.2 nm, respectively (Roccatano et al., 2005). The crystallographic unit cell of this 
structure contains two chains; A and B and the entrance distance were about 0.87 and 1.09 
nm respectively and it was reduced further to 0.7 for chain A when it was measured in water. 
This closing in the SAC explain the hardness in releasing the substrates from the active site. 
MD Simulation on the Phe87Ala mutant in the same conditions reported that this mutant has 
similar distances as the crystallographic structures for both peaks of the bimodal distributions 
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(Roccatano et al., 2006). MD simulations of the free-substrate wildtype structure (PDB 
ID:1BU7) in 14% (v/v) DMSO/water mixtures concluded the tendency of the protein to retain 
the open SAC in the presence of solvents. On contrary, adding DMSO did not affect the 
shape of the bimodal distribution of the Phe87Ala mutant. However, the presence of DMSO 
shift both peaks to 1.6 and 1.8 nm causing entrance expanding. This widening increases the 
flexibility of the EF helix subdomain the presence of DMSO in comparison to the WT and 
gives more chance to DMSO to access the active site and reducing the catalytic activity of 
the enzyme (Roccatano et al., 2006).  
Another way to identify the changed in protein structure and dynamic behaviour due to the 
solvents effect is the measure of the root mean square deviations (RMSD) and fluctuations 
(RMSF) (Sørensen & Mortensen, 2005). RMSD and RMSF were measured in the presence 
of DMSO in respect the starting crystallographic structure of the WT. A high deviations and 
fluctuations were highlighted in the region of E, F-G helices (Sørensen & Mortensen, 2005).  
To have better understanding of the effect of DMSO on P450 BM-3 activity for both the WT 
and Phe87Ala mutant, both the WT and Phe87Ala heme domain crystal structures permeated 
with low and high concentration of DMSO were determined (Bailey, 1995; Kuper et al., 
2007). The crystals structures of P450 BM-3 were solved after soaking them in 14 % (v/v) 
DMSO (PDB ID: 2J4S) and 28 % (v/v) DMSO/water mixture (PDB ID: 2J1M). Both crystal 
structures do not show large conformation change in comparison to the crystal structure in 
water.  In 2J4S structure, the iron coordinating water molecules displaced to a distance of 
0.377 nm with a nonplanar distortion in the heme region. However, 2J1M structure showed 
a replacement of water molecule by one of DMSO and it was confirmed that this molecule 
coordinates the iron with its sulfur atom. on contrast, high concentration of DMSO caused 
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significant changes in the active site such as increasing the I-helix kinking (Kuper et al., 
2007).  
On the other hand, the Phe87Ala mutant crystal structures of the hemein the presence of 
DMSO concentrations 14% (v/v) (PDB ID: 2X7Y and 28% (v/v) (PDB ID: 2X80) were also 
solved and compared with the WT structures in the same conditions (Bailey, 1995). The 
structure (2X7Y) showed a similar structure as in water solution while a higher RMSD was 
observed in the case of 2X80.  In both structures, a DMSO molecule was found in the active 
site (they were oriented towards the heme iron but not coordinating it) with Fe-ODMSO 
distances of 0.325 and 0.303 nm for the 2X7Y and 2X80, respectively.  
To conclude, in the WT and when the concentration of DMSO is low, the residue Phe87 is 
able to play its role and preventing DMSO from replacing water molecules from the 
coordination site of the iron atom but when the concentration of DMSO increase the chance 
of its molecules to access the SAC increase too.  However, replacing the Phe residue by the 
Ala residue in the Phe87Ala variant facilitate the access of DMSO into the active site even 
in the low solvent’s concentrations.  
 
5.8.1 Mutants of P450 BM-3 F87A and their tolerance to organic co-solvents 
The effect of DMSO and tetrahydrofuran (THF) on the activity of WT P450 BM-3 and its 
mutants was highlighted experimentally by Wong and co-workers (Wong et al., 2004). 
Random mutations were introduced into the P450 BM-3 F87A parents. In the first round, the 
tolerance of 6,520 clones was checked against 22.5% DMSO and 2.8% THF. From this round 
two mutants with multiple solvent resistances were chosen; F87AB5 (T(ACG)235A(GCG); 
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S(AGT) 1024R(AGA)) and F87APEC3 (R(CGC)471C(TGC)). F87AB5 showed 3.7 and 5.3-
fold enhancement at 10% (v/v) DMSO and 2% (v/v) THF respectively so this mutant was 
selected as starting point to the next step which is saturation mutagenesis. This step produced 
a triple mutant F87ASB3 which has significantly higher total activity compared to F87AB5 
in the presence of organic cosolvents. A random mutagenesis was applied again on F87ASB3 
this time generating mutant F87A5F5 (E(GAA)494K(AAA) and R(AGA)1024E(GAG)). 
The specific activity of F87A5F5 is increased 5.5-fold at 10% (v/v) DMSO and 10-fold at 
2% (v/v) THF in comparison to F87A. 
As mentioned above cytochrome P450 BM-3 WT is significantly more tolerance to organic 
cosolvents than the F87A variant. To investigate the effect of F87A mutants on the WT 
resistance, position A87 was mutated back to phenylalanine in the evolved sequences (Wong 
et al., 2004). This back mutation yielded a very tolerant mutant (W5F5 from parent F87A5F5) 
against cosolvents especially DMSO. This final mutant showed 6-fold enhancement against 
25% DMSO and 3.4-fold improvement in 2% THF as well as it is observed that W5F5 is also 
resistance to other cosolvents like acetone, acetonitrile, DMF, and ethanol (Wong et al., 
2004). Due to its outstanding resistance against many organic solvents this back mutant 
(W5F5) was chosen in this project to investigate its tolerance against green solvents and 
compare it to the WT.  
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6 Materials and Methods  
 
6.1 Chemical and biological materials  
All chemicals are of analytical grade or higher quality and purchased from VWR Prolabo 
(Belgium), AppliChem (Germany), Sigma (UK), Merck KGaA (Germany) and Formedium 
LTD (UK). All biological materials used in this project are high quality and purchased from 
Sigma (UK), Complete Mini Roche (UK) and New England BioLab (UK). 
 
6.2 Kits 
QIAprep Spin Miniprep kit (Qiagen, Germany) was used for pETM-11 W5F5 and pETM-
11 WT plasmid extraction.  
 
6.3 Media 
Auto-induction media (Terrific Broth base): To prepare 1 L of media, the following 
chemicals were used: 12 g tryptone, 24 g yeast extract, 3.3 g (NH4)2SO4, 6.8 g KH2PO4, 7.1 
g Na2HPO4, 0.5 g glucose, 2.2 g α-lactose monohydrate, and 0.31 g MgSO4.7H20.  
Auto-induction media (2×TY): 16 g tryptone, 10 g yeast extract, 3.3 g (NH4)2SO4, 6.8 g 
KH2PO4, 7.1 g Na2HPO4, 0.5 g glucose, 2.1 g α-lactose monohydrate and 0.31 g 
MgSO4.7H2O.  
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Auto-induction media (Super Broth base): (NH4)2SO4, 6.8 g KH2PO4, 7.1 g Na2HPO4, 0.5 
g glucose, 2.2 g α-lactose monohydrate and 0.31 g MgSO4.7H20. 
2×TY media: 16 g tryptone, 10 g yeast extract and 5 g NaCl were mixed with deionised 
water to prepare 1 L of media. 
TYE agar media: 10g tryptone, 5g yeast extract, 8 g NaCl and 15 g agar. Kanamycin was 
added when temperature reached 50–60ºC. 
  
6.4 Strains and vectors 
Dr Tuck Seng Wong graciously provided me with pETM-11 vectors encoding the wild type 
P450 BM-3 WT and the modified P450 BM-3 W5F5 genes. The constructs had a kanamycin 
resistance gene to allow selection, polyhistidine tag and TEV-site to facilitate the purification 
process and lac repressor induction control. The E. coli strain DH5α was used for all routine 
cloning experiments, whereas the E. coli strains BL21 (DE3) and C41 (DE3) were used for 
recombinant protein expression. 
 
6.5 P450 BM-3 expression   
A self-replicating circular DNA (pETM11) bearing the sequences coding for the P450 BM-
3 of interest was isolated using a QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany) 
based on the alkaline lysis of bacterial cells. The plasmid DNA was quantified and evaluated 
using a spectrophotometer from Expedeom, UK. Both pETM11-P450 BM-3 WT and 
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pETM11-P450 BM-3 W5F5 plasmids were introduced into E. coli competent cells by 
transformation. In this process, 50 mM CaCl₂ was used to make E. coli cells porous, so they 
could take up foreign DNA. The plasmid (1 mM) was introduced to E. coli BL21 (DE3) or 
C41 (DE3) cells/CaCl₂ mixture and incubated on ice for 10 min before heat shock at 42°C 
for 1 min. Then, the mixture was immediately cooled on ice for 2 min. The cells were 
regenerated with 2×TY media by incubation for 1 hr at 37°C and 200 rpm. The transferred 
cells were then plated on TYE agar plates with 50 µM kanamycin. For validation, the plates 
with plasmid DNA were grown along with a plate of E. coli cells with no plasmid DNA.    
After transformation, protein expression was induced using auto-induction media containing 
a low glucose concentration and a high lactose concentration. By using this technique, both 
the wild type and the mutant of P450 BM-3 were expressed. The expression of P450 BM-3 
W5F5 was optimised using a variety of conditions such as different growth medium and 
various DE3 lysogen E. coli strains. Growth media was supplemented with 50 µg/ml 
kanamycin, 1 mM trace elements and 1 mM δ-aminolevulinic acid before inoculation with 
broth culture. Then, it was incubated for 24 hr at 30°C and 200 rpm. Expression using 
induction agent isopropyl β-D-1-thiogalactopyranoside (IPTG) was also investigated; the 
media was left to grow at 37°C until the OD 600 reached ~0.6, then expression was induced 
using 1 mM IPTG. The solution was incubated overnight (typically 12–16 hr) at 30°C and 
200 rpm, before the cells were harvested by centrifugation at 4°C and 6000 rpm for 5 min. 
The pellets were stored at -20°C for later use. 
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6.6 Protein purification using affinity chromatography  
The ÄKTA pure system from EG Healthcare, Germany was used for all protein purification 
during this project. E. coli cell pellets with P450 BM-3 variants were resuspended in 
equilibration buffer (buffer A1: 50 mM NaH2PO4, 200 mM NaCl, pH 8). The solution was 
supplemented with one tablet of the proteinase inhibitor and 1 mM of DNase and RNase. 
Bacterial lysis was performed via ultrasonication (Sonics Vibra Cell VCX 130, Sonics, USA) 
on ice for a total of 5 min (10 sec bursts and 20 sec cooling time) and 70% AMPL. Cell debris 
was eliminated by centrifugation (60 min, 6000 rpm, 4°C). The supernatant was filtered 
through a 0.45 µm filter to produce a clarified cell lysate. Then, protein purification was 
performed by affinity chromatography. Firstly, the 5 ml HisTrap prepacked column from GE 
Healthcare (Germany) was pre-equilibrated using buffer A1, then the filtrated sample was 
loaded and the desired protein was eluted using a gradient of buffer B1 (buffer A1 plus 250 
mM imidazole, pH 8) to buffer A1. Finally, the fractions with the desired protein were pooled 
for the next step of purification. For optimisation, different elution times (10 min, 20 min and 
40 min) at a constant flow rate of 2 ml/min were applied. 
   
6.7 Ion exchange chromatography 
The fractions with the desired protein from the affinity step were reloaded into the ion 
exchange step (IEX) to separate targeted protein as well as to concentrate the fraction volume 
to a volume suitable for the next step (gel filtration). Two buffers were used in this step, 
equilibration buffer (buffer A2: 100 mM Tris-HCl, pH 8) and elution buffer B2 (buffer A2 
plus 2 M NaCl, pH 8). Fractions with the desired protein from the affinity step were diluted 
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8 times using buffer A2 to reduce the NaCl concentration from 300 mM to 37.5 mM and then 
loaded onto the ion exchange column pre-equilibrated with buffer A2. Finally, the desired 
protein was eluted using step elution (100% of buffer B2). Two different types of ion 
exchange columns were used for optimal purification, DEAE and super Q. The same steps 
were performed for each column, column washing, sample loading and sample elution. The 
fractions with desired protein were pooled for the next purification step. 
6.8 Gel filtration chromatography (size exclusion chromatography) 
The fractions with the desired concentrated protein from ion exchange chromatography were 
transferred to a 320 ml Hiload 26/600 Superdex 200 pg gel filtration column. The column 
was pre-equilibrated with 1.5 column volume (CV) of buffer C (50 mM Tris-HCl, 1mM 
EDTA, 10% (v/v) glycerol, pH 7.2). Then, the concentrated sample (up to 5 ml) was loaded 
onto the column and circulated buffer washed out proteins sequentially from a large to small 
volume. The flow rate used during this step was no more than 1.5 ml/min. Samples are eluted 
isocratically from a SEC column, using a single buffer system.  
 
6.9 SDS-PAGE electrophoresis  
Purified proteins were analysed using SDS-PAGE electrophoresis. A 10% acrylamide-SDS 
gel was used for the analysis throughout the experiments due to the high molecular weights 
of the proteins expressed. The gel was prepared in two layers, the lower part (resolving gel) 
was prepared first and left to solidify for one hour before adding the upper layer (stacking 
gel). After 30 min, 5 μl of PageRulerTM unstained broad range protein ladder (Thermo 
Fisher) and 10 μl of samples were loaded. Electrophoresis running conditions were 200 V, 
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400 A for 60 min. Commassie Brilliant Blue was added to stain the gel and a gel 
documentation system was used to capture the gel picture.     
 
6.10 Large-scale expression and purification 
After optimising the expression and purification of P450 BM-3 W5F5, the optimum strain, 
media and conditions were applied for the large-scale expression and purification of the wild 
type and mutant proteins (400 ml). For expression, the BL21 (DE3) strain was used to 
inoculate the SB AIM at 30°C for 24 hr. For protein purification, three chromatography steps, 
affinity, ion exchange and gel filtration, were used in their optimum conditions to produce a 
high yield of the desired purified P450s.  
 
6.11 Spectroscopic measurement 
In order to define the spectral features of P450 BM-3 WT and P450 BM-3 W5F5, the spectra 
of purified P450s were measured between 250–750 nm using a UV-3100PC 
spectrophotometer (VWR, USA). Both proteins were diluted with buffer (50 mM Tris-HCl, 
1 mM EDTA and 10% v/v glycerol, pH 7.2) using a 3:1 dilution rate. The spectra obtained 
were used to evaluate the purity of the wild type and the mutant variant by calculating the 
Reinheitzahl value (RZ) (RZ is a ratio of P450 heme absorbance at 418 nm to the absorbance 
of all proteins in the solution at 280 ratio nm). The purest fractions by this criterion were 
stored for further use.  
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6.12 Enzyme concentration quantification  
The protein concentration was calculated from the spectra using the Beer-Lambert law 
according to the following equation: 
 
 
 
Where, A is the absorbance at 280 nm (A = -log (It/Io) = -log (T)), where It is the radiant flux 
transmitted by that material, Io is the radiant flux received by that material and T is the 
transmittance of that material), ε is the extinction coefficients in M-1 cm-1 at 280 nm measured 
in water, L is the length of path the light passes through in cm and C is the protein 
concentration in M. 
 
6.13 Enzymatic assay via NADPH consumption 
The activity of purified P450 BM-3 WT and P450 BM-3 W5F5 enzymes was evaluated by a 
NADPH consumption assay. For evaluation of the activity of the P450s, 1 ml volume of the 
reaction mixture contained 100 mM potassium phosphate buffer (pH 7), 800 µM lauric acid 
and 0.5% (v/v) P450 BM-3 W5F5 or P450 BM-3 WT. The reaction was induced by adding 
250 µM NADPH and the fatty acid oxidation was measured by monitoring the absorption 
change at 340 nm. This assay was applied to the solvent-free medium as well as reaction 
media containing different concentrations of 1-butanol, 2-butanol, and dimethyl carbonate to 
assess the proteins’ tolerance towards different green solvents by calculating the relative 
   𝑨 = 𝜺𝑳𝑪    ……….…………………….        (Equation 6.1) 
  
87 
 
activity ratio (relative activity is the ratio of specific activity in the presence of organic co-
solvent to that in the absence of organic co-solvent). The P450-BM-3 wild type relative 
activity was compared to the mutant variants. Trace amounts of methanol used to dissolve 
the substrate were not taken into account.  
To ensure that the activity which has been shown by P450s variants is not due to the effect 
of these solvents on the protein structure, the spectra of the free-solvent protein and the 
spectra in the presence of different solvents was compared within the wavelengths 250–750 
nm to identify any change such as red or blue shifts in the Soret band as a result of adding 
these solvents.      
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7 Tolerance of cytochrome P450 BM-3 to non-
conventional solvents  
 
7.1 Optimisation of protein expression and purification 
7.1.1 Expression and purification of P450 BM-3 mutant using E. coli C41(DE3) 
P450 BM-3 W5F5 was expressed by using TB AIM depending on metabolism changes, that 
is, the switch from glucose to lactose. In the absence of lactose, the E. coli RNA polymerase 
that transcribes mRNA for protein production cannot bind to the promotor sequence because 
the repressor lac I links to the promotor and prevents T7 RNA polymerase expression. After 
switching to lactose, the latter will bind to lac I and make it fall off. Therefore, T7 RNA 
polymerase will be transcribed and translated, and the targeted protein will be expressed 
(Ramos et al., 2004). 
Firstly, E. coli C41 (DE3) strain was used for W5F5 expression. This strain was reported as 
superior as a host for protein overexpression (Miroux & Walker, 1996). After expression, 
cell pellets were centrifuged, filtrated and lysed as described in section 6.6. Then, the protein 
was purified by affinity chromatography. In this project, pETM-11W5F5 and pETM-11WT 
were designed to express a protein with a histidine tag in its C-terminus to facilitate the 
protein purification process. The histidine tag is a highly efficient tool for recombinant 
protein purification using affinity chromatography because it does not require prior 
knowledge about the biochemical properties of the protein. The targeted protein separates in 
this method depending on the tag ability to interact reversibly with a ligand linked to a 
chromatography medium, metal ions (Ni2+) within an immobilised metal chelate, which has 
the ability to link to the histidine tag of P450 BM-3 (Janson & Rydén, 1989). From the 
  
89 
 
chromatogram in Figure 7-1 A, the desired protein can be distinguished by the increase of 
UV absorption at 280 nm, which can be seen as a blue peak in fraction 5 and 6 at 
approximately 50% (v/v) of the elution buffer.  
Purified protein was analysed using 10% SDS-PAGE electrophoresis. This technique 
separates proteins depending on the mobility of molecules, which is a function of their length 
and mass-to-charge ratio. SDS was used to linearise the proteins and give them a negative 
charge. When an electric field was applied across the gel, the negatively charged proteins 
migrated towards the anode at the bottom of the electrophoresis tank, with the distance 
depending on their size, so small protein molecules moved easily down the gel, while the 
larger molecules were trapped in the gel closer to the cathode (Rath et al., 2009). 
 Figure 7-1 B, Lanes 3 and 4 in SDS gel picture showed no P450 BM-3 W5F5 from the 
column during both loading and the washing process, indicating successful binding between 
the column matrix and the desired protein. In line 6, P450 BM-3 W5F5 is expressed 
successfully at 118 kDa, but it is combined with a high rate of non-target proteins at lower 
kDa values. The high level of impurities prompted attempts to improve the purification 
efficiency as well as investigate the expression using other host cells.  
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Figure 7-1: A. Chromatogram to monitor the purification of P450 BM-3 W5F5 from 
C41 (DE3) by affinity chromatography, 45 ml of sample was loaded onto the His Trap 
5 ml column and the protein was eluted at approximately 50% elution buffer. The 
purification conditions were 2 ml/min flow rate and 100% elution within 10 min. B. 
SDS-PAGE protein analysis, the arrow indicates the P450 BM-3 W5F5 at 118 kDa. 
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7.1.2 The effect of purification duration on protein purity 
It is important to have a balance between resolution and time during purification. 
Furthermore, the purity of the protein depends on the purpose that it is intended for. In a 
functional study, as in this project, a high purification level is required.  Therefore, P450 BM-
3 W5F5 was expressed in C41 (DE3) and purified again using affinity chromatography, but 
this time the elution period was increased from 10 min to 20 min using the same flow rate (2 
ml/min). The protein fractions from this process were checked by SDS-PAGE. By increasing 
the elution period, a slight enhancement in protein quantity was observed, while the level of 
impurities was still high (Figure 7-2). 
7.1.3 Expression and purification of P450 BM-3 mutant using E. coli 
BL21(DE3) 
The expression of P450 BM-3 W5F5 protein was also checked using E. coli BL21 (DE3), a 
common bacterial strain used for P450 expression. The same expression and purification 
conditions for expressed protein in C41 (DE3) were also used with this strain and the results 
are shown in Figure 7-3. By comparing the gel picture of the protein expressed in C41 (DE3) 
with the same protein expressed in BL21 (DE3), it could be observed that the latter is 
preferred due to the high concentration of P450 BM-3 W5F5 produced; however, the protein 
purity still needs to be improved.  
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In an attempt to reach the desired protein purity, the elution period during the affinity step 
was increased from 20 min into 40 min. By slowing down the elution process, the peak in 
the chromatogram seemed to be split into two intersecting peaks (Figure 7-4); peak 1 (lanes 
5) and peak 2 (lanes 6-8). The P450 protein in peak 2 showed a significant improvement in 
terms of purity and concentration. The eluted fractions of peak 2 showed chromatic gradients 
from light yellow to dark red, light red then to light yellow, again referring to the heme 
protein concentration in these fractions (Figure 7-5).    
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Figure 7-2: SDS-PAGE protein analysis of the eluted protein fractions from the affinity 
chromatography step, the arrow indicates the P450 BM-3 W5F5 at 118 kDa. Protein was 
expressed in C41 (DE3) and the elution flowrate was 2 ml/min for 20 min.  
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Figure 7-3: SDS-PAGE protein analysis of the eluted protein fractions from the affinity 
chromatography step, the arrow indicates the P450 BM-3 W5F5 at 118 kDa. Protein was 
expressed in BL21 (DE3) and the elution flowrate was 2 ml/min for 20 min.  
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Figure 7-4: A. Chromatogram monitored during the purification of P450 BM-3 W5F5 
from BL21 (DE3) strain by affinity chromatography, 45 ml of sample was loaded to 
the HiTrap 5 ml column, the Peak represents eluted proteins at about 45% (v/v) elution 
buffer. The purification conditions are: 2 ml/min, 40 min. B. SDS-PAGE protein 
analysis, the arrow indicates the P450 BM-3 W5F5 at 118 kDa 
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7.1.4 Using different expression inducing methods and media for W5F5 mutant 
expression  
Before moving to another purification step, three types of auto-induction media were 
assessed for P450 BM-3 W5F5 expression in E. coli BL21 (DE3), 2×TY AIM, Terrific broth 
AIM (TB AIM) and Super broth AIM (SB AIM). The expression levels were visualised and 
quantified using SDS-PAGE gel analysis. From Figure 7-6, it can be seen that P450 BM-3 
W5F5 expression level from highest to lowest could be achieved by using SB AIM, TB AIM 
and 2×TY AIM. The improvement in the expression gained by using SB AIM may due to 
the richness of this media by tryptone (35 g/l). In addition, the expression using IPTG instead 
of auto-induction media was investigated for P450 BM-3 production, but the protein showed 
a very low expression level. The harvested cell pellets of P450 BM-3 W5F5 from the 
expression using 50 ml 2×TY induced by 1 mM IPTG and the expression using 50 ml SB 
AIM are shown in Figure 7-7 A. The pellet using SB AIM shows a sign of high expression 
Figure 7-5: The chromatic gradients of the protein fractions from the affinity 
purification step from light yellow for low hemoprotein concentration to dark red for 
high hemoprotein concentration.  
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distinguished by the redness of this pellet in comparison to the pellet from the expression 
using IPTG, which was less red in colour.  The low expression by using IPTG was also 
noticed throw the SDS gel image (Figure 7-7 B). 
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Figure 7-6: SDS-PAGE protein analysis using different ALM in BL21 (DE3); 2×TY, TB 
and SB. The expression was taken place at 30°C. The arrow indicates the P450 BM-3 
W5F5 at 118 kDa.  
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7.1.5 Ion exchange chromatography 
The fractions with the desired protein from the affinity purification step were diluted and 
loaded onto the ion exchange column. This technique purifies proteins according to 
Figure 7-7: A. The pellets from the expression of P450 BM-3 W5F5 in E. coli BL21 
(DE3). I. by using 50 ml 2×TY induced by 1 mM IPTG. II. by using 50 ml SB AIM. B. 
SDS-PAGE analysis of the P450 BM-3 W5F5 expressed by using 1 mM IPTG. The protein 
was  purified by affinity chromatography. The purification conditions are: 2  ml/min, 40 
min. The arrow indicates the P450 BM-3 W5F5 at 118 kDa          
(II) 
(I) 
(B) 
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differences in their net surface charge (Janson & Rydén, 1989). Two types of ion exchange 
column were compared for P450 MB-3 W5F5 purification and concentration, DEAE and 
super Q. From Figure 7-8, it can be concluded that the purity of protein did not improve by 
using any of these columns, but the protein was more concentrated using the super Q column. 
These results showed the importance of the addition of a third purification to achieve the 
desired purity. 
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Figure 7-8: SDS-PAGE protein analysis during the purification of P450 BM-3 W5F5 
from BL21 (DE3) strain by using two types of ion exchange  chromatography columns 
I) DEAE 5 ml column II) Q 5 ml column. 40 ml of diluted sample (37.5 mM NaCl) 
was loaded to each column. 100% (v/v) of elution buffer and 2 ml/min were used. The 
arrow indicates the P450 BM-3 W5F5 at 118 kD 
kDa 
212 — 
158 —  
116 — 
97.2 — 
66.4 — 
42.7 — 
27 — 
118 
kDa 
20 — 
  
100 
 
7.1.6 Gel filtration chromatography 
Two proteins were eluted from the first and second purification steps, the desired protein at 
118 kDa and non-target proteins at lower kDa values, approximately 50 kDa. The two 
proteins were different in size and could be separated using gel filtration chromatography 
(size exclusion). In this step, proteins are separated according to differences in their 
molecular size as they pass through a gel filtration medium (Janson & Rydén, 1989). 
During this process, proteins are diluted extensively against buffer C (50 mM Tris-HCl, 1mM 
EDTA, 10% (v/v) glycerol, pH 7.2), consequently, the target protein was expressed using 
100 ml of SB AIM instead of 50 ml and the sample was passed through affinity and ion 
exchange steps before it was ready for gel filtration. In order to check the efficiency of this 
technique for protein purification, 4 ml of the concentrated P450 BM-3 W5F5 solution was 
loaded onto a 320 ml Hiload 26/600 Superdex 200 pg gel filtration column. The 
chromatogram showed two separate peaks, peak 1 for the larger size protein and peak 2 for 
the smaller one. The fractions from both peaks were analysed using SDS-PAGE analysis 
(Figure 7-9). Visualisation of the gel indicated that the two proteins from the previous ion 
exchange column fractions were separated efficiently depending on the difference in size; 
large protein at 118 kDa and a smaller protein at approximately 50 kDa.  
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Figure 7-9: SDS PAGE analysis for the proteins from two peaks of gel filtration 
chromatography.  A. SDS PAGE analysis for the first peak fractions (9 fractions from 8-
16). B. SDS PAGE analysis for the second peak fractions (5 fractions from 20-24). 100 
ml of SB AIM was used to express P450 BM-3 W5F5 at 30 C, the expression period was 
24 hr. Target protein can be distinguished at 118 kDa while other unwanted protein at 
about 50 kDa.  
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7.2 Large-scale expression and purification 
In order to achieve the desired protein concentration for use in the future functional 
investigation, 1200 ml of SB AIM was used to express P450 BM-3 W5F5. The optimum 
expression and purification conditions were performed. The pellets from the large-scale 
expression had a dark red colour, indicating a high expression level (Figure 7-10). The 
chromatograms of the three purification steps and SDS-PAGE gel images are shown in 
(Figure 7-11, Figure 7-12 and Figure 7-13). From the gel picture in Figure 7-13 B, it was 
evident that P450 BM-3 W5F5 was expressed and purified successfully, so could proceed 
with the enzyme activity assessment. The separation of two proteins in the protein solution 
when they passed through gel filtration column is presented in Figure 7-14   
 
 
For comparison purposes, 400 ml of SB AIM was used to express the wild type protein, P450 
BM-3 WT, with the same expression and purification conditions used for the mutant. The 
fractions from the last purification step, gel filtration chromatography, were analysed by 
electrophoresis and the SDS-PAGE gel showed good expression and purification levels 
(Figure 7-15).  
Figure 7-10: P450 BM-3 W5F5 cell pellets from 1200 ml expression culture. Each pellet 
comes from 400 ml expression media (SB AIM). The expression was taken place at 30°C 
and 200 rpm for 24 hr.  
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Figure 7-11: A. Chromatogram monitored during the large scale purification of P450 
BM-3 W5F5 from E. coli BL21 (DE3) strain by affinity chromatography. The elution 
conditions were: 2 ml/min, 40 min. B. SDS-PAGE protein analysis for the first peak 
fractions (7-10) and second peak fractions (15-19) 
(B) 
(A) 
500 - 
1000 - 
        0 - 
60 30 0 ml 
AU 
 Elution buffer 
 Fractions 
 UV 
118 
kDa 
kDa 
250 — 
150 —  
100 — 
70 — 
50 — 
40 — 
30 — 
  
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 
P
ro
tein
 la
d
d
er 
F
ra
ctio
n
 6
 
(T
h
e p
ea
k
) 
F
ra
ctio
n
 7
 
(T
h
e p
ea
k
) 
F
ra
ctio
n
 8
 
(T
h
e p
ea
k
) 
F
ra
ctio
n
 9
 
(T
h
e p
ea
k
) 
F
ra
ctio
n
 1
0
 
(T
h
e p
ea
k
) 
Figure 7-12: A. Chromatogram monitored during the large scale purification of P450 
BM-3 W5F5 from E. coli BL21 (DE3) strain by ion exchange chromatography. The 
more pure fractions from affinity run (15-22) were loaded into super Q column. The 
elution conditions were: 2 ml/min, step elution. B. SDS-PAGE protein analysis for 
the peak fractions 6-10 
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Figure 7-13: A. Chromatogram monitored during the large scale purification of P450 
BM-3 W5F5 by gel filtration chromatography. B. SDS-PAGE protein analysis for the first 
peak fractions 13-18 and second peak fraction 33. The elution conditions were: 1.5 
ml/min, step elution. 
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(A) (B) 
Figure 7-14: Protein purification by using gel filtration chromatography.  A. the loaded 
sample before separation. B. two bands can be noticed due to proteins separation  based 
on the difference in size 
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Figure 7-15: SDS-PAGE protein analysis of the large scale purification of P450 BM-3 
WT by gel filtration chromatography for the first peak (fractions 15-19) and the second 
peak (fraction 33). The elution conditions were: 1.5 ml/min, step elution. 
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7.3 Water miscibility of solvents 
Six solvents are considered green according to the GSK classification in 2010, 1-butanol, 2-
butanol, butyl acetate, isopropyl acetate, propyl acetate and dimethyl carbonate. Before 
beginning the enzyme activity assay in the presence of these solvents, the solubility and 
miscibility of these solvents in water were checked depending on the information provided 
by PubChem; the online database tool of chemical molecules. According to the PubChem 
(https://pubchem.ncbi.nlm.nih.gov), butyl acetate, propyl acetate and isopropyl acetate are 
water immiscible with a very low solubility in water; 14 g/L, 18.9 g/L and 29 g/L (at 20 °C) 
respectively. On the other hand, the moderate solubility of 1-butanol, 2-butanol and dimethyl 
carbonate; 68 g/L, 181 g/L and 138 g/L respectively has increased the miscibility of these 
solvents. Different concentrations of these solvents 0–25% (v/v) were mixed with 100 mM 
potassium phosphate buffer (pH 7) and incubated for 30 min at RT. After the incubation 
period, the solutions were examined visually to indicate any separation in phases. Figure 7-16 
shows that 1-butanol, 2-butanol and dimethyl carbonate were partially miscible in buffer, 
showing good miscibility at low concentrations, from 0–10% (v/v), however 1-butanol and 
dimethyl carbonate became immiscible at concentrations ≥ 15% (v/v) while 2-butanol stay 
miscible up to 20% (v/v). Depending on these results and to ensure homogenous reaction 
environment, P450s activity was investigated using no more than 10% (v/v) of the green 
solvents.  
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Figure 7-16: Miscibility of three green solvents: A. 1-butanol B. 2-butanol and C. 
dimethyl carbonate in 100 mM potassium phosphate buffer (pH 7). The solution started 
to show turbidity at concentrations ≥ 15% (v/v) of 1-butanol and ≥ 20% (v/v) of 2-
butanol while the immiscibility of dimethyl carbonate became clear through the biphasic 
at concentrations equal or greater than15 % (v/v).  
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7.4 Effects of solvent on optical spectra 
To check the features of the purified wildtype and its mutant W5F5, the UV-visible 
absorption properties of spectra at 250–750 nm were assessed. For both proteins, the spectral 
feature of the heme were clearly evident. The Soret band had a maximum absorption at 420 
nm, with alpha/beta bands at 564 nm and 531 nm respectively, as shown in Figure 7-17. In 
addition, the purity of enzymes was evaluated by the RZ values (light absorbance at 420 nm 
for hemoprotein/light absorbance at 280 nm for total protein content in the solution). RZ 
values were 0.69 and 0.59 for the parents and the mutant respectively. After that, the spectra 
of the enzyme-solvent solutions were examined. There were no significant optical changes 
observed when these solvents were added to the P450 BM-3 WT and its mutant W5F5, as 
shown in Figure 7-18 to Figure 7-23. These results confirm that all green solvents used in 
this project do not affect the P450s structure or cause any blue shifts (as substrate) or red 
shifts (as inhibitor). Consequently, no interaction between these solvents and heme cofactor 
was observed through optical spectra scanning.  
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Figure 7-17: Spectra measurement of the purified enzyme. The scanning applied for the 
wavelengths between 250-750 nm. A. P450 BM-3 W5F5. B.  Wildtype P450 BM-3 WT. 
The Soret bands of both the wildtype and the mutant W5F5 are shown at 420 nm and 
the alpha/beta bands at 564 nm and 531 nm respectively.  
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Figure 7-18: Effect of 5% (v/v) dimethyl carbonate on the spectra of P450 BM-3 W5F5. 
Light absorbance was checked between 300-800 nm to detect any interaction between the 
solvent and the heme cofactor of the protein.The concentration 5%(v/v) of dimethyl 
carbonate was chosen as this was the maximum concentration that used for P450 activity 
evaluation.   
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Figure 7-19: Effect of 2.5% (v/v) 1-butanol on the spectra of P450 BM-3 W5F5. Light 
absorbance was checked between 300-800 nm to detect any interaction between the 
solvent and the heme cofactor of the protein.The concentration 2.5%(v/v) of 1-butanol was 
chosen as this was the maximum concentration that used for P450 activity evaluation.   
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Figure 7-20: Effect of 3.5% (v/v) 2-butanol on the spectra of P450 BM-3 W5F5. 
Light absorbance was checked between 300-800 nm to detect any interaction between 
the solvent and the heme cofactor of the protein.The concentration 3.5% (v/v) of 2-
butanol was chosen as this was the maximum concentration that used for P450 activity 
evaluation.   
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Figure 7-21: Effect of 5% (v/v) dimethyl carbonate on the spectra of P450 BM-
3 WT. Light absorbance was checked between 300-800 nm to detect any 
interaction between the solvent and the heme cofactor of the protein.The 
concentration 5%(v/v) of dimethyl carbonate was chosen as this was the 
maximum concentration that used for P450 activity evaluation 
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Figure 7-22: Effect of 2% (v/v) 1-butanol on the spectra of P450 BM-3 WT. Light 
absorbance was checked between 300-800 nm to detect any interaction between the solvent 
and the heme cofactor of the protein.The concentration 2%(v/v) of 1-butanol was chosen 
as this was the maximum concentration that used for P450 activity evaluation 
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7.5 Effects of protein dilution on protein stability 
In this part of the project, different quantities of the enzyme were assessed to select an 
enzyme concentration which is able to perform in a range in which the plot of NADPH 
consumption versus time is linear when all other factors, including temperature, substrate 
concentration, reaction time and volume, are fixed. It can be seen from Figure 7-24 that 0.5% 
(v/v) W5F5 gave a high catalytic activity as well as a linear light absorbance within 60 sec. 
The concentration of 0.5% (v/v) was also used for the wildtype. The possibility of enzyme 
Figure 7-23: Effect of 2.5% (v/v) 2-butanol on the spectra of P450 BM-3 WT.  Light 
absorbance was checked between 300-800 nm to detect any interaction between the 
solvent and the heme cofactor of the protein.The concentration 3.5% (v/v) of 2-butanol 
was chosen as this was the maximum concentration that used for P450 activity evaluation 
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denaturation over the experimental time was also assessed. Enzyme activity using two 
dilution ratios, 33.33% and 3.33%, were examined over a 6-hr experimental time period. 
High dilution of enzyme caused a significant decrease in enzyme activity from 100% to 69% 
after 6 hr, while decreasing the dilution ratio to 3.33% maintained the enzyme activity at a 
high rate of approximately 100%. This could be very well due to enzyme monomerisation 
which may be happened as a result of the excessive dilution (Whitehouse et al., 2012)(see 
Figure 7-25).  
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(A) 
(B) 
Figure 7-24: P450 BM-3 W5F5 concentration selection. A. NADPH 
consumption rate within different enzyme concentration (% v/v). B. Absorbance  
at 340 nm within 60 second using 5% (v/v) enzyme concentration. This 
absorbance indicates the decrease in NADPH quantity in the reaction mixture 
with time due to the reaction activity.  
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Figure 7-25: Relative activities of P450 BM-3 W5F5 variant as a function of time at two 
dilution ratios. Relative activity in this experiment is the ratio of specific activity at any time 
during the experiment to that at time zero 
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7.6 Tolerance of P450 BM-3 wildtype and W5F5 mutant to 1-butanol, 2-
butanol and dimethyl carbonate 
 
In order to examine the tolerance of P450 BM-3 WT and its mutant W5F5, the relative 
activity of these enzymes was calculated in the absence and presence of three green solvents: 
1-butanol, 2-butanol and dimethyl carbonate. A continuous assay was applied to record the 
NADPH consumption at 340 nm per second. NADPH absorbs UV light exclusively in its 
reduced form and shows no absorption in oxidised forms at 340 nm. So, the decrease in 
NADPH concentration can be followed spectrophotometrically at 340 nm within the reaction 
period, and the enzyme activity is evaluated depending on this property (Noble et al., 1999) 
However, this assay was applied for 300 sec, but only the initial rates of the activity (60 sec) 
were used for the relative activity calculation. The relative activities of the purified parents 
and mutant in the presence of green solvents are presented in Figure 7-26, Figure 7-27 and 
Figure 7-28. Compared to wildtype, variant W5F5 showed a slight improvement in activity 
in 1-butanol and 2-butanol, but in general, the relative activity in these solvents was low, 
falling sharply to zero at co-solvent concentrations between 2–3.5% (v/v). Figure 7-28 
indicates that variant W5F5 can tolerate significantly higher concentrations of dimethyl 
carbonate than the parent. The variant W5F5 showed approximately 128% relative activity 
in 5% (v/v) dimethyl carbonate in comparison to 30% (v/v) for the wild type. In contrast, 6% 
(v/v) dimethyl carbonate seems to be a critical value as the relative activity at this value is 
drastically reduced to approximately 80% (v/v) for the mutant variant.    
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Figure 7-26: Relative activities of P450 BM-3 W5F5 variant and WT as a 
function of 1-butanol concentration. Relative activity in this experiment is the 
ratio of specific activity at any time during the experiment to that at time zero 
Figure 7-27: Relative activities of P450 BM-3 W5F5 variant and WT as a 
function of 2-butanol concentration. Relative activity in this experiment is the 
ratio of specific activity at any time during the experiment to that at time 
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Figure 7-28: Relative activities of P450 BM-3 W5F5 variant and WT as a function of 
dimethyl carbonate concentration. Relative activity in this experiment is the ratio of 
specific activity at any time during the experiment to that at time  
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7.7 Conclusion  
Cytochrome P450 BM-3 WT and its mutant W5F5 were successfully expressed in two E. 
coli strains, C41(DE3) and BL21(DE3). The characteristic red colour of the cell pellet reflects 
the ability of these strains to produce the heme cofactor. Although it is reported that 
C41(DE3) is superior for overexpression of seven recombinant proteins (Miroux & Walker, 
1996) the yield of protein was higher in BL21(DE3). Aiming to optimise the expression of 
W5F5 variant, many expression factors were examined, such as induction methods and 
media, with the results revealing that the auto-induction media was preferable over using 
IPTG to induce the expression and the SB AIM was the best media for high protein 
expression levels.  
In the preparation of microsomal monooxygenases for the functional study, the purity of 
protein is a vital issue. Three different steps were applied to achieve efficient separation of 
P450s: affinity chromatography, ion exchange chromatography and gel filtration 
chromatography (size exclusion). The purification efficiency of affinity chromatography step 
was increased by increasing the elution period from 20 min to 40 min, which slowing down 
the elution and increasing the efficiency of the purification process . This step was able to 
eliminate the majority of impurities from the crude protein extract. However, P450 BM-3 
W5F5 was accompanied by a protein at lower kDa (approximately 50 kDa) as shown in 
Figure 7-4. The second purification step (ion exchange chromatography) in addition to 
improving protein purity, was utilised to concentrate the protein and reduce the protein 
fraction size to an acceptable level for the next step. The final step (gel filtration) aims to take 
advantages of the different physical properties of the proteins in the solution, in particular 
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different sizes. This step offered an excellent level of purity, with complete removal of the 
undesired protein (Figure 7-9).      
Many parameters were checked prior to the investigation of the wild type and the mutant 
P450s’ tolerance towards green solvents, such as the effect of these solvents on protein 
spectra and whether they interact with the heme cofactor of P450 BM-3 through scanning the 
protein spectra in the presence of these solvents, green solvent miscibility in water and the 
effect of dilution on protein activity. The activity evaluation of P450 BM-3 showed that the 
variant W5F5 is more tolerant than the wild type towards all green solvents tested. This is in 
agreement to a report by Wong and co-workers (2004), when they functionally compared 
this mutant with the wild type in the presence of many organic co-solvents classified as 
orange and red according to the GSK classification in 2010 (Wong et al., 2004). When the 
effect of these three green solvents on enzyme activity was investigated, it is found that the 
impact of 1-butanol and 2-butanol on both WT and W5F5 was high. The enzyme activity 
dropped to zero at solvent concentrations between 2-3.5% (v/v). In contrast, the variant 
W5F5 showed a significantly high tolerance against dimethyl carbonate; 128.5% relative 
activity at 5% (v/v) solvent concentration in comparison to 30% relative activity for the wild 
type at the same dimethyl carbonate concentration (Figure 7-28). The behaviour of the W5F5 
variant in the presence of dimethyl carbonate is similar to its previously reported behaviour 
towards DMSO. Wong and co-workers recorded about 110% relative activity of the variant 
W5F5 at 5% (v/v) DMSO, but W5F5 remained active up to 25% (v/v) by using the later 
solvent, while it started to drop at 6% (v/v) dimethyl carbonate. This may be due to the 
immiscibility of dimethyl carbonate which was observed at 10% (v/v) and above.              
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P450s from Cupriavidus necator H16 
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8 Introduction to Cupriavidus necator H16 
(Ralstonia eutropha H16) 
 
8.1 Cupriavidus necator H16 
Cupriavidus necator H16 is a Gram-negative bacterium found in both freshwater and soil, 
which multiplies by binary fission. It is a mesophilic rod-shaped bacteria, which in contrast 
to many other Gram-negative bacteria, is not pathogenic. This bacterium belongs to the order 
Burkholderiales, class Betaproteobacteria and it was isolated 60 years ago from soil near 
Goettingen, Germany (Alagesan et al., 2018). Cupriavidus necator H16 attracted the 
attention of bioscientists due to its ability to utilise a wide range of substrates and produce 
large quantities of polyhydroxyalkanoate (PHA), the biodegradable plastic with a wide range 
of applications (Pohlmann et al., 2006).    
It was previously known as Hydrogenomonas eutropha, Wautersia eutropha, Alcaligenes 
eutrophus and Ralstonia eutropha, possibly due to its ability to utilise a variety of materials 
as nutrient sources. Recently, due to its high resistance to copper and genomic similarity with 
Cupriavidus necator strains, it was officially named as Cupriavidus necator H16, but many 
researchers contain to use Ralstonia eutropha in their articles (Lu et al., 2016; Vandamme & 
Coenye, 2004). In comparison to other family members, C. necator H16 represents one of 
the larger bacterial genomes, with a total size of 7,416,677 bp, the sizes of other members lie 
between 5.8 and 8.6 Mbp (Holden et al., 2004; Nierman et al., 2004; Salanoubat et al., 2002).   
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8.2 Genome 
The C. necator H16 genome consists of two chromosomes and one megaplasmid: 
“chromosome 1 (4,052,032 bp), chromosome 2 (2,912,490 bp) and megaplasmid pHG1 
(452,156 bp)”. The G+C content is nearly identical in chromosome 1 and chromosome 2, 
with the proportion of coding regions almost the same in both chromosomes. C. necator H16 
genome has 59 transfer RNA (tRNA) genes, the majority of which (51) are carried on 
chromosome 1, the reset genes are distributed as seven on chromosome 2 and one on the 
plasmid (pHG1). Five ribosomal RNA (rRNA) operons were reported in C. necator H16 
genome, three on chromosome 1, two on chromosome 2. In addition, seven out of fourteen 
insertion elements are located on pHG1. From the gene distribution analysis of this organism, 
it was observed that the majority of key functions are located on chromosome 1, including 
DNA replication, transcription and translation, while chromosome 2 represents a refuge for 
many major reactions, such as aromatic compound decomposition, and utilisation of nitrogen 
sources as alternative nutrients. Nonetheless, all three replicons carry genes responsible for 
the synthesis of chemotaxis proteins and cell appendices (Pohlmann et al., 2006).  
   
8.3 Metabolism and substrate utilisation 
Over last 30 years, C. necator H16 was extensively studied because of its ability to produce 
PHA bioplastic on an industrial scale. This bacterium metabolises a wide range of organic 
substrates such as starch, fatty acids, tricarboxylic acid cycle intermediates, alcohols, polyols 
and sugars. Recently, agricultural residues were also investigated as substrates for this 
bacterium. In addition to the traditional organic substrate, C. necator H16 can also grow 
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autotrophically, it has the ability to use oxygen, hydrogen and carbon dioxide as alternative 
nutrients and energy sources (Lu et al., 2016). 
8.3.1 Lithoautotrophic metabolism 
C. necator can digest both carbon dioxide and formate (HCO2
−) as carbon and energy sources 
via the Calvin-Benson-Bassham cycle (CBB). Lithoautotrophic/organoautotrophic 
metabolism can occur even under heterotrophic conditions. CO2 is fixed by specified 
enzymes encoded in two cbb operons on chromosome 2 and pHG1, these operons are 
activated by a LysR-type transcriptional regulator (CbbR) located on chromosome 2. It 
became clear from the results of many studies that C. necator can induce CO2 utilisation 
whenever required, but the roles of the cbb regulator and the positive effector (reduced 
metabolite) are as yet unclear and require further investigation (Bowien & Kusian, 2002). 
Two enzymes were reported for carbon fixation in C. necator: carbonic anhydrase (CA) and 
ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO). Four types of CA enzymes 
achieve efficient carbon fixation, encoded by the genes can, can2, caa and cag. Each gene 
plays a different role in CO2 fixation. Can has important role in cell growth under 
atmospheric CO2 as well as providing RuBisCO with CO2. Caa helps in trapping the CO2 
inside the cell by converting it into more soluble bicarbonate when it passes through the cell 
membrane. The position of caa in the periplasm and being the favoured substrate for CO2 
helps this enzyme to perform its function. The functions of cag and can2 have not been fully 
elucidated, but it is thought that can2 helps in controlling the pH levels and cag could also 
work to supply CO2 to RuBisCO. The second fixation enzyme is RuBisCO, this enzyme 
contributes to CO2 fixation when two molecules of 3-phosphoglycerate are formed as a result 
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of the spontaneous split of an unstable intermediate (ribulose-1,5,-bisphosphate) during 
carbon fixation (Lu et al., 2016).   
8.3.2 Heterotrophic carbon metabolism 
C. necator H16 uses numerous organic components for heterotrophic growth as a carbon 
source. Fatty acids and lipids, when they are used as carbon sources by C. necator H16, gave 
more energy per mole carbon than any other source for carbon. Triacylglycerols from fatty 
acids cannot be metabolised directly by this bacterium, first they have to be digested by the 
extracellular lipase LipA into glycerols and free fatty acids. Chromosome 1 carries genes 
coding for the metabolism of organic acids, while chromosome 2 carries three genes coding 
for enzymes responsible for the degradation of 2-ketogluconate, glucosaminate, glucose and 
fructose. C. necator H16 has two sets of β-oxidation pathway genes (Embden-Meyerhoff-
Parnas and the oxidative pentose phosphate pathways), both of which are vital for the cell 
growth. Moreover, the fatty acyl-CoA intermediates from these pathways contribute to the 
production of PHA from oils and fats (Pohlmann et al., 2006).  
In contrast to many microorganisms, C. necator H16 is unable to digest many carbohydrates. 
Sugar as carbon source is restricted in the wild type of this bacterium to fructose, gluconate, 
xylose and N-acetyl-d-glucosamine (NAG), while the engineered variants of this organism 
have the ability to utilise glucose (Brandt et al., 2012; Holder et al., 2011; Raberg et al., 
2012).  
Cellulosic biomass is also reported as a carbon source for this bacterium. Wheat was used 
for PHB production as well as levulinic acid (refining cellulosic biomass) applied as a carbon 
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source. Recently, hydrolysed sago starch and sugarcane bagasse were used successfully to 
produce PHA (Koutinas et al., 2007; Wang et al., 2013; Yu & Stahl, 2008).  
An interesting source of carbon for C. necator H16 is the aromatic compounds like phenol 
and benzoate. The ability of this organism to metabolise the organic compounds (known 
environmental pollutants) could make it a potential tool for environmental pollution 
treatment in the future (Johnson & Stanier, 1971; Pohlmann et al., 2006).  
Engineered C. necator H16 can utilise some unique substrates as carbon sources. A short 
chain alcohol like ethanol has been converted to PHA when used by a C. necator variant. In 
addition, the by-products from various industries were used by different variants of this 
bacterium to produce PHA, including lactate, acetate, C2 α-hydroxy acid glyoxylate, 
glycolate and unprocessed crude glycerol (Lu et al., 2016). Figure 8-1 shows the difference 
in technique between the lithoautotrophic and the heterotrophic metabolism.  
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8.3.3 Anaerobic metabolism    
C. necator is able to grow under anaerobic conditions by using nitrogen compounds as an 
electron acceptor instead of oxygen. This denitrification process can be achieved by four 
reductase enzymes encoded on the pHG1: “Nitrate (NO3−) is sequentially reduced to nitrite 
(NO2
−), nitric oxide (NO), and nitrous oxide (N2O), respectively, by nitrate reductase (NAR), 
nitrite reductase (NIR), nitric oxide reductase (NOR), and nitrous oxide synthase (NOS)”. It 
was suggested that sulphur also could be used as an alternative terminal electron acceptor 
Figure 8-1: Cupriavidus necator H16 metabolism systems to digest different types of 
substrates and produce polyhydroxyalkanoate (PHA) A. Lithoautotrophic metabolism, 
when the bectrium uses different organic components for growth as a carbon source B. 
heterotrophic metabolism, the digestion of both carbon dioxide and formate (HCO2
−) as 
carbon and energy sources via the Calvin-Benson-Bassham cycle (CBB). of This image 
acquired with permission from (Pohlmann et al., 2006). 
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under anaerobic conditions through the sulphur reduction pathway. However, the genome 
sequence of C. necator H16 does not contain enzymes that form the sulphur reduction 
pathways such as “ArsRtype transcription regulator, sulphur dehydrogenase, sulphur-
chelating/binding complex, thiosulfate-oxidising complex, and sulphate thioesterase”, so 
reducing sulphur instead of nitrogen has not proved to date (Lu et al., 2016; Pohlmann et al., 
2006).  
 
8.4 Potential industrial applications 
The ability of Cupriavidus necator H16 to metabolise diverse carbon sources and produce 
many value-added compounds means it represents an excellent microbial factory. In 
particular, this bacterium attracted bioscientists’ interest due to its ability to produce and store 
many types of biopolymer, such as hydroxyhexanoate (PHH) and hydroxybutyrate (PHB), 
under stress conditions like nitrogen limitation or non-carbon nutrient starvation (Brigham et 
al., 2012). PHA represents an outstanding biodegradable replacement for petroleum-based 
polymer (as an example of PHA, chemical structure of PHB is presented in Figure 8-2).  
 
 
 
 
 
Figure 8-2: Structure of poly-(R)-3-hydroxybutyrate (PHB), a type of 
polyhydroxyalkanoate. The structure is generated by using ChemBioDrwa Ultra 
(http://www.perkinelmer.com/ chemdraw)   
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PHA polymers have a wide range of applications in packaging, agricultural and waste 
treatment, and disposable household products but the most impressive application is in the 
medical sector to manufacture many items such as surgical meshes, implants, sutures and 
scaffolds (Brigham & Sinskey, 2012; Lu et al., 2016). Many different types of monomers can 
be synthesised by C. necator H16, each with different thermal and mechanical properties: I) 
short chain monomer (C3-C5), (scl) PHA such as homopolymer (PHB); II) medium-chain 
monomers (C6-C12), (mcl) PHA and III) combination of scl and mcl monomers (scl-co-mcl 
PHA). Due to its advantageous properties and similarity to petroleum-based plastics scl-co-
mcl, PHAs from engineered C. necator H16 became the goal of production (Lu et al., 2016).   
C. necator was also used to produce non-alcohol biofuel when PHA was converted into 
methyl esters by an acid-catalysed hydrolysis. Free fatty acids, which can also be converted 
to methyl esters, were produced from engineered C. necator with inactivated PHB 
biosynthesis and β-oxidation pathways. This strain was also able to produce another fuel, 
methyl ketone (Chen, 2009; Müller et al., 2013; Torella et al., 2013). Another engineered 
strain of this bacterium, with no PHA production genes, has been shown to produce 
isobutanol and isopropanol by redirecting the extra energy produced as a result of PHA gene 
elimination (Lu et al., 2016).  
Each hydroxyalkanoate monomer has a chiral centre on the carbon atom with two functional 
groups, a hydroxyl group and a carboxyl group (see Figure 8-2), which enable the bacterium 
to produce different fin chemicals like perfumes, vitamins and antibiotics (Gao et al., 2011). 
The monomer unit, (R)-3-hydroxybutyric in the PHB is an essential element for the 
production of antibiotics from C. necator. In starving conditions, there are seven 
depolymerases in this bacterium responsible for the hydrolysis of PHB into (R)-
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hydroxyalkanoate acid monomers without any in vitro hydrolysis step. (R)-hydroxyalkanoate 
precursors are also produced by the elimination of the PHA synthase genes from C. necator, 
which allows the production and direct isolation of (R)-hydroxyalkanoates. The ability of C. 
necator to synthesise multi-monomer lengths of PHA increases the chance to produce 
different hydroxyalkanoate chiral compounds (Lee & Lee, 2003). In addition, the ability of 
C. necator to digest different types of organic compounds makes it an outstanding biological 
tool for bioremediation. This bacterium was used successfully to clean up soils from two 
pollutants, p-nitrophenol and 2,4-dichlorophenoxyacetic acid (Chen et al., 2004; Watanabe, 
2001).  The ability of C. necator H16 to produce different value-added chemicals is 
demonstrated in  Figure 8-3  
 
Figure 8-3: Scheme explaining the ability of C. necator H16 to metabolise and produce a 
variety of materials. The substrates are in red color and the products are in green. . 
 
 
  
136 
 
8.5 Summary of known cytochrome P450 enzymes from Cupriavidus sp. 
The genome sequence study of many Cupriavidus sp led to the identification of numerous 
genes which were classified as cytochrome P450 enzymes according to the BLAST database. 
Cytochrome P450 enzymes were distinguished in many Cupriavidus sp such as Ralstonia sp. 
GA3-3, Cupriavidus sp. SK-4, Cupriavidus sp. UYPR2.512, Cupriavidus sp. IDO and 
Cupriavidus sp. taiwanensis (for the full list of P450s from Cupriavidus sp., go to BLAST 
(www. blast.ncbi.nlm.nih.gov)).  
Although, the genome sequence analysis of many Cupriavidus sp. identified cytochrome 
P450 as a part of these sequences and gave information about the genome sequence of P450, 
to date only one characterisation study published in 2012 analysed the spectroscopic, 
biochemical and catalytic properties of a member of the Cupriavidus sp, CYP116B1 from 
Cupriavidus metallidurans (Warman et al., 2012).     
CYP116B1 is a redox partner fusion enzyme in which the electrons are typically derived 
from NAD(P)H and are delivered to the P450 by the iron-sulphur centre (2Fe-2S) and FMN. 
A spectrophotometric scanning of this enzyme showed the feature of P450 with a Soret 
maximum at 418 nm and alpha/beta bands at 566 and 532 nm, respectively. The scattering 
of light indicated that CYP116B1 is a monomer enzyme (Warman et al., 2012). Three 
unsaturated fatty acids (palmitoleic, myristoleic and arachidonic acids) showed a substrate-
protein binding feature (Type I) but the protein was unable to oxidise these fatty acids. 
However, this protein showed catalytic activity towards two herbicides, S-propyl 
dipropylthiocarbamate (vernolate) and S-ethyl dipropylthiocarbamate (Warman et al., 2012).  
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The following chapters (chapters 9-11) present the first report of the modelling, cloning, 
expression, purification, spectroscopic, substrate binding possibility and activity evaluation 
of four C. nectar H16 P450 enzymes (H16_B2406, H16_B1743, H16_B1279 and 
H16_B1009).   
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9 Methods and Materials  
9.1 Chemicals 
All chemicals are of analytical grade or higher quality and purchased from VWR Prolabo 
(Belgium), AppliChem (Germany), Sigma (UK), Merck KGaA (Germany) and Formedium 
LTD (UK). All biological materials used in this project are in high quality and purchased 
from Sigma (UK), Roche (UK) and New England BioLab (UK). The devises, kits and media 
used in this part of the thesis were mentioned in sections 6.2-6.3.   
 
9.2 Strains and vectors 
Dr Tuck Seng Wong and Dr Kang Lan Tee graciously provided four pETM-11 vectors 
encoding four P450 genes: H16_B2406, H16_B1743, H16_B1279 and H16_B1009. Each 
construct has a kanamycin resistance gene to allow selection, polyhistidine tag and TEV-site 
to facilitate the purification process and lac repressor induction control. The E. coli strain 
DH5α was used for all routine cloning experiments, while E. coli strains BL21 (DE3) and 
C41 (DE3) and HMS 174 (DE3) were used for recombinant protein expression. 
9.3 Identification, sequence alignment and structure modelling of novel 
putative P450s in the Cupriavidus necator H16 genome 
Although the protein genome sequences of four P450s from Cupriavidus necator H16 (CYP-
H16-B2406, CYP-H16-B1743, CYP-H16-B1279 and CYP-H16-B1009) were reported, 
there was a lack of detailed information regarding sequence analysis, sequence alignment or 
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3D protein structure. Many online tools were used for P450s characterisation and structure 
modelling, a list of these tools and their functions and websites were presented in Table 9-1.  
Expasy ProtParam online tool analysis was used to determine the detailed information about 
P450s such as predicted molecular weight, theoretical pI and extinction coefficient, which 
are important for protein expression and purification. For each protein sequence, a list of 
homologues that share a high level of similarity with its most closely related sequence was 
achieved using BLAST sequence alignment analysis and the top homologue sequences were 
chosen and subjected to the Clustal W online alignment tool. Prosite, another online tool was 
used to identify the motifs and the fingerprint sequences for the four proteins.   
In the absence of structural data, a modelling study was performed to produce predicted 
structures of four P450s from C. necator H16 using two online tools; SWISS MODEL and 
Phyre. SWISS MODEL was used to build the heme domain of all P450 while the later was 
applied for modelling the reductase domains of B1279 and B1009. Same procedure was 
followed by using both tools. Firstly, sequences of proteins were submitted to both servers 
(SWISS MODEL and Phyre2). Next, models with the best hit by each tool was chosen for 
heme and reductase domains. Then, the quality of the 3D models was verified by using 
VERIFY 3D and the final models were visualised by using PyMol 2.2 program.  The heme 
of the crystal structure of the templates were used to build the heme cofactor of the four 
P450s models. For further qualification of the predicted models, the 3D structure of each 
protein was superimposed with the crystal structure of the templet that used to build this 
model to determine the match between each model and its template. As well as the overall 
root mean deviation (RMSD) between each model and its template was calculated using 
PyMol 2.2. In addition, sequences alignment between models and their templates were 
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checked by Pairwise ClustalW alignment tool and the hydrophobic residues that bound to the 
heme in each heme domain were highlighted in the sequence alignment and labelled in the 
structure pictures. Furthermore, heme domain 3D models that produced by using SWISS 
MODEL were compared by models suggested by Phyre for the same heme domain in case 
the templates that suggested by these two servers are different. In order to extend our 
knowledge of these proteins, a detailed analysis of the intact enzymes was also applied using 
the SnapGen programme.     
 Table 9-1: List of software tools for C. necator H16 P450s modilling and their functions 
and links of the websites.  
 
Software tool Function Link 
BLAST 
To compare proteins 
sequences and determine the 
closest sequences to a protein 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?
PROGRAM=blastp&PAGE_TYPE=Bla
stSearch&LINK_LOC=blasthome 
ClustalW To find sequences alignment 
https://embnet.vital-
it.ch/software/ClustalW.html 
 
Expasy ProtParam 
To determine the protein 
sequence of unknown 
nucleotides 
http://web.expasy.org/protparam/ 
Phyre 2 
Create prediction of protein 
structure based on sequence 
alignment and existing protein 
crystal structure data 
http://www.sbg.bio.ic.ac.uk/~phyre2/ht
ml/page.cgi?id=index 
 
PROSITE 
To identify fingerprint 
sequence motifs of proteins 
https://prosite.expasy.org/ 
 
Protein Data Bank 
(PDB) 
To obtain structure 
information of the previously 
crystalized protein 
http://www.rcsb.org/pdb/home/home.do 
PyMol 
3D protein model 
investigation and imaging 
https://www.pymol.org/ 
SnapGene 
To identify plasmid sequence 
features 
http://www.snapgene.com/ 
 
SWISS MODEL 
Create prediction of protein 
structure based on sequence 
alignment and existing protein 
crystal structure data 
https://swissmodel.expasy.org/ 
 
  
141 
 
9.4 Cloning of Cupriavidus necator H16 P450 enzymes  
Four genes from Cupriavidus necator H16_B2406, H16_B1743, H16_B1279 and 
H16_B1009, were cloned and transferred into the expression vector pETM11 by Dr Kang 
Lan Tee using the standard molecular biology techniques of PCR, DNA digestion, ligation, 
transformation and isolation. The resultant colonies were verified by DNA sequencing. A 
QIAprep Spin Miniprep kit was used to isolate four high purity plasmids, pETM11-H16-
B2406, pETM11-H16-B1743, pETM11-H16-B1279 and pETM11-H16-B1009, from DH5α 
cells. The concentrations and purities of these plasmids were measured by 
spectrophotometry. 
 
9.5 Protein expression and purification 
Four BL21 (DE3) cultures were grown overnight and each one was transformed with one of 
the Cupriavidus necator H16 P450 vectors using the CaCl2 heat shock method for pETM11-
P450 BM-3 transformation (see section 6.5). For Cupriavidus necator H16 P450 expression, 
Traffic Broth AIM was supplemented with 50 µg/ml kanamycin, 1 mM trace elements and 1 
mM δ-aminolevulinic acid before inoculation with 1:200 BL21 (DE3) overnight culture and 
incubated at 30°C for 16–18 hr. Then, the cells were harvested by centrifugation at 4°C and 
6000 rpm for 5 min and cell pellets were stored at -20°C. The frozen pellets were thawed in 
50 mM potassium phosphate buffer, lysed chemically using lysozyme and analysed for 
protein expression and solubility by SDS-PAGE electrophoresis. The molecular weights, IPs 
and the extension coefficients of the four proteins were calculated by the ProtParam 
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programme and these molecular weights were used to identify the target protein bands in the 
SDS-PAGE gel.      
The optimal purification conditions for P450 BM-3 were applied during the purification of 
the four P450s from Cupriavidus necator H16. Pellets from 50 ml expression culture were 
lysed physically by sonication, centrifuged, filtrated and loaded onto the affinity column 
(HisTrap). The column was pre-equilibrated in buffer A1 (50 mM NaH2PO4, 200 mM NaCl, 
pH 8), then the targeted protein was eluted using a gradient of buffer A1 to buffer B1 (buffer 
A1 plus 250 mM imidazole, pH 8). Fractions with the desired proteins were then pooled and 
analysed by SDS-PAGE electrophoresis to evaluate protein expression and purity after 
purification and specify the possibility of moving to another purification step. Protein 
features and concentrations were checked after the affinity step by spectra measurement at 
250–300 nm as described previously.  
9.5.1 Expression optimisation of B1279 and B1009 
Proteins that were lowly expressed (B1279 and B1009) were optimised under a variety of 
conditions (growth medium, growth temperature and DE3 lysogen E. coli strains BL21 
(DE3) and C41 (DE3)). Each protein was expressed in twelve different expression conditions 
as shown in Figure 9-1. After analysis, the optimal expression conditions were applied to 
produce 50 ml of B1279 and B1009, and the affinity purification was repeated to compare 
these results with the previous results before optimisation.  
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Figure 9-1: The expression optimisation of H16-B1279. Two E. coli strains were used;  
BL21(DE3) and C41(DE3), each strain was used to express P450 protein in three different 
AIM; 2×TY, TB and SB at two expression tempuratures; 25°C and 30°C.  
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9.5.1.1 B1009 expression  
The expression of B1009 was investigated to obtain a sufficient quantity for functional 
studies. In addition to previous expression trials which were performed using two E. coli 
strains BL21 (DE3) and C41 (DE3) under a variety of conditions, B1009 expression using 
E. coli HMS174 (DE3) strain was investigated. The isolated plasmid pETM11-H16-B1009 
was introduced to pre-cultured HMS174 (DE3) supplemented with 200 µg/ml rifampicin (10 
mg/ml stock concentration in 67% methanol and 0.17 N NaOH) and 30 µg/ml kanamycin 
(30 mg/ml stock concentration) by transformation using CaCl₂ with a heat shock method. 
For protein expression, a single clone from HMS174 (DE3) pETM-11-H16-B1009 was 
selected and grown overnight in 5 ml of 2×TY media supplemented with 200 µg/ml 
rifampicin and 30 µg/ml kanamycin. The expression was examined using two different 
induction methods, auto-induction media (SB) and IPTG. Standard protocols for the 
expression using both AIM and IPTG were followed in this experiment, with only a deviation 
in the stock concentration of kanamycin (30 mg/ml was used instead of 50 mg/ml which had 
been used for the expression using both BL21 (DE3) and C41 (DE3)). The expression was 
investigated at two expression temperatures, 25°C and 30°C and the results were analysed 
for concentration, purity and solubility using SDS-PAGE electrophoresis.  
    
9.6 Large-scale expression and purification 
The expression was scaled up to 400 ml for three Cupriavidus necator H16 P450 enzymes 
(B2406, B1743 and B1279), which showed high expression in the small-scale production. 
The optimal expression conditions and the same protocol for the small-scale expression were 
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performed. Protein concentrations were checked visually depending on the pellet colour and 
protein bands on the SDS gel. The same affinity purification conditions that were applied in 
the small-scale purification were used with the large scale. Fractions from the affinity step 
with the desired proteins were pooled, diluted with buffer A2 (100 mM Tris-HCl, pH 8) and 
loaded onto the ion exchange column (Q-super) pre-equilibrated with buffer A2. P450 
proteins were concentrated and eluted using step elution of buffer B2 (buffer A2 plus 2 M 
NaCl, pH 8). Concentrated proteins were then subjected to gel filtration to de-salt and 
separate proteins according to their sizes.   
9.7 Spectroscopic measurement 
The purified P450 proteins (B2406, B1743 and B1279) were identified optically by scanning 
the UV-visible spectra between 250 to 800 nm in a 1-cm path length cuvette using an UV-
3100PC spectrophotometer from VWR (USA). Protein samples were diluted in buffer C (50 
mM Tris-HCl, 1mM EDTA, 10% (v/v) glycerol, pH 7.2) using 3:1 (v/v) as a dilution rate. 
The spectra obtained were also used to indicate protein purity by calculating the RZ ratio.  
 
9.8 Enzyme concentration estimation 
The Beer-Lambert law was used as before (equation 6.1) to calculate the initial 
concentrations of the Cupriavidus necator H16 P450 proteins using the spectra at 280 nm, 
path length in cm and the extinction coefficient in M-1 cm-1 at 280 nm. 
  
  
146 
 
9.9 Purification optimisation of B1279  
Different purification strategies were investigated in an attempt to enhance the concentration 
of the purified B1279. First, to overcome protein loss during the ion exchange process, this 
step was omitted so that the purest fractions of the desired protein from the affinity step were 
then purified by gel filtration. Secondly, gradient elution was used instead of step elution in 
the ion exchange step to check the purity after this step and decide if it was possible to skip 
the final step (gel filtration), especially as the protein was diluted extensively at this stage. 
Also, the concentration of imidazole was increased in the elution buffer in the first 
purification step (affinity) from 250 mM to 500 mM to increase the quantity of eluted protein 
from this step. In addition, ultrafiltration of the purified protein after the final purification 
step (gel filtration) was investigated. Finally, B1279 was expressed on a large scale using 
C41 (DE3) and purified to compare the results with that expressed in BL21 (DE3).  
 
9.10 Substrate binding 
Analysis of interactions of three P450s from Cupriavidus necator H16 (B2406, B1743 and 
B1279) with a range of saturated fatty acids, unsaturated fatty acids, aromatic component and 
herbicides was applied by a progressive titration in buffer C (50 mM Tris-HCl, 1mM EDTA, 
10% (v/v) glycerol, pH 7.2). List of components used in this experiment are shown in Table 
9-2. Spectra were scanned between 300–800 nm after the addition of each substrate. 
Titrations were carried out at RT and substrates were dissolved either in MilliQ water, 
methanol or DMSO, with the final concentration of all substrates in solution being no more 
than 1000 µM, except vernolate which was increased up to 2000 µM. Spectra for the titration 
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of the methanol-P450 and DMSO-P450 complex were assessed for any denaturation in the 
protein structure as a result of the addition of the solvents.     
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Table 9-2: Protocol and materials were used in substrate binding experiment.  
 
 
 
 
 
 
  
Component Negative control 
for B2406 & 
B1743 (µl) 
Positive control 
for B2406 & 
B1743 (µl) 
Negative control 
for B1279 (µl) 
Positive control 
for B1279 (µl) 
(1)* Buffer 245 245 95 95 
(2)** Substrate I, 
II 
0 0.5, 1, 1.5, 2 then 
0.5 µl was added 
every run 
0 0.5, 1, 1.5, 2 then 
0.5 µl was added 
every run 
(3)*** Enzyme 750 750 900 900 
Total volume 995 995.5, 996, 
996.5… 1000 
995 995.5, 996, 
996.5…. 1000 
*Component (1): 50 mM Tris/HCl buffer, 1 mM EDTA, pH 7.2.  
**Component (2): I) 0.1 M of: a) lauric acid, MW 200.32 g/mole, 0.2 g was dissolved in 10 ml of 
methanol; b) myristic acid, MW 228.38 g/mole, 0.23 g was dissolved in 10 ml of methanol; c) 
palmitic acid, MW 256.42g/mole, 0.26 g was dissolved in 10 ml of methanol d) malonic, MW 148.03 
g/mole, 0.15 g was dissolved in 10 ml of MilliQ water; e) adipic acid, MW 146.14 g/mole, 0.15 g 
was dissolved in 10 ml of DMSO; f) indole, MW 117.15 g/mole, 0.12 g was dissolved in 10 ml of 
DMSO; g) naphthalene, MW 128.17 g/mole, 0.13 g was dissolved in 10 ml of DMSO; h) 3-
phenoxytoluene, MW 184.24 g/mole, density 1.05 g/ml, 175 µl was dissolved in 10 ml of DMSO; i) 
butyric acid, MW 88.11 g/mole, density 0.96 g/ml, 91 µl was dissolved in 10 ml of MilliQ water; j) 
EPTC, MW 189.32 g/mole, density 0.96 g/ml, 19.7 µl was dissolved in 1 ml of methanol. II) 0.4 M 
vernolate, MW 203.34 g/mole, density 0.954 g/ml, 85 µl was dissolved in 1 ml of methanol.  
***Component (3): B2406 or B1743 proteins 
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9.11 Enzymatic assay via NADPH or NADH consumption 
Activity of the Cupriavidus necator H16-B1279 was tested using the NADPH and NADH 
consumption assay; this assay technique was explained previously in section 6.13. The total 
reaction volume was 1 ml and assay was performed at RT. The reaction mixture consisted of 
four basic components: I) reaction buffer (50 mM Tris/HCl, 1 mM EDTA, pH 7.2); II) 
substrates, 100 mM stock concentration of all substrates (butyric acid, myristic acid, 3-
phenoxytoluene, lauric acid, naphthalene, EPTC, malonic, adipic acid, indole, palmitic acid) 
was used except for vernolate, 400 mM stock concentration was used; III) B1279 purified 
protein, 100 nM was used as the total enzyme equivalent concentration, and V) the induction 
factors either 250 µM NADPH or 200 µM NADH final concentrations were used to start the 
reaction. These components were mixed according to the order and concentrations shown in 
Table 9-3. 
The induction factors were added 5 seconds after the reaction start. The substrates 
concentrations were chosen taking into consideration the miscibility of the fatty acid 
solutions in the reaction buffer. Two different solvents in addition to water were used, 
methanol and DMSO, and trace amounts of these solvents used to dissolve the substrates 
were disregarded from calculations.  
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Table 9-3: Protocol and components used for B1279 activity evaluation 
 
 
 
 
 
Component Negative control 
(µl) 
Positive control 
(µl) 
Positive control 
concentrations 
(µM) 
(1) Activity buffer 840 
837.5* 41.90 
835** 41.75 
830*** 41.50 
(2) Substrate 0 
2.5* 250 
5** 500 
10*** 1000 
(3) Enzyme 60 60 0.1 
(4) NADPH/NADH 100 100 250/200 
Total volume 1000 1000 
* Myristic acid, palmitic acid or 3- phenoxytoluene., 
**Lauric acid or naphthalene 
***Adipic acid, butyric acid, indol, malonic acid, EPTC or vernolate 
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10 Genetic analysis and structure modelling of 
putative cytochrome P450s from Cupriavidus 
necator H16 
 
10.1 Identification and sequence alignment of the genome of novel 
putative P450s 
By using Expasy ProtParam analysis, essential information for each P450 expression analysis 
and purification was determined. The detailed information of P450-H16-B2406, P450-H16-
B1743, P450-H16-B1279 and P450-H16-B1009 are presented in Table 10-1.   
Table 10-1: Expasy ProtParam analysis for recombinant B2406, B1743, B1279 and B1009. 
 B2406 B1743 B1279 B1009 
Number of amino acids 
405 429 810 1126 
Molecular weight (kDa) 
42.13 48.15 90 123 
Total negatively 
charged residues (Asp + 
Glu)  
37 61 110 126 
Total positively charged 
residues (Arg + Lys)  
30 47 85 112 
Extinction coefficient  
(M-1 cm-1 at 280 nm 
measured in water)  
42315 55015 95310 127365 
Theoretical pI 
6.08 5.90 5.75 6.15 
Estimated half-life  
 
30 hours (mammalian reticulocytes, in vitro). 
>20 hours (yeast, in vivo). 
>10 hours (Escherichia coli, in vivo). 
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BLAST analysis gave many homologous sequences to all P450s from Cupriavidus necator 
H16. The top two closest relatives in BLAST were selected and subjected to ClustalW tool 
analysis for sequence alignment of B2406, B1743, B1279 and B1009 (Figure 10-1 to Figure 
10-4). Furthermore, the CYP 116 B1 sequence was also compared with the four P450 
sequences. This protein showed 82%, 75% and 55% identity with B1279, B1009 and B2406 
respectively and is the only protein from Cupriavidus sp. that has been characterised 
(Warman et al., 2012).  
The motifs and the fingerprint sequences of four P450 sequences were identified using 
PROSITE, the online tool, to achieve a better understanding of their structure and activity. 
By using this tool, (FGHGRHACPG), (FGVGVHRCLG), (FGYGSHQCMG) and 
(FGNGERACIG) in the N-terminal of B2406, B1743, B1279 and B1009 respectively, 
matched the PROSITE consensus motif (FGXGXXXCXG) which represents the cytochrome 
P450 cysteine heme iron ligand and the cysteine residue is the heme iron fifth ligand (Minerdi 
et al., 2015).  
The C-terminal region of P450-H16-B1279 showed sequence homology to reductase proteins 
as it contains three basic functional parts an FMN binding domain, a NADH binding domain 
and a ferredoxin-like [2Fe2S] domain. Sequence SRGGS of B1279 corresponded to the 
PROSITE consensus FMN binding motif [G/S]RGGS, while GIGITP corresponds to the 
consensus motif GXGXXP for NADH binding. Another signature sequence is represented 
by the [2Fe2S] ferredoxin motif CXX[G/A]XC[G/A/S/T]XC which is represented as 
CEEGLCGSC in this protein (Minerdi et al., 2015). Three of the four cysteines involved in 
binding the iron-sulphur cluster are located in the [2Fe2S] motif, while the fourth one is 
residue CYS 792. The results from the sequence analysis of B1279 showed that this protein 
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is a catalytically self-sufficient cytochrome P450 enzyme composed of a heme and a 
reductase domain.  
B1009 sequence analysis via PROSITE indicated that this protein is also a self-sufficient 
cytochrome P450 enzyme because of the presence of both a heme domain and reductase 
domain. Cys463 represents the fifth cysteine heme ligand, while the reductase domain 
consists of a flavodoxin-like domain (FLAVODOXIN_LIKE) and ferredoxin reductase-type 
FAD binding domain (FAD_FR).   
 
 
necator H16    1 MKHHHHHHPMSDYDIPTTENLYFQGAHMPDTDIDPLSAVTHPDPYPYYRELAASQPFFRD 
SK-4           1 ---------------------------MPDTDIDPLSAVTHPDPYPYYRELAASQPFFRD 
UYPR2.512      1 -----------------------------DTDIDPLSAVTHPDPYPYYRELAASQPFFRD 
metallidurans  1 ---------------------------------DPLSAVTHPDPYPYYRELAASQPFFRD 
                                                  *************************** 
nactar           DRLGLWVAAGPQEVADVLAHSDCRVRPPAQPVPPALAGTAAGELFGRLVRMNDGAAHAPL 
SK-4             DRLGLWVAAGPQEVADVLAHSDCRVRPPAQPVPPALAGTAAGELFGRLVRMNDGAAHAPL 
UYPR2.512        DRLGLWVAAGPQEVADVLAHSDCRVRPPAQPVPPALAGTAAGELFGRLVRMNDGAAHAPL 
Cupriavidus      DRLGLWVAAGPQEVADVLAHSDCRVRPPAQPVPPALAGTAAGELFGRLVRMNDGAAHAPL 
                 ************************************************************ 
nactar           KALLMPMLAGID---PAAAAQRATVLAAVLDAGEASWAAMSGECINRWLFTLPVVTVADL 
SK-4             KALLMPMLAGID---PAAAAQRATVLAAVLDAGEASWAAMSGECINRWLFTLPVVTVADL 
UYPR2.512        KALLMPMLAGID---PAAAAQRATVLAAVLDAGEASWAAMSGECINRWLFTLPVVTVADL 
Cupriavidus      KALLMPMLAGI---DPAAAAQRATVLAAVLDAGEASWAAMSGECINRWLFTLPVVTVADL 
                 ***********    ********************************************* 
nactar           LGLPVAN--EGSSAAEAAQRVAAFAGAQSPLADAPAVRAGAEAAQWLGHWLADAADG--- 
SK-4             LGLPVAN--EGSSAAEAAQRVAAFAGAQSPLADAPAVRAGAEAAQWLGHWLADAADG--- 
UYPR2.512        LGLPVAN--EGSSAAEAAQRVAAFAGAQSPLADAPAVRAGAEAAQWLGHWLADAADG--- 
Cupriavidus      LGLPVA--NEGSSAAEAAQRVAAFAGAQSPLADAPAVRAGAEAAQWLGHWLADAAD---- 
             ******   *********************************************** 
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nactar           -AGPLPALRQAARAAGIDAQAVAANIIGLLVQACEATAALAGNTLLRLGRDTTQSGLPLD 
SK-4             -AGPLPALRQAARAAGIDAQAVAANIIGLLVQACEATAALAGNTLLRLGRDTTQSGLPLD 
UYPR2.512        -AGPLPALRQAARAAGIDAQAVAANIIGLLVQACEATAALAGNTLLRLGRDTTQSGLPLD 
Cupriavidus      GAGPLPALRQAARAAGIDAQAVAANIIGLLVQACEATAALAGNTLLRLGRDTTQSGLPLD 
                  *********************************************************** 
nactar           AVVARVAREDPPVQNTRRFLAADAQLCGHAVKAGDAVLVLLAAASCS-GAAASERPWTFG 
SK-4             AVVARVAREDPPVQNTRRFLAADAQLCGHAVKAGDAVLVLLAAASCS-GAAASERPWTFG 
UYPR2.512        AVVARVAREDPPVQNTRRFLAADAQLCGHAVKAGDAVLVLLAAASCS-GAAASERPWTFG 
Cupriavidus      AVVARVAREDPPVQNTRRFLAADAQLCGHAVKAGDAVLVLLAAASCS-GAAASERPWTFG 
                 *********************************************** ************ 
nactar           HGRHACPGDRLAQALAAATVAALRARGADPAALAQAFRYRPSLNARIPHFLSTOP 405 
SK-4             HGRHACPGDRLAQALAAATVAALRARGADPAALAQAFRYRPSLNARIPHF----- 374 
UYPR2.512        HGRHACPGDRLAQALAAATVAALRARGADPAALAQAFRYRPSLNARIPHFL---- 372 
Cupriavidus      HGRHACPGDRLAQALAAATVAALRARGADPAALAQAFRYRPSLNARIPHFLST-- 380 
        ************************************************** 
 
Figure 10-1: Amino acid sequence alignment of P450-H16_B2406 with other P450s from 
Cupriavidus sp. The key residues are marked as following: the conserved heme in green, 
the fifth ligand of heme (cysteine) in red. (*) indicating similar identity, (.) is for strongly 
similar residues and (:) to indicate weak similarity. The alignment was produced by using 
data from BLAST and ClustalW online tool. 
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C.necator H16         MKHHHHHHPMSDYDIPTTENLYFQGAHMTDTNQHALLHDGYDLLSDHYVQEAHALWRDIR 
C.IDO                 ---------------------------MTDTNQHALLHDGYDLLSDHYVQEAHALWRDIR 
Actinobacteria        ----------------------------------------YDLLSDHYVQEAHALWRDIR 
P.fungorum            ---------------------------MTDTNQHALLHDGYDLLSDHYVQEAHALWRDIR 
                                                              ******************** 
C.necator H16         SSGCPVAHSEKWGGSWLPTTYDDIHHVAQNPAVFSSRAAEIAGEVPPQGSG-LVLPPLTS 
C.IDO                 SSGCPVAHSEKWGGSWLPTTYDDIHHVAQNPAVFSSRAAEIAGEVPPQGSG-LVLPPLTS 
Actinobacteria        SSGCPVAHSEKWGGSWLPTTYDDIHHVAQNPAVFSSRAAEIAGEVPPQGSG-LVLPPLTS 
P.fungorum            SSGCPVAHSEKWGGSWLPTTYDDIHHVAQNPAVFSSRAAEIAGEVPPQGSG-LVLPPLTS 
                      *************************************************** ******** 
C.necator H16         DPPDHKIHRDLLEPYFTPARVAAIEPYAQSLARDLARRVAVKGEADLGEDYSKPFVLSLL 
C.IDO                 DPPDHKIHRDLLEPYFTPARVAAIEPYAQSLARDLARRVAVKGEADLGEDYSKPFVLSLL 
Actinobacteria        DPPDHKIHRDLLEPYFTPARVAAIEPYAQSLARDLARRVAVKGEADLGEDYSKPFVLSLL 
P.fungorum            DPPDHKIHRDLLEPYFTPARVAAIEPYAQSLARDLARRVAVKGEADLGEDYSKPFVLSLL 
                      ************************************************************ 
C.necator H16         TRFLDVPDDRQERFMDWAIRVLKYGPFDQELRKAAFDEAFADLEQLLKEREQDPGEDLVS 
C.IDO                 TRFLDVPDDRQERFMDWAIRVLKYGPFDQELRKAAFDEAFADLEQLLKEREQDPGEDLVS 
Actinobacteria        TRFLDVPDDRQERFMDWAIRVLKYGPFDQELRKAAFDEAFADLEQLLKEREQDPGEDLVS 
P.fungorum            TRFLDVPDDRQERFMDWAIRVLKYGPFDQELRKAAFDEAFADLEQLLKEREQDPGEDLVS 
                      ************************************************************ 
C.necator H16         HIALATIDGKPISRKHRIGSLLLAVLAGADTTWNALNASLNHLADHPADRATLINEPGLL 
C.IDO                 HIALATIDGKPISRKHRIGSLLLAVLAGADTTWNALNASLNHLADHPADRATLINEPGLL 
Actinobacteria        HIALATIDGKPISRKHRIGSLLLAVLAGADTTWNALNASLNHLADHPADRATLINEPGLL 
P.fungorum            HIALATIDGKPISRKHRIGSLLLAVLAGADTTWNALNASLNHLADHPADRATLINEPGLL 
                      ************************************************************ 
C.necator H16         RTTAVEELLRFYAPLSIARVTTEEVELKGRCIGAGERVILAYPAANRDPAVFENPDEVQL 
C.IDO                 RTTAVEELLRFYAPLSIARVTTEEVELKGRCIGAGERVILAYPAANRDPAVFENPDEVQL 
Actinobacteria        RTTAVEELLRFYAPLSIARVTTEEVELKGRCIGAGERVILAYPAANRDPAVFENPDEVQL 
P.fungorum            RTTAVEELLRFYAPLSIARVTTEEVELKADTTWNALNASLNHLADHPADRATLINEPGLL 
                      ****************************.     . .. * : * :    .    :   * 
C.necator H16         DRKRNRHLTFGVGVHRCLGSHLARMEMRVAIEEWLKAIPNFERIS-GAVKWSAGNARGPE 
C.IDO                 DRKRNRHLTFGVGVHRCLGSHLARMEMRVAIEEWLKAIPNFERIS-GAVKWSAGNARGPE 
Actinobacteria        DRKRNRHLTFGVGVHRCLGSHLARMEMRVAIEEWLKAIPNFERIS-GAVKWSAGNARGPE 
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P.fungorum            RTTAVEELLRFYAPLSIARVTTEEVELKVAIEEWLKAIPNFE-RISGAVKWSAGNARGPE 
                        .  ..*    .          .:*::**************    ************** 
C.necator H16         NVRIRVVSTOP  
C.IDO                 NVRIRVV---- 
Actinobacteria        NVRIR------ 
P.fungorum            NVRIRV----- 
                      *****       
 
Figure 10-2: Amino acid sequence alignment of P450-H16_B1743 with other P450s from 
Cupriavidus sp. The key residues are marked as following: the conserved heme in green, 
the fifth ligand of heme (cysteine) in red. (*) indicating similar identity, (.) is for strongly 
similar residues and (:) to indicate weak similarity. The alignment was produced by using 
data from BLAST and ClustalW online tool. 
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C.necator            MKHHHHHHPMSDYDIPTTENLYFQGAMANPSPSAARSGCPIDHSALTAPNGCPVSHNAAQ 
F.nantongensis       ---------------------------MTISATGAARGCPIDHSTLAAPNGCPVSHNAAQ 
B.UYPR2.512          --------------------------MANPSPSAARSGCPIDHSALTAPNGCPVSHNAAQ 
C.metallidurans      --------------------------MPQTNAPASSGSCPIDHSALRAPNGCPVSHQAAA 
                                                    .  :   *****.:: *********:**  
C.necator            FDPFGDGYQQDPPEYVRWSREQEPVFYSPRLGYWVVTRYEDIKAIFRDNLTFSPSIALEK 
F.nantongensis       FDPFGDGYQQDPPEYVRWSREQEPVFYSPQLGYWVVTRYDDIKAIFRDNLTFSPSIALEK 
B.UYPR2.512          FDPFGDGYQQDPPEYVRWSREQEPVFFSPRLGYWVVTRYQDIKAIFRDNLTFSPSIALEK 
C.metallidurans      FDPFEDGYQQDPPEYVRWSRAQEPVFYSPKLGYWVVTRYDDIKAIFRDNITFSPSIALEK 
                     **** *************** *****:**:*********:*********:********** 
C.necator            ITPTGDEANAVLASYGYAMNRTLVNEDEPAHMPRRRALMAPFTPAELAHHEPLVRRLARE 
F.nantongensis       ITPTGDEANAVLASYGYAMNRTLVNEDEPAHMPRRRALMAPFTPAELAHHEPLVRRLTRE 
B.UYPR2.512          ITPTGDEANAVLASYGYAMNRTLVNEDEPAHMPRRRALMAPFTPAELAHHEPLVRRLARE 
C.metallidurans      ITPTGEAANAVLASYGYAMNRTLVNEDEPAHMPRRRALMEPFTPAELAHHEPMVRKLTRE 
                     *****: ******************************** ************:**:*:** 
C.necator            YVDRFIDDGRADLVDQMLWEVPLTVALHFLGVPEEDMDLLRQYSIAHTVNTWGRPKPEEQ 
F.nantongensis       YVDRFIDDGRADLVDQMLWEVPLTVALHFLGVPEEDMDLLRQYSIAHTVNTWGRPKPEEQ 
B.UYPR2.512          YVDRFIDDGRADLVDQMLWEVPLTVALHFLGVPEEDMDLLRQYSIAHTVNTWGRPKPEEQ 
 
C.metallidurans      YVDRFIDNGRADLVDEMLWEVPLTVALHFLGVPEEDMDLLRQYSIAHTVNTWGRPKPEEQ 
                     *******:*******:******************************************** 
C.necator            VAVAHAVGNFWQLAGRILDKMREDPSGPGWMQYGLRKQKELPDVVTDSYLHSMMMAGIVA 
F.nantongensis       VAVAHAVGNFWQLAGRILDKMREDPSGPGWMQYGLRKQKELPEVVTDSYLHSMMMAGIVA 
B.UYPR2.512          VAVAHAVGNFWQLAGRILDKMREDPSGPGWMQYGLRKQKDLPEVVTDSYLHSMMMAGIVA 
C.metallidurans      VAVAHAVGNFWQLAGRILDKMREDPSGPGWMQYGLRKQRELPEVVTDSYLHSMMMAGIVA 
                     ***********************:**************::**:***************** 
C.necator            AHETTANASANAIKLLLQHPDAWREICDDPSLIPNAVEECLRHNGSVAAWRRLVTRDAEV 
F.nantongensis       AHETTANASANAIKLLLQHPDAWRELCEDPALIPNAVEECLRHNGSVAAWRRLVTRDAEV 
B.UYPR2.512          AHETTANASANAVKLLLQHPDAWREICDDPSLIPNAVEECLRHNGSVAAWRRLVTRDAEV 
C.metallidurans      AHETTANASANAIKLLLQHPDVWREICEDPALIPNAVEECLRHNGSVAAWRRLVTRDTEV 
                     ************:********.***:*:**:**************************:** 
C.necator            GGIRLPAGSKLLIVTSSANHDERHFADADLFDIRRDNASEQLTFGYGSHQCMGKNLARME 
F.nantongensis       GGIRLPAGSKLLIVTSSANHDERHFADADLFDIRRDNASEQLTFGYGSHQCMGKNLARME 
B.UYPR2.512          GGIRLPAGSKLLIVTSSANHDERHFADADLFDIRRDNASEQLTFGYGSHQCMGKNLARME 
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C.metallidurans      GGMSLAVGSKLLIVTSSANHDEHHFADADLFDIHRDNASDQLTFGYGSHQCMGKNLARME 
                     **: *..***************:**********:*****:******************** 
E C.necator            MQVFLEELTRRLPHMRLAEQTFTYVPNTSFRGPEHLLVEWDPAQNPERRDPALLEVHQPV 
F.nantongensis       MQVFLEELTRRLPHMRLAEQTFTYVPNTSFRGPEHLLVEWDPAQNPERRDPALLAVRQPV 
B.UYPR2.512          MQVFLEELTRRLPHMRLAGQAFTYVPNTSFRGPEHLLVEWDPAQNPERRDPAVLDVRQPV 
C.metallidurans      MQIFLEELTSRLPHMRLAAQRFTYVPNTSFRGPEHLWVEWEPARNPERTDPTVLAPRDAV 
                     **:****** ******** * *************** ***:**:**** :*::*  ::.* 
C.necator            RIGEPSAHTIARTVVVERVTPAADGVVRLRLAAPDGKPLPRWAPGSHIDVECGDTGLSRQ 
F.nantongensis       RIGEPSAHTIARTVLVERATPAADGVLRLRLVAPDGKPLPRWAPGSHIDVECGDTGLSRQ 
B.UYPR2.512          RIGEPSAHTIARTVVIERVTPAADGVVRLRLAAPDGKPLPRWAPGSHIDVECGDTGLSRQ 
C.metallidurans      RIGEPTGGTTGRTLVVERVETAAEGVVRIRLVSPDGRALPRWSPGSHIDVECGHTGISRQ 
                     *****:. * .*::::**. .**:**:*:**.:***:.****:**********.**:*** 
C.necator            YSLCGDPDDTGALEIAVLRDPDSRGGSAWVHGSVQAGDRLRIRGPRNHFRFDEGCGRAIF 
F.nantongensis       YSLCGDPDDAAALEIAVLRDPASRGGSAWVHGSVRAGDRLRIRGPRNHFRFDEQCGRAIF 
B.UYPR2.512          YSLCGDPDDAAALEIAVLRDPDSRGGSAWVHGSVRAGDRLRIRGPRNHFRFDESCKRAIF 
C.metallidurans      YSLCGDPADTGAFEIAVLREPESRGGSAWIHASLHAGDKLKVRGPRNHFRLDETCRRAIF 
                     ******* *:.*:*****::* *******:*.*:.***:*::********:** * **** 
C.necator            IAGGIGITPVSAMARRARALGIDYEFHYCGRSRQAMAMLDELQALHGARLHVHASDEGQR 
F.nantongensis       IAGGIGVTPVSAMARRARALGIDYTFHYCGRSRQAMAMLDELQALHGTRLQVHASDEGRR 
B.UYPR2.512          IAGGIGITPVSAMARRARALGIDYEFHYCGRSRKAMAMPDELQALHGARLQVHASDEGQR 
C.metallidurans      IAGGIGVTPVSAMARRAKELGVDYTFHYCGRSRASMAMIDELRALHGDRVRIHAADEGQR 
                     ******:**********: **:** ******** :*** ***:**** *:::**:***:* 
C.necator            ADFGKLLARPDPRTQIYACGPQRMLDALAESCAAWPEDALRVEHFVSKLGTLDASKELPF 
F.nantongensis       ADFGKLLGQPDADTQIYACGPQRLLDALAECCAAWPAEALRVEHFVSRLGTLDASKEQPF 
B.UYPR2.512          ADFGKLLAQPDPRTQIYACGPQRMLDALAECCAAWPEDALRVEHFVSRLGTLDASQEQPF 
C.metallidurans      ADLAQVLGAPDANAQIYACGPARMVEALEALCAAWPEDSLRVEHFSSQLGTLDPSREQPF 
                     **:.::*. **. :******* *:::**   ***** ::****** *:*****.*:* ** 
C.necator            SVELKDSGLVMEVPAGQTLLSALRGANIDVQSDCEEGLCGSCEVRVLAGQVDHRDVVLTR 
F.nantongensis       TVELKDSGLVLEVPAGQTLLGALRGANIDVQSDCEEGLCGSCEVRVLAGQVDHRDVVLTR 
B.UYPR2.512          TVELKDSGLVMEVPAGQTLLSALRSANIDVQSDCEEGLCGSCEVRVLAGQVDHRDVVLTR 
C.metallidurans      TVELKDSGLTLEVPPDQTLLATLRAANIDVQSDCEEGLCGSCEVRVLAGEIDHRDVVLTR 
                     :********.:***..****.:**.************************::********* 
C.necator            SEREANQRMMACCSRACGGGRLVLELSTOP 
 
F.nantongensis       AERDANHRMMACCSRACGGGRLVLEL---- 
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B.UYPR2.512          SEREANQRMMACCSRACGGGRLVLEL---- 
C.metallidurans      GEREANNRMMACCSRAAKGGKIVLGL---- 
                     .**:**:*********. **::** *     
 
Figure 10-3: Amino acid sequence alignment of P450-H16_B1279 with other P450s from 
Cupriavidus sp. The key residues are marked as following: the conserved heme in green, 
the fifth ligand of heme (cysteine) in red, the FMN binding motif in pink, the NADH 
binding motif in gray and the 2Fe-2S cluster in yellow. (*) indicating similar identity, (.) 
is for strongly similar residues and (:) to indicate weak similarity. The alignment was 
produced by using data from BLAST and ClustalW online tool. 
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C.necator            MKHHHHHHPMSDYDIPTTENLYFQGAHMPPPIELSSPDQASDAPHQAPARSMHAPIPEPI 
E.GA3-3              ---------------------------MPPPIELSSPDQASDAPHQTPARSIHATIPEPI 
D.SK-4               ---------------------------MPPPIELSSPDQASDAPHQTPARSMHAPIPEPI 
C.metallidurans      -----------------------------------------------MSTATPAAALEPI 
                                                                     :     .  *** 
C.necator            PRDPGWPLVGNLLQITPGALGQHLLARSRHHDGIFELNFAGRRVPFVTSVALASELCDAA 
E.GA3-3              PRDPGWPLVGNLLQITPGALGQHLLARSRHHDGIFELNFAGRRVPFVTSVALASELCDAA 
D.SK-4               PRDPGWPLVGNLLQITPGALGQHLLARSRHHDGIFELNFAGRRVPFVTSVALASELCDAA 
C.metallidurans      PRDPGWPIFGNLFQITPGEVGQHLLARSRHHDGIFELDFAGKRVPFVSSVALASELCDAT 
                     * *** *:.***:**.** :*****************:***:*****:*****:*:***: 
C.necator            QFRKYIGPPVSYLRGMAGDGLFTARSDEANWGKAHRILMPAFSQRAMKGYFDVMLRVANR 
E.GA3-3              QFRKYIGPPLSYLRGMAGDGLFTARSDEANWGKAHRILMPAFSQRAMKGYFDVMLRVANR 
D.SK-4               QFRKYIGPPLSYLRGMAGDGLFTARSDEANWGKAHRILMPAFSQRAMKGYFDVMLRVANR 
C.metallidurans      RFRKIIGPPLSYLRDMAGDGLFTAHSDEPNWGCAHRILMPAFSQRAMKAYFDVMLRVANR 
                     :*** ****:****.*********:***.*** ***************.*********** 
C.necator            LVDKWDQQGPDADIAVADDMTRLTLDTIALSGFGYDFESFASTELHPFIEAMVGALEEAM 
E.GA3-3              LVDKWDQQGPDADIAVADDMTRLTLDTIALSGFGYDFESFASAELHPFIEAMVGALEEAM 
D.SK-4               LVDKWDRQGPDADIAVADDMTRLTLDTIALSGFGYDFESFASAELHPFIEAMVGALEEAM 
C.metallidurans      LVDKWDRQGPDADIAVADDMTRLTLDTIALAGFGYDFASFASDELDPFVVAMVGALGEAM 
                     ******:***********************:****** ***  :*.**: ****** *** 
C.necator            SKLTRFALQDRFMHAAHQKFDQDTRFMRDLVDDVIRRRRAGDAAERPGGTANDLLGLMLE 
E.GA3-3              SKLTRFALQDRFMHAAHQKFDQDTRFMRDLVDDVIRRRRAGDAAERPGGTANDLLGLMLE 
D.SK-4               SKLTRFALQDRFMHAAHQKFDQDTRFMRDLVDDVIRRRRAGDAAERRGGTANDLLGLMLE 
C.metallidurans      QKLTRLPIQDRFMGRAHRQAAEDIAYMRNLVDDVIRQRRVSPTSG------MDLLNLMLE 
                      ****:.:*****  **::  :*  :**:*******:**.. :.        ***.**** 
C.necator            ARDPDTDQRLDDENIRNQVITFLIAGHETTSGLLTFALYELLRNPGVMAQAYAEVDAVLP 
E.GA3-3              ARDPDTDQRLDDENIRNQVITFLIAGHETTSGLLTFALYELLRNPGVMAQAYAEVDAVLP 
D.SK-4               ARDPDTDQRLDDENIRNQVITFLIAGHETTSGLLTFALYELLRNPGVMAQAYAEVDAVLP 
C.metallidurans      ARDPETDRRLDDANIRNQVITFLIAGHETTSGLLTFALYELLRNPGVLAQAYAEVDTVLP 
                     ****:*.:**** **********************************:********:*** 
C.necator            GDAAPVYADLARLPVLDRVLKETLRLWPTAPAFAVAPFEDTLLGGRYLIRKDRRLSVVLT 
E.GA3-3              GDAAPVYADLARLPVLDRVLKETLRLWPTAPAFAVAPFEDTLLGGRYLIRKDRRLSVVLT 
D.SK-4               GDAAPVYADLARLPVLDRVLKETLRLWPTAPAFAVAPFEDTLLGGRYLIRKDRRLSVVLT 
C.metallidurans      GDAPPVYADLARMPVLDRVLKETLRLWPTAPAFAVAPFDDVVLGGRYRLRKDRRISVVLT 
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                     ***.*:******:*************************:*.:***** :*****:***** 
C.necator            ALHRDPKVWADPERFDIDRFLPEQEAKLPRHAYMPFGNGERACIGRQFALTEAKLALALM 
E.GA3-3              ALHRDPKVWADPERFDIDRFLPEQEAKLPRHAYMPFGNGERACIGRQFALTEAKLALALM 
D.SK-4               ALHRDPKVWADPERFDIDRFLPEQEAKLPRHAYMPFGNGERACIGRQFALTEAKLALALM 
C.metallidurans      ALHRDPKVWANPERFDIDRFLPENEAKLPAHAYMPFGQGERACIGRQFALTEAKLALALM 
                     **********:************.**:** *******:********************** 
C.necator            LRNFQFTDAHDYQFRIKETLTIKPDGFTVRARRRRPHERIAAAPLC-TAQAPRAGPDVQG 
E.GA3-3              LRNFQFTDAHDYQFRIKETLTIKPDGFTVRARRRRPHERIAAVPLAGTAQAPRAGPDVQG 
D.SK-4               LRNFQFTDAHDYQFRIKETLTIKPDGFTVRARRRRPHERIAAAPLAGTAQAPQAGPDVQG 
C.metallidurans      LRNFAFQDPHDYQFRLKETLTIKPDQFVLRVRRRRPHERFVTQQAS-QAVADAAQTDVRG 
                     **:* * *.******:********* :.:*.********:.:      : *  * .:* * 
C.necator            RGRTLAVLCGSSLGTARELAEQVHAGALAAGFDATLRDLDDVADALPTTGLAVIIAATYN 
E.GA3-3              RGRTLAVLCGSSLGTARELAEQVHAGALAAGFDATLRDLDDVADALPTTGLAVIIAATYN 
D.SK-4               GGRPLAVLCGSSLGTARELAEQVHAGALAAGFDATLRDLDDVADALPTTGLAVIIAATYN 
C.metallidurans      HGQAMTVLCASSLGTARELAEQIHAGAIAARFDAKLADLDDAVGALPTSGLAVVVAATYN 
                      *:.::***.************:****:** ***.* ***:...***.:*:**::***** 
C.necator            GRAPDSARRLEALLDSGAASGYRAEALSVAVLGCGNSQWPTYQAFPRRVYEFFTNAGASP 
E.GA3-3              GRAPDSARRLEALLDSGAASGYRAEALSVAVLGCGNSQWPTYQAFPRRVYEFFTNAGASP 
D.SK-4               GRAPDSARRLEALLDSGAASGYRAEALSVAVLGCGNSQWPTYQAFPRRVYEFFTNAGASP 
C.metallidurans      GRAPDSGRKFEAMLDADDASGYRANGVRLALLGCGNSQWATYQAFPRRVFDFFITAGAVP 
                     ******.*::**:**:. ****** .: :*:********.*********.:**  *** * 
C.necator            LLPRGEADGNGDFDQAVERWLALLWQALQAGDGVGGPAHGTPPVRVQVKDVAEIRASTLP 
E.GA3-3              LLPRGEADGNGDFDQAAERWLALLWQALQAGDGVGGPAHGTPPVRVQVKDVAEIRASTLP 
D.SK-4               LLPRGEADGNGDFDQAAERWLALLWQALQAGGGVGGPAHGTPPVRVQIRDVAEIRASTLP 
C.metallidurans      LLPRGEADGNGDFDQAAERWLAQLWQALQADGADTGGLG----VDVQVRSMAAIRAETLP 
                     ****************.***** *******...  *       : **::.:* ***.*** 
C.necator            ANTEAFTVLANTELVNDPSGLWDFSHEAPRTSTRDIRLRLPDGVRYATGDHLAVYPQNQP 
E.GA3-3              ANTEAFTILANAELVNDPSGLWDFSREAPRTSTRDIRLRLPDGVRYATGDHLAVYPQNQP 
D.SK-4               ANTQGFTVLANTELVNDPSGLWDFSREAPRTSTRDIRLRLPEGVRYATGDHLAVYPQNQP 
C.metallidurans      AGTQAFTVLSNDELVGDPSGLWDFSIEAPRTSTRDIRLQLPPGITYRTGDHIAVWPQNDA 
                     *.*: **:*:* ***.**:*****: ************:** *: * ****:**:***:. 
C.necator            GMVAALCERIGIDPDAIVTLSASGGAARGLPLGEALSVRQLLTHFVELQDVVSRHTLRLL 
E.GA3-3              GMVAALCERIGIDPDAIVTLSASGGAARGLPLGEALSVRQLLTHFVELQDVVSRHTLRLL 
D.SK-4               GMVAALCERIGIDPEAIVTLSASGGAARGLPLGEALSVRQLLTHFVELQDVVSRHTLRLL 
C.metallidurans      QLVSDLCERLDLDPDAQATISAPHGMGRGLPIDQSLPVRQLLTHFIELQDVVSRQTLRAL 
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                      :*: ****:.:**:* .*:**. * .****:.::*..*******:********:*** * 
C.necator            SQSSRCPVTRQALRQLASDDAGSGYAAQVAPRRLGLADVLDRFPAIEVDLAGLLACTVPM 
E.GA3-3              SQSSRCPATRQALRQLASDDAGSGYAAQVAPRRLGLADVLDRFPAIEMDLAGLLACTVPM 
D.SK-4               SQSSRCPVTRQALQQLASDDAGSGYAAQVAPRRLGLADVLDRFPAIEVDLAGLLACTVPM 
C.metallidurans      AQATRCPFTKQSIEQLASDDAEHGYATKVVARRLGILDVLVEHPAIALTLQELLACTVPM 
                     :* :*** *:*::.*****:*  **:::*..****: *** ..*** : *  ****:*** 
C.necator            RPRFYSIASSPLVSPGVATITVGTVWSPALSGRGLFRGVASTWLQGLAPGAMVAGAIRTP 
E.GA3-3              RPRFYSIASSPLVSPDVATITVGTVWSPALSGRGLFRGVASTWLQGLAPGAMVAGAIRTP 
D.SK-4               RPRFYSIASSPLVSPDVATITVGTVWSPALSGRGLFRGVASTWLQSLAPGAAVAGAIRTP 
C.metallidurans      RPRLYSIASSPLVSPDVATLLVGTVCAPALSGRGQFRGVASTWLQHLPIGARVSASIRTP 
                     ***:***********.***: ** * :.****:* ********** *. ** *:.:**** 
C.necator            NPTFAPAADPATPMILIGPGTGIAPFRGFLEERAAQQAAGQPVAPVQLYYGCRHPAHDWL 
E.GA3-3              NPTFAPAADPATPMILIGPGTGIAPFRGFLEERAAQQAAGQPMAPVQLYYGCRHPAHDWL 
D.SK-4               NPTFAPAADPATPMILIGPGTGIAPFRGFLEERAAQQAAGQPEAPVQLYYGCRHPAHDWL 
C.metallidurans      NPPFAPDPDPTAPMLLIGPGTGIAPFRGFLEERALRKMAGNAVTPAQLYFGCRHPQHDWL 
                     **.*** .**::**:******************* :: **:. :*.***:***** **** 
C.necator            YRNNVERWQAQGVVQVHLACSVVDGEPRYVQDLLWQRRADVWARLNQGAIIYVCGDGRHM 
E.GA3-3              YRNDVERWQAQGVVQVHLACSVVGGEPRYVQDLLWQRRADVWARLNQGAIIYVCGDGRHM 
D.SK-4               YRDDVERWQAQGVVQVHLACSVVDGEPRYVQDLLWHRRADVWARLNQGAMLYVCGDGRHM 
C.metallidurans      YREDIERWAGQGVVEVHPAYSVVPDAPRYVQDLLWQRREQVWAQVRDGATIYVCGDGRRM 
                     **:::*** .***.::* * *** . *********:** :**::: :** :*******:* 
C.necator            APAVRQVLIQIGAEQGGMTPEAASDWLADLVSAGRYRQDVFNSTOP 
E.GA3-3              APAVRQVLIQIGAEQGGMTAEAASDWLAELVSAGRYRQDVFN---- 
D.SK-4               APAVRQVLIQIGAEQGGMTPEAASDWLAELVSAGRYRQDVFN---- 
C.metallidurans      APAVRQTLIDIGKAQGGMTDEAASDWFGGLVAQGRYRQDVFN---- 
                     ******.*::**  ***** ******:. **: *********     
Figure 10-4: Amino acid sequence alignment of P450-H16_B1009 with other P450s from 
Cupriavidus sp. The key residues are marked as following: the conserved heme in green, 
the fifth ligand of heme (cysteine) in red, FMN in pink and FAD in yellow. (*) indicating 
similar identity, (.) is for strongly similar residues and (:) to indicate weak similarity. The 
alignment was produced by using data from BLAST and ClustalW online tool. 
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10.2 P450 structure modelling 
The online tool SWISS-MODEL was used to predict 3D protein structures for B2406, B1743, 
B1279 and B1009 heme domains.  This web service is designed to provide protein structure 
homology modelling at different levels of complexity. Building a protein homology model 
by SWISS-MODEL can be achieved by four basic steps; I) structural templates selection II) 
sequences alignment between targeted model protein and proteins of the templates III) model 
building depending on the alignment IV) model qualification (Schwede et al., 2003).  
A list of 50 templates were suggested by SWISS-MODEL for each protein depending on 
sequences alignment and structures similarity. These models were visualised by using 
PyMol, this molecular graphics system able to graphically generate proteins structures in 
three dimensions and produce high-quality 3D images of biological molecules, such as 
proteins (Sevrioukova et al., 1999). The 3D predicted structures of four C. necator H16 heme 
domains were displayed in figures (Figure 10-5 A to Figure 10-7 A and Figure 10-9 A). 
Generally, all heme domain structures displayed typical P450 folds with expected helical 
features (α helices, β sheets and loops). Structures showed that these four proteins are 
probably monomers, folded into α/β domains characteristic of P450s. The heme prosthetic 
group of each protein appeared at the centre of the heme domain structure (shown as a stickin 
all heam domain structures). The heme cofactor was obtained from the crystal structure of 
the template of each protein.  
The predicted structures of models were superimposed and compared with the crystal 
structures of their templates. The overlapping by using PyMol was displayed in figures 
(Figure 10-5 B to Figure 10-7 B and Figure 10-9 B). From the way that the secondary 
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structure elements of protein folding shaped, it can be concluded that all heme domains are 
very similar to their templets structures except minor differences that were found in the loop, 
N-terminal regions and C-terminal and these limited variations in the structure between 
P450s members are a known phenomenon because these regions are highly variable in the 
primary sequence (Sirim et al., 2010).  
The heme cofactors of all P450s likely to be bound to highly conserved hydrophobic residues 
that were labelled in (Figure 10-5 C to Figure 10-7 C and Figure 10-9 C). Some of the models 
binding residues different from the templates once but they occupied the same position and 
have very similar functions to each other. The templates and the models details and PDB 
codes were displayed in  Table 10-2. As well as the binding residues of templates and models 
were shown in Table 10-3.  In addition, sequence alignment between P450s primary 
structures and their templets showed highly conserved binding residues (highlighted in 
yellow in Appendix I). Sequences alignments were applied by using ClustalW online tool, 
ClustalW is an alignment tool run with several sets of starting parameters and in each case, 
the alignments applied according to an objective function. ClustalW considers the individual 
weight of the sequence and residue-specific gaps and positions (Roccatano, 2015) 
Templates that were offered by SWISS-MODEL (50 templates) covered only the heme 
domain of P450s, so another program was used to model the reductase domain of B1279 and 
B1009, Phyre the modelling online tool was chosen for reductase domain modelling because 
it provides an extended list of the suggested models (120 templates including both the heme 
and the reductase domain).The Phyre2 server predicts the three-dimensional structure of a 
protein sequence using the techniques of homology modelling, it is provides advanced 
interface and fully updated fold library (Bennett et al., 2008). The 3D structures of the 
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reductases domains of B1279 and B1009 were shown in Figure 10-8 A and Figure 10-11 A 
and the results of superimposing the models to their templets were shown in Figure 10-8 A 
and Figure 10-11 B. Two ligands can be recognised in the structure of reductase domain of 
B1279; the FMN and the iron-sulphur binding motifs (can be seen as sticks in Figure 10-8). 
For B1009 reductase structure three ligands were noticed in the structure, these ligands are; 
FAD, FMN and (nicotinamide-adenine-dinucleotide phosphate) NADP binding motifs (these 
ligands can be seen as sticks Figure 10-11).  
The resulting models were qualified by using VERIFY 3D online tool and a final model was 
obtained. VERIFY 3D is an online tool measures the compatibility of a protein model (3D) 
with its sequence (1D). The position of each residue in the 3D structure is identified by its 
environment (alpha, beta, loop, polar, apolar etc). This profile is represented by the average 
3D-1D score for each residue in the protein structure. According to VERIFY 3D a model will 
considered successful and it passes the test if 80% or more of protein’s residues show average 
(3D-1D) ≥ 0.2 (Lüthy et al., 1992). In general, all models that have been shown in this chapter 
passed the qualification evaluation applied by VERIFY 3D test with more than 80% of 
residues scored average (3D-1D) ≥ 0.2 as can be seen in Appendix II.   
More details about models and their templates for each P450 protein and their functions, 
ligands and binding residues were mentioned below: 
10.2.1 B2406 structure analysis 
Among the templets that offered by SWISS MODEL, cytochrome CYP144A1 (PDB ID: 
5hdi. 1. A) was chosen to build a 3D structure of cytochrome P450 B2406 heme domain 
since it was the best hit with 21.51% sequence identity to the target protein (by SWISS 
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MODEL as well as Phyre) and 0.89 coverage. This model passed the qualification evaluation 
performed by VERIFY 3D with 82.02% of the protein’s residues showed average (3D-1D) 
≥ 0.2 (Appendix II). CYP144A1 is a monomer cytochrome isolated from mycobacterium 
tuberculosis (strain ATCC 25618 / H37Rv) and it is classified as oxidoreductase. The crystal 
structure of CYP144A1 was solved as substrate-free at 1.54 Å resolution (Noble et al., 1999).   
A comparative structural analysis applied by superimposing the predicted model with the 
template showed that B2406 and P450 144 have nearly the same structural organization. For 
more assurance on the quality of the model, the RMSD between the resulting model and the 
templet was also measured and it was 1.59Å. Furthermore, the residues that bound to the 
heme (displayed as sticks in Figure 10-5 C) are highly conserved and this can be noticed in 
both the 3D structure and the sequence alignment between the templet and the model (these 
residues are highlighted in yellow in Appendix I). From the structure analysis of the heme 
cofactor, it was observed that three residues in the template structure bound to the heme; 
H129, R133 and R327 against three residues in the model structure; H117, K121 and R309 
respectively. It could be shown that some of the secondary structure elements merge together 
to structure modules due to this absolute conservation. However, Arg133 in the template was 
replaced by Lys121 in the mode, both amino acids have positively charged side chains and 
very similar structures and functions.    
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Figure 10-5: Structural analysis of P450 H16 B2406 heme domain. (A) 3D model of 
B2406 with heme cofactor. The heme cofactor is shown as stick and it is coloured by 
elements (carbon in green, nitrogen in blue, oxygen in red and sulphur in orange). 
Secondary structures are displayed in cyan (helices), magenda (sheets) and pink (coils). 
(B) Comparative structural analysis of B2406 model with structure (PDB ID: 5hdi. 1. A ). 
Superimposed image of B2406 model (cyan) with CYP144A1 crystal structure (gold) is 
shown in the Figure. (C) Active site close view of B2406. Prosthetic group appearing at 
the centre of the active site is shown along with hydrogen bonds at yellow. Residues bound 
to the heme cofactor are shown as sticks and coloured by elements (hydrogen in gray, 
nitrogen in blue, oxygen in red and carbon atoms are coloured in cyan for the model and 
gold for the template.  Amino acids in the model structure which bound to the heme 
cofactor are labelled in figure while the template’s residues are listed in Table 10-3. This 
model was generated by using SWISS MODEL 
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10.2.2 B1743 structure analysis 
C. necator H16 P450 B1743 model was built by SWISS MODEL using the template CYP130 
(PDB ID: 2uvn. 1. A) isolated from mycobacterium tuberculosis (strain ATCC 25618 / 
H37Rv). CYP130 crystal structure was solved as econazole-bound CYP130 at 3 Å 
resolutions and it was classified as oxidoreductase (Rath et al., 2009). CYP130 was the best 
hit (by both SWISS MODEL and Phyre); it has 28.68 % sequence identity to P450 B1743 
with 0.89 coverage. This model scored 98.70% in the VERIFY 3D quality evaluation 
(Appendix II).  
The superimposing of the model to CYP130 structure showed good similarity with 1.41 Å 
RMSD over 376 residues. The structure analysis of the template showed 5 residues bound to 
the heme: H97, R101, R295, Y318 and S348 while the residues of the model that share the 
same positions with the above residues were as following: H124, R128, R318, Y341 and 
G370 respectively. It can be seen that 4 out of five residues are the same while the fifth one 
S348 in template was replaced by G370 in the model (Figure 10-6 C).  
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Figure 10-6: Structural analysis of P450 H16 B1743 heme domain. (A) 3D model of B1743 
with heme cofactor. The heme cofactor is shown as stick and it is coloured by elements 
(carbon in green, nitrogen in blue, oxygen in red and sulphur in orange). Secondary 
structures are displayed in cyan (helices), magenda (sheets) and pink (coils). (B) 
Comparative structural analysis of B2406 model with structure (PDB ID: 2uvn. 1. A ). 
Superimposed image of B2406 model (cyan) with CYP130 crystal structure (gold) is shown 
in the Figure. (C) Active site close view of B2406. Prosthetic group appearing at the centre 
of the active site is shown along with hydrogen bonds at yellow. Residues bound to the 
heme cofactor are shown as sticks and coloured by elements (hydrogen in grey, nitrogen in 
blue, oxygen in red and carbon atoms are coloured in cyan for the modwl and gold for the 
template. Amino acids in the model structure which bound to the heme cofactor are labelled 
in figure while the template’s residues are listed in Table 10-3 This model was generated 
by using SWISS MODEL 
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10.2.3 B1279 structure analysis 
10.2.3.1 B1279 heme domain: 
The crystal structure of tepidiphilus thermophilus P450 heme domain (PDB ID: 6gii 1. A) 
was suggested by SWISS MODEL as well as Phyre as a best hit with 62.92 % sequence 
identity to build P450 B1279 3D model.  The tepidiphilus thermophilus P450 heme domain 
is a monomer cytochrome and it is classified as oxidoreductase. The crystal structure of this 
template was solved as substrate-free at 1.9 Å resolution (Carugo, 2007). This model passed 
the qualification evaluation performed by VERIFY 3D with 94.95% of the protein’s residues 
showed average (3D-1D) ≥ 0.2 (Appendix II). 
The superimposing of the model to the template structure showed a very high similarity with 
0.078 Å RMSD over 416 residues. The structure analysis of the template and the model 
showed that both structure have the same residues bound to the heme and these residues share 
the same positions which reflect the high accuracy of the predicted model. These residues 
are: H159, R163, R360 and H417and H151, R155, R352 and H409 of the template and the 
model respectively (Figure 10-7 A).  
10.2.3.2 B1279 reductase domain: 
P450 B1743 reductase domain model was built by Phyre using the template of CYP153A 
reductase (PDB ID: 2pia. 1. A) isolated from burkholderia cepacia. CYP153A crystal 
structure was solved at 2 Å resolutions and classified as phthalate dioxygenase reductase 
(Janson & Rydén, 1989). CYP153A was the best hit with 34 % sequence identity to P450 
B1743. This model scored 96.21% in the VERIFY 3D quality evaluation (Appendix II).  
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When CYP153A structure superimposed to the model it showed good similarity with 1.03 Å 
RMSD. Two prosthetics groups: 2Fe-2S and FMN were noticed and represented as sticks in 
Figure 10-8. It is observed that four cysteine residues in both template and model bound to 
the 2Fe-2S ligand.  Further, 9 residues in the template structure as well as model bound to 
the FMN and 7 out of 9 are the same while the other two are functionally similar and all 
binding residues occupied the same position. This structure analysis leads to the belief that 
the reliability of the predicted model is high and the ferredoxin reductase in the model is 
likely to be bound to the structure by the above binding residues. A list of the binding residues 
for both ligands were listed in Table 10-3. 
10.2.4 B1009 structure analysis 
10.2.4.1 B1009 heme domain: 
C. necator H16 P450 B1009 3D heme domain model was built by SWISS MODEL using the 
template CYP102A1 (PDB ID: 1bu7. 1. A) isolated from bacillus megaterium (strain ATCC 
14581 / DSM 32 / JCM 2506 / NBRC 15308 / NCIMB 9376 / NCTC 10342 / VKM B-512). 
P450 BM-3 crystal structure was solved in complex with  FMN-binding domains of bacterial 
cytochrome P450BM-3 at 1.65 Å resolutions and was classified as oxidoreductase 
(Sevrioukova et al., 1999). This template’s structure was the best hit with 46.89% sequence 
identity to P450 B1009 and 0.83 coverage. This model scored 90.52% in the VERIFY 3D 
quality evaluation (Appendix II). 
A comparative structural analysis applied by superimposing the predicted model with the 
template showed that B1009 heme domain and P450 BM-3 are very similar and the RMSD 
between the resulting model and the templet was also measured and it was 0.37 Å which 
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indicates the high accuracy of the generated model. Furthermore, the residues that bound to 
the heme are highly conserved and this can be noticed from Figure 10-9 C. From overlapping 
the template to the model structure, it observed that three residues in the template structure 
bound to the heme; K69, W96 and R398 and the same residues in the model structure also 
bound to the heme cofactor which are; K124, W151 and R461 respectively these highly 
conserved binding residues increase the probability that the model predicted structure likely 
connects to the heme cofactor of the template.  
Different model was suggested by Phyre. This model was analysed in order to compare it 
with the model that was offered by SWISS MODEL. Same protein was suggested by Phyre 
as a template which is P450 BM-3 but in deferent solved crystal structure (PDB ID: 2ij2. 1. 
A). This crystal structure is also for P450 BM-3 but in a novel substrate-free state when the 
mobile (helical) structural elements was reorganised resulting in a more open activity site 
cavity. This template has 46% identity with the model and 91.92% quality evaluation by 
VERIFY 3D (Appendix II).  
When the model (PDB ID: 2ij2. 1. A) was superimposed to the template, it gave a highly 
similar result to what has been gained from the overlapping by using the template that was 
suggested by SWISS MODEL (PDB ID: 1bu7. 1. A) with the exactly same residues bound 
to the heme cofactor for both the model and the template (see Figure 10-10).  However, the 
RMSD by using the structure that was suggested by Phyre2 (2ij2. 1. A) was high (1.01 Å) in 
comparison to the RMSD of the template given by SWISS MODEL (1bu7. 1. A), 0.37 Å and 
that make the first suggested template by SWISS MODEL (PDB ID: 1bu7. 1. A) more 
accurate (see Table 10-2.    
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R352 
R155 
H409 
H151 
Figure 10-7: Structural analysis of P450 H16 B1279 heme domain. (A) 3D model of 1279 
with heme cofactor. The heme cofactor is shown as stick and it is coloured by elements 
(carbon in green, nitrogen in blue, oxygen in red and sulphur in orange). Secondary 
structures are displayed in cyan (helices), magenda (sheets) and pink (coils). (B) 
Comparative structural analysis of the model with structure (PDB ID: 6gii 1. A). The model 
is shown in cyanand the template crystal structure in gold. (C) Active site close view of 
B2406. Prosthetic group appearing at the centre of the active site is shown along with 
hydrogen bonds at yellow. Residues bound to the heme cofactor are shown as sticks and 
coloured by elements (hydrogen in grey, nitrogen in blue, oxygen in red and carbon atoms 
are coloured in cyan for the B1279 modek and gold for the template.  Amino acids in the 
model structure which bound to the heme cofactor are labelled in figure while the 
template’s residues are listed in Table 10-3. This model was generated by using SWISS 
MODEL 
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C762 
C792 
C759 
R564 
R539 
G566 
S567 
Q540 
S542 
T608 
A556 
L558 
Fe-S 
FMN 
FMN 
Fe-S 
Figure 10-8: Structural analysis of P450 H16 B1279 reductase domain. (A) 3D model of 
B1279 reductase with two ligands. The ligands are shown as stick and it is coloured green 
for FMN and red for Fe-S cluster. Secondary structures are displayed in cyan (helices), 
magenda (sheets) and pink (coils). (B) Comparative structural analysis of B1279 model 
with structure (PDB ID: 2pia. 1. A). Superimposed image of the model (cyan) with CYP153 
A crystal structure (grey) is shown in the Figure. (C) Reductase domain close view of 
B1279. Prosthetic groups appearing along with hydrogen bonds at yellow and they are 
coloured by elements (carbon in green, nitrogen in blue, oxygen in red and sulphur in 
orange). Residues bound to the heme cofactor are shown as sticks and coloured by elements 
(hydrogen in grey, nitrogen in blue, oxygen in red and carbon atoms are coloured in cyan 
for the model and grey for template).  Amino acids in the model structure which bound to 
the heme cofactor are labelled in figure while the template’s residues are listed in Table 
10-3. This model was generated by using Phyre2.  
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K12
R461 
W151 
Figure 10-9: Structural analysis of P450 H16 B1009 heme domain. (A) 3D model of 
B1009 with heme cofactor. The heme cofactor is shown as stick and it is coloured by 
elements (carbon in green, nitrogen in blue, oxygen in red and sulphur in orange). 
Secondary structures are displayed in cyan (helices), magenda (sheets) and pink (coils). 
(B) Comparative structural analysis of B1009 model with structure (PDB ID: 1bu7. 1. A). 
Superimposed image of B2406 model (cyan) with CYP102A1 crystal structure (gold) is 
shown in the Figure. (C) Active site close view of B2406. Prosthetic group appearing at 
the centre of the active site is shown along with hydrogen bonds at yellow. Residues bound 
to the heme cofactor are shown as sticks and coloured by elements (hydrogen in grey, 
nitrogen in blue, oxygen in red and carbon atoms are coloured in cyan for the model and 
gold for template.  Amino acids in the model structure which bound to the heme cofactor 
are labelled in figure while the template’s residues are listed in table Table 10-3. This model 
was generated by using SWISS MODEL 
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W151 R461 
K124 
Figure 10-10: Structural analysis of P450 H16 B1009 heme domain. (A) 3D model of 
B2406 with heme cofactor. The heme cofactor is shown as stick and it is coloured by 
elements (carbon in green, nitrogen in blue, oxygen in red and sulphur in orange). 
Secondary structures are displayed in cyan (helices), magenda (sheets) and pink (coils). (B) 
Comparative structural analysis of B1009 model with structure (PDB ID: 2ij2. 1. A). 
Superimposed image of the model (cyan) with P450 BM-3 crystal structure (gold) is shown 
in the Figure. (C) Active site close view of B2406. Prosthetic group appearing at the centre 
of the active site is shown along with hydrogen bonds at yellow. Residues bound to the 
heme cofactor are shown as sticks and coloured by elements (hydrogen in grey, nitrogen in 
blue, oxygen in red and carbon atoms are coloured in cyan for the model and gold for the 
template). Amino acids in the model structure which bound to the heme cofactor are 
labelled in figure while the template’s residues are listed in Table 10-3. This model was 
generated by using Phyre2.  
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10.2.4.2 B1009 reductase domain: 
P450 B1009 reductase domain 3 D model was built by Phyre2 using the template from rat 
reductase complexed with nicotinamide-adenine-dinucleotide phosphate (NADP)(+) (PDB 
ID: 1j9z. B) isolated from rattus norvegicus . The template crystal structure was solved at 
2.7 Å resolutions and classified as NADPH-cytochrome P450 reductase (Hubbard et al., 
2001). This template was the best hit with 28% sequence identity to P450 B1009. This model 
scored 93.29% in the VERIFY 3D quality evaluation (Appendix II).  
From superimposing the model to its template, a good similarity was observed with 1.16 Å 
RMSD over 576 residues. In Figure 10-11, three prosthetics groups were distinguished: a 
flavodoxin-like domain FMN, ferredoxin reductase-type FAD binding domain (FAD_FR) 
and nicotinamide-adenine-dinucleotide phosphate (NADP). These three ligands were shown 
as sticks in figure 10-11 and together formed a typical reductase structure.  
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Figure 10-11: Structural analysis of P450 H16 B1009 reductase domain. (A) 3D model of 
B1009 reductase with three ligands. The ligands are shown as stick and it is coloured green 
for FMN, red for FAD and blue for NADP. Secondary structures are displayed in cyan 
(helices), magenda (sheets) and pink (coils). (B) Comparative structural analysis of B1009 
model with structure (PDB ID: 1j9z. B). Superimposed image showed the model in cyan  
and the template crystal structure in grey. This model was generated by using Phyre2. 
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Table 10-2: List of the the results for the homology modelling of four C. necator H16 P450 
proteins  and templates used for this modilling. 
 
 
 
 
 
 
 
 
 
Target model Server Template PDB 
ID 
Organism  Identity 
(%) 
Overall 
RMSD 
(Ǻ) 
B2406 heme 
domain 
 
SWISS 
MODEL 
CYP144 
5hdi. 
A 
Mycobacterium 
tuberculosis 
21.51 1.59 
B1743 heme 
domain 
 
SWISS 
MODEL 
CYP130 
2uvn
. A 
Mycobacterium 
tuberculosis 
28.68 1.41 
B1279 heme 
domain 
 
SWISS 
MODEL 
P450 heme 
domain 
6gii. 
A 
Tepidiphillus 
thermophilus 
62.92 0.08 
B1279 reductase 
domain 
 
Phyre 2 CYP153A 
2pia. 
A 
Marinobacter 
aquaeolei 
34 1.03 
B1009 heme 
domain 
 
SWISS 
MODEL 
P450 BM-3 
1bu7 
A 
Bacillus 
megaterium 
46.89 0.37 
Phyre 2 
 
P450 BM-3 
2ij2. 
A 
Bacillus 
megaterium 
46 1.01 
B1009 reductase 
domain 
 
Phyre 2 
NADPH-P450 
reductase 
1j9z. 
B 
Rattus 
norvegicus 
28 1.16 
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Table 10-3: This table lists the residues that bound to theprosthetic groups in models and 
their templates of four C. necator H16 P450 proteins    
 
 
 
 
 
  
Target model Ligands 
Binding residues 
in the model 
structure 
Template 
Binding residues in 
the template 
structure 
B2406 heme 
domain 
 
Heme 
cofactor 
H117, K121, R309 
CYP144 
(PDB ID: 5hdi. A) 
H129, R133, R327 
B1743 heme 
domain 
 
Heme 
cofactor 
H124, R128, R318, 
Y341, G370 
CYP130 
(PDB ID: 2uvn. A) 
H97, R101, R295, 
Y318, S348 
B1279 heme 
domain 
 
Heme 
cofactor 
H151, R155, R352, 
H409 
P450 heme domain 
(PDB ID: 6gii. A) 
H159, R163, R360, 
H417 
B1279 reductase 
domain 
Fe-S 
C754, C759, C762, 
792 
CYP153 
(PDB ID: 2pia. A) 
C272, C277, C280, 
C308 
FMN 
R539, Q540, S542, 
A556, L558, R564, 
G566, S567, T608 
R55, T56, S58, A72, 
K74, R80, G82, S83, 
T124 
B1009 heme 
domain by 
SWISS MODEL 
 
Heme 
cofactor 
K124, W151, R461 
P450 BM-3 
(PDB ID: 1bu7. A) 
K69, W96, R398 
B1009 heme 
domain by Phyre 
 
Heme 
cofactor 
K124, W151, R461 
P450 BM-3 
(PDB ID: 2ij2. A) 
K69, W96, R398 
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10.3 Study of the basic configuration of the P450 expression vectors  
The pETM-11 plasmid from Novagen was chosen in this study as an expression vector to 
express four P450s, B2406, B1743, B1279 and B1009, due to its ability to produce a high 
level of soluble and nontoxic recombinant proteins in E. coli, the expression vectors of these 
proteins are shown in Figure 10-12 to Figure 10-15. In this system, the expression of the 
target gene is controlled by the T7 phage RNA polymerase promoter in production hosts 
containing a prophage (λDE3) (Baneyx, 1999). 
A commercial expression vector is designed with at least one affinity tag to allow efficient 
purification of large amount of protein, while some of these tags were used to enhance the 
protein’s solubility. There are many known affinity tags such as glutathione S-transferase 
(GST), maltose binding protein (MBP) and polyhistidine tag (His), but the most commonly 
used is the polyhistidine tag consisting of 2–10 residues, which facilitate the production of 
pure protein in large quantities. The pETM-11 plasmid in this study was designed with a His-
tag to allow easy separation of pure proteins. In spite of the advantages of using fusion 
proteins, in some cases they could negatively affect enzyme activity. Consequently, cleavage 
factors were added to the expression vector to separate the recombinant protein from affinity 
tags. For the pETM-11 plasmid used in this project, tobacco etch virus protease (TEV) was 
inserted for this purpose. The His domain was connected to the plasmid by a linker region, 
which enhances the flexibility and mobility of the protein to achieve an efficient purification 
and tag cleavage. In addition, this linker region helps to improve protein solubility. 
Furthermore, many restriction sites were included in the pETM-11 to cut and ligate the 
recombinant DNA ends into the plasmid according to changes in the requirements during the 
experimental work. 
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Figure 10-12: pETM11 expression plasmid (6483 bp) encoded H16_B2406 gene 
(green). The pETM11 vector contains the N-terminal T7 promoter and kanamycin 
resistance selection marker. Plasmid image was produced using SnapGene software.  
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Figure 10-13: pETM11 expression plasmid (6555 bp) encoded H16_B1743 gene 
(green). The pETM11 vector contains the N-terminal T7 promoter and kanamycin 
resistance selection marker. Plasmid image was produced using SnapGene software. 
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Figure 10-14: pETM11 expression plasmid (7692 bp) encoded H16_B1279 gene (green). 
The pETM11 vector contains the N-terminal T7 promoter and kanamycin resistance 
selection marker. Plasmid image was produced using SnapGene software. 
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Figure 10-15: pETM11 expression plasmid (8646 bp) encoded H16_B1009 gene 
(green). The pETM11 vector contains the N-terminal T7 promoter and kanamycin 
resistance selection marker. Plasmid image was produced using SnapGene software 
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11 Characterisation of putative cytochrome 
P450s from Cupriavidus necator H16  
 
11.1  Putative cytochrome P450s from Cupriavidus necator H16  
When the concentration and the purity of the isolated plasmids; pETM11-H16-B2406, 
pETM11-H16-B1743, pETM11-H16-B1279 and pETM11-H16-B1009 were checked, it is 
found that all concentrations ranged between 70–80 nM and the A260/A230 and A260/A280 ratios 
were equal or more than 2 indicating the high purity of plasmids and their capability to be 
used in further investigations.    
These four isolated plasmids; pETM11-H16-B2406, pETM11-H16-B1743, pETM11-H16-
B1279 and pETM11-H16-B1009 were transferred into E. coli BL21 (DE3) cells and showed 
a significant growth on TYE agar media supplemented with 50 µg/ml kanamycin in 
comparison to no growth on the control plate (free-plasmid E. coli BL21 (DE3) cells) (Figure 
11-1). The expression was carried out in TB auto-induction media at 30°C for 24 hr. The 
transformation and expression protocols were described in detail in section 9.5. Collected 
pellets after 24 hr were red in colour, indicating successful heme protein expression. Different 
expression levels can be observed depending on the pellet colour as shown in Figure 11-2.   
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B2406 B1743 B1279 B1009 
 
Control 
H16-B2406 
H16-B1743 
H16-B1009 
H16-B1279  
Figure 11-1: The resulting clones from the transformation of pETM11 plasmid 
into BL21 (BM3). Four genes were transformed. The plates from transformation 
were presented as: 1) H16-B2406. 2) H16-B1009. 3) H16-B1743.  4) H16-B1279 
5) the control. 
 
Figure 11-2: The pellet from the expression of four genes  in BL21 (BM3). Those gees 
are: 1) H16-B2406 2) H16-B1743 3) H16-B1279 4) H16-B1009, 50 ml of TB AIM media 
was used for the expression of each protein at 30°C. The incubation period was 24 hr.   
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The solubility of Cupriavidus necator H16 P450s were checked by SDS-PAGE as described 
in section 9.5. The protein bands are surrounded by yellow rectangles to clarify the 
soluble/insoluble fractions (Figure 11-3). From the comparison of the soluble fractions (lane 
2-5) to the insoluble fractions (lane 6-9) of the same proteins, it could be concluded that all 
Cupriavidus necator H16 P450 protein are soluble in water when they expressed in E. coli 
BL21 (DE3) as a host cells.  
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Figure 11-3: SDS-PAGE analysis for the soluble and insoluble fraction of four genes in 
pETM11 plasmid: H16-B2406, H16-B1743, H16-B1279 and H16-B1009. The yellow 
boxes surround the target proteins that clarified in the table underneath each lane. 
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11.2 Optimisation of protein expression and purification 
After testing the possibility of expressing P450s from Cupriavidus necator H16 and checking 
the solubility of these proteins, it is prudent to check the yield of each protein and the 
possibility to purify these proteins. Proteins from 50 ml of expression culture were lysed and 
loaded onto a HisTrap column. The purification was performed as described in section 9.5. 
From Figure 11-4 and Figure 11-5, it can be observed that two proteins, B2406 and B1743, 
showed a very good yield and purity from the first step of purification, while the yield of 
B1279 was lower and associated with unknown protein at 50 kDa (Figure 11-6). In contrast, 
the expression and purity of B1009 was very low (Figure 11-7). These results indicate that 
both B2406 and B1743 can be expressed on a large scale using the optimal conditions, while 
the large-scale expression of B1279 and B1009 requires further improvement. 
Two E. coli strains and a variety of conditions were applied in the expression optimisation 
of B1279 and B1009, which was described in section 9.5.1. The expression of B1009 
remained very low with no significant deference between the expression in E. coli BL21 
(DE3) and E. coli C41 (DE3), also no enhancement was observed when the incubation 
temperature was decreased from 30°C to 25°C and when 2×TY AIM or SB AIM were used 
as shown in Figure 11-8. However, using a lower expression temperature (25°C) increased 
B1279’s expression when the other factors were fixed. Also, using SB AIM gave the highest 
protein production in both E. coli BL21 (DE3) and E. coli C41 (DE3). In addition, from the 
gel picture (Figure 11-9), C41 (DE3) strain provided higher B1279 expression compared to 
E. coli BL21 (DE3), while the later gave the purest protein. Based on these results, the 
optimal conditions of SB AIM, 25°C and E. coli BL21 (DE3) were used to express B1279 
on large-scale using the protocol described in section 9.6.  
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The expression of B1009 was also investigated in E coli HMS174 (DE3) strain. The induction 
using auto-induction media and IPTG were examined at 25°C and 30°C incubation 
temperatures. The results showed an improvement in B1009 expression in E. coli HMS174 
(DE3) using  auto-induction media at 30°C but the protein was insoluble by using this strain 
(Figure 11-10 and Figure 11-11). From the results, it could be indicated that E. coli HMS174 
(DE3) is favourite over E. coli BL21(DE3) and E. coli C41(DE3) for B1009 expression. 
However, solubility of B1009 need to be improved by using one or more of proteins’ 
improvement solubility strategies.  
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Figure 11-4: SDS-PAGE analysis of B2406 protein for the fractions eluted from 
affinity chromatography for the protein expressed in BL21 (DE3), 50 ml of sample 
was loaded to the HisTrap 5 ml column. The purification conditions were: 2 ml/min, 
40 min. 
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Figure 11-5: : SDS-PAGE analysis of B1743 protein for the fractions eluted from 
affinity chromatography for the protein expressed in BL21 (DE3), 50 ml of sample was 
loaded to the HisTrap 5 ml column. The purification conditions were: 2 ml/min, 40 min. 
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Figure 11-6: SDS-PAGE analysis of B1279 protein for the fractions eluted from 
affinity chromatography for the protein expressed in BL21 (DE3), 50 ml of sample 
was loaded to the HisTrap 5 ml column. The purification conditions were: 2 ml/min, 
40 min. 
kD
a 
  90 
kDa 
  
195 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
250 
150 
100 
70 
50 
40 
30 
1 2 3 4 5 6 7 8 9 
P
ro
tein
 lad
d
er 
C
ru
d
e extract 
Flo
w
-th
ro
u
gh
 
 
W
ash
 
 
Fractio
n
 9
 
Fractio
n
 10
 
Fractio
n
 11
 
Fractio
n
 12
 
Fractio
n
 13
 
  
Figure 11-7: SDS-PAGE analysis of B1009 protein for the fractions eluted from 
affinity chromatography for the protein expressed in BL21 (DE3), 50 ml of sample 
was loaded to the HisTrap 5 ml column. The purification conditions were: 2 ml/min, 
40 min. 
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Figure 11-8: SDS-PAGE analysis of B1009 expression optimisation. The protein was 
expressed in BL21 (DE3) and C41 (DE3) using three AIM: 2×TY, SB and TB under 
two different temperatures: A. 25˚C B. 30 ˚C.  The yellow boxes surround the target 
protein. 
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Figure 11-9: SDS-PAGE analysis of B1279 expression optimisation. The protein was 
expressed in BL21 (DE3) and C41 (DE3) using three AIM: 2×TY, SB and TB under 
two different temperatures: A. 25˚C B. 30 ˚C. The yellow boxes surround the target 
protein.   
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Figure 11-10: SDS-PAGE analysis of B1009 expression and solubility. The protein 
was expressed in E. coli HMS 174(DE3) using SB AIM at different incubation 
temperatures: 25˚C and 30˚C. The incubation was carried out for 24 hr. The yellow 
boxes surround the target proteins. 
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Figure 11-11: SDS-PAGE analysis of B1009 expression and solubility. The protein 
was expressed in HMS 174(DE3) using 100 µM IPTG at different incubation 
temperatures: 25˚C and 30˚C. The incubation was carried out for 6 hr and 18 hr after 
induction to investigate the solubility. The yellow boxes surround the target protein. 
 
 
kDa 
250 — 
150 —  
100 — 
70 — 
50 — 
40 — 
30 — 
  
200 
 
11.3 Large-scale expression and purification 
The production of the three Cupriavidus necator H16 P450s successfully expressed in E. coli 
BL21 (DE2) was scaled up to 400 ml cultures. The expression was followed by three 
purification steps, affinity chromatography, ion exchange chromatography and gel filtration 
chromatography, as described in section 7.2. 
The chromatograms and the SDS gel pictures of the purified P450s, indicated a good yield 
and purity of all three proteins after the affinity step as the first step of purification (Figure 
11-12). In the second step (ion exchange), the three proteins were successfully concentrated 
(Figure 11-13) in preparation for the final step of purification, gel filtration chromatography 
to purify proteins depending on their size. The concentration and the purity of B2406 and 
B1743 after the final purification step were sufficient to proceed with the functional study 
(Figure 11-14 and Figure 11-15). However, while the third protein was of satisfactory purity, 
the concentration was still too low (1.6 nM in comparison to 17 and 20 nM for B1743 and 
B1279 respectively), Figure 11-16 
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Figure 11-12: SDS-PAGE protein analysis for the first peak (19-20) and the second peak (21-
24) from protein purification using affinity chromatography. The purification was carried out 
for 400 ml expression culture of: A. B2406 B. B1743 and C. B1279. Gradient elution was used, 
the flow rate was 2 ml/min for 40 min.  
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Figure 11-13: SDS-PAGE protein analysis for the peak (6 and 7) from protein purification 
using ion exchange chromatography of three P450s A. B2406 B. B1743 and C. B1279. 
step elution was used, the flow rate was 2 ml/. 
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Figure 11-14: A. Chromatogram monitored during the large scale purification of H16-
B2406 by gel filtration chromatography. B. SDS-PAGE protein analysis for the first peak 
fraction 11 and second peak fractions (20-22).  
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Figure 11-15: A. Chromatogram monitored during the large scale purification of H16-
B1743 by gel filtration chromatography. B. SDS-PAGE protein analysis for the eluted 
fractions at  chromatogram’s peaks. The desired protein was observed at 4th peak.  
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Figure 11-16: A. Chromatogram monitored during the large scale purification of H16-
B1279 by gel filtration chromatography. B. SDS-PAGE protein analysis for the eluted 
fractions at  chromatogram’s peaks. The desired protein was observed at 4th peak.   
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11.4 Optical properties 
The chromatogram and protein electrophoresis analysis provided an initial judgement on the 
protein concentrations and purities, but for more accurate visualisation, the absorbance of 
these proteins were scanned between 250–800 nm for more comprehensive data regarding 
the protein features, concentrations and purity. Figure 11-17 displaying the spectra of B2406, 
B1743 and B1279, all three proteins showed typical features of heme cofactors of P450s with 
a Soret peak at 416 nm for B2406 and 418 nm for B1743 and B1279. Alpha/beta bands were 
also observed at 571/535 nm, 569/537 nm and 567/533 nm for B2406, B1743 and B1279 
respectively. In addition, the estimated concentrations of proteins depending on the UV 
absorbance and the extinction coefficients of the proteins were calculated from the spectrum 
values using the Beer-Lambert law (equation 6.1), which were 20, 17 and 1.6 nM for B2406, 
B1743 and B1279 respectively. The concentration for the later protein could be a barrier to 
verifying the binding of substrates and identifying potential substrates, which prompted 
further attempts to improve the purification of this protein.         
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Figure 11-17: Spectra measurement for three proteins from Cupriavidus necator H16; 
A. H16-B2406 B. H16-B1743 C. H16-B1279. Proteins were scanned for the wavelength 
250-750 nm. All three proteins showed typical features of heme cofactors of P450s with 
a Soret peak at 416 nm for B2406 and 418 nm for B1743 and B1279. Alpha/beta bands 
were also observed at 571/535 nm, 569/537 nm and 567/533 nm for B2406, B1743 and 
B1279 respectively 
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11.5 B1279 purification optimisation  
With regard to the SDS gel pictures of B1279 (Figure 11-6), it was noticed that the 
concentration of this protein was high in the crude extract, but then decreased during the 
subsequent purification steps, indicating that it is the purification process that requires 
improvement, not the expression. Many attempts were made to overcome this problem. 
Firstly, the ion exchange step was omitted to reduce the amount of protein lost during the 
purification process, but this did not increase the protein concentration (Figure 11-18). 
Secondly, the elution in the ion exchange step was changed from a step elution to a gradient 
elution and the gel filtration was omitted as the protein is higly diluted in this final step. 
However, as shown in Figure 11-19, the protein after ion exchange was not pure and applying 
gel filtration chromatography is vital. Next, the purification of B1279 expressed in another 
E. coli strain C41 (DE3) was investigated, but this protein was also associated with a higher 
yield of untargeted protein at approximately 50 kDa (Figure 11-20). Other attempts to 
enhance B1279 concentration, such as increasing the amount of imidazole in the affinity 
elution buffer and applying ultrafiltration after the final purification step were not effective.    
A comparison of the estimated concentrations of B1279 expressed in both BL21 (DE3) and 
C41 (DE3) after purification and B1743 protein is presented in Table 11-1. Both proteins 
have a similar concentration in the crude extract but the recovery of B1279 was nearly half 
that of B1743 after each purification step, leading to a decrease in concentration from 5.2 nM 
in the crude extract to 1.6 nM after the gel filtration step. This is probably due to the high 
hydrophobicity and tendency of this protein to non-specific bind to the matrix materials of 
the purification column and filtration membranes.  
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Due to the low concentration of B1279, it was decided not to proceed with the investigation 
of substrates binding to this protein, which requires a high protein concentration to indicate 
the changes in P450 features as a result of substrate binding. Instead, the activity of this 
protein to catalyse the reaction of different saturated, unsaturated, aromatic and herbicides 
substrates was assessed.     
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Figure 11-18: The first attempt at B1279 purification optimisation. The effect of 
skipping the second purification step; ion exchange on the yield of B1279 was checked 
by. A. spectra scanning B. SDS electrophoresis analysis.    
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Figure 11-19: The second attempt at B1279 purification optimisation. The effect of 
using gradient elution in the ion exchange step instead of step elution on the yield of 
B1279 was tested by. A. spectra scanning B. SDS electrophoresis analysis.   
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Figure 11-20: The third attempt at B1279 purification optimisation. B1279 was expressed 
in C41 (DE3) instead of BL21 (DE3) to evaluate the yield of B1279. The results were 
analysed by: A. spectra scanning B. SDS electrophoresis analysis. The yellow boxes 
indicate the target protein.  
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Table 11-1: Comparison of the purification of B1279 in BL21 (DE3) and C41 (DE3) and the 
purification of B1743 
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11.6  Substrate binding 
when the binding of 11 substrates to B2406 and B1743 proteins was assessed as described in 
section 9.10, no significant optical changes in the B2406 spectra were detected with any of 
the 11 examined substrates, while type I shifts were observed in the B1743 spectra with two 
substrates, lauric acid and 3-phenoxytoluene as shown in Figure 11-21.  
The binding of 3-phenoxytoluene to B1743 induced a very small shift in the Soret band from 
418 to 417 (blue shift), reducing the UV absorbance to 0.69 nm instead of 0.71 nm in the free 
substrate protein. Similar spectral changes were observed when 3-phenoxytulen was titrated 
to the B1743 solution; a blue shift towards 390 in the Soret maximum and the UV value 
decreased from 0.70 nm to 0.57 nm. 
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(A) 
(B) 
Figure 11-21: Analysis of two substrates binding to B1743. A. Spectral titration 
for B1743 with lauric acid. B. Spectral titration for B1743 with 3-
phenoxytoluene. Arrows indicate the progressive decrease in the ferric LS Soret 
band (at 418 nm) and the associated increase in the ferric HS feature at about 
390 nm 
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11.7 Activity measurement 
Among the three P450s that have been successfully expressed in E. coli and purified during 
this project, B1279 was selected to be functionally analysed. In contrast to B2406 and B1743, 
B1279 is the only protein that contains a reductase module (FMN and 2Fe-2S) fused to its 
heme domain according to the genome analysis and 3D structure modelling in chapter 10, 
thereby increasing the probability of B1279 being catalytically active as a self-sufficient 
protein. 
The activity evaluation of B1279 showed that the consumption rates of the redox partner, 
NADH, were very low, approaching its rate in the background reactions (0.048 nmole/s) with 
all substrates (lauric acid, palmitic acid, myristic acid, butyric acid, adipic acid, malate, 
indole, naphthalene, 3-phenoxytoluene, EPTC and vernolate) (Figure 11-22). The standard 
probability value “p-value” was more than 0.05 for all tested substrates. In biology, 
difference between two groups considered significant if the p-value < 0.05 (Bailey, 1995). 
When NADPH was used instead of NADH as electrons donor, five substrates showed a 
significant consumption of NADPH with p-value > 0.05. These substrates as can be seen in 
Figure 11-23are: indol, EPTC, malonic acid, adipic acid and 3-phenoxytolouene. As a result, 
B1279 is likely to be catalytically active with these five substrates. 
In general, the low catalytic activity may be because the protein was extensively diluted 
during the purification process. Losing activity as a result of extensive dilution may be due 
to either monomerisation of the enzyme domains which could affect the transformation of 
the required electrons from the cofactor to the active site or to the FMN depletion if the 
enzyme was incubated for an extended period in the dilute solution (Whitehouse et al., 2012)       
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Figure 11-22: B1279 activity analysis towards eleven substrates. The bars represent the 
NADH consumption rate as a result to use the cofactor during the reaction. The NADH 
consumption indicates an interaction with the protein that is directly proportional to the 
reaction rate. Three independent experiments were performed with triplicates with error 
bar in the standard error of the mean (SEM). The calculation of the p-value showed that 
all the results from this experiment is not significant with p-value >0.05.    
 
 
Background NADH consumption 
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Background NADPH consumption 
Figure 11-23: : B1279 activity analysis towards eleven substrates. The bars represent 
the NADPH consumption rate as a result of using the cofactor during the reaction. The 
NADPH consumption indicates an interaction with the protein that is directly 
proportional to the reaction rate. Three independent experiments were performed with 
triplicates with error bar in the standard error of the mean (SEM). The star above each 
bar (*) indicates that the result is significant with p-value <0.05 and the (-) shows that 
the result is not significant with p-value >0.05.      
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11.8 Conclusion  
Although numerous bacterial cytochrome P450 enzymes have been identified and their 
structures and functions extensively investigated, only one cytochrome from Cupriavidus sp. 
has been studied structurally and functionally, CYP116B1from Cupriavidus metallidurans 
(Warman et al., 2012). In this chapter, the first characterisation, absorbance, relevant 
substrates and activity of four cytochrome P450s from Cupriavidus necator H16 were 
reported. 
A PROSITE online tool and CLUSTALW multi-alignment of the amino acid sequences of 
these proteins with other P450 sequences from BLAST showed the conserved regions and 
the level of similarity. The homology search indicated similarity between three C. necator 
H16 P450s and the self-sufficient P450, CYP116B1. This protein showed 82%, 75% and 
55% similarity with B1279, B1009 and B2406 respectively, but there was no similarity with 
B1743 in the top twenty BLAST sequences.  
The generated 3D models of four C. necator H16 P450s showed a typical P450 fold with α 
helices, β sheets and loops. From Figure 10-5to Figure 10-7 and Figure 10-9, it is evident 
that the heme cofactors of all proteins are buried deeply in the heme domain structures where 
the heme cofactor would be expected (heme from the crystal structure of templets were used 
for this purpose) suggesting no aberration in the P450 heme domains for all four proteins.  
Generally, all heme domain structures displayed a typical P450 fold with expected helical 
features (α helices, β sheets and loops), structures’ images showed that these four proteins 
are probably monomers, folded into α/β domains characteristic of P450s. 
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From overlapping the predicted models of each heme domain and reductase domain to its 
template, a high similarity was observed and this similarity was evident as the majority of 
the secondary structure elements merge together to structure modules due to this absolute 
conservation. However, some differences in N-terminal, C-terminal and loops. Differences 
in these regions of the P450 structure was reported previously and it could be due to the 
highly variable in the primary sequence of these regions (Sirim et al., 2010). The calculated 
RMSD between all predicted models and the crystal structures of their templates were less 
than 2 Å and this low RMSD indicates the high accuracy of the generated model (Carugo, 
2007). As well as the quality of all models were checked by the quality verifying online tool 
(VERIFY 3D) and more than 80% of all models’ residues showed average (3D-1D) ≥ 0.2.  
The structure analysis of the hydrophobic residues that bound to the identified heme cofactor 
in the heme domains of B2406, B1743, B1279 and B1009 showed a very high conservation 
between the templets’ and the models’ binding residues. This high conservation also 
observed by sequences alignment of all models with the sequences of their templates. 
However few differences were noticed in some limited cases between binding residues of the 
generated models and templates but these residues still occupied same positions and have 
very similar functions to each other. The primary and the secondary structure analysis of four 
P450 from C.necator H16 leads to the belief that the reliability of all predicted models are 
high and the prosthetic groups (heme) in all heme domains are likely to be bound to the 
structure. Therefore, it is believed that all C. necator H16 P450 heme domains would be 
functionally active if they fused naturally or genetically to a proper redox partner.  
In B1279 3D model reductase, a typical structure of ferredoxin reductase was clearly 
observed by the identification of FMN and Fe-S binding motifs with the presence of four Cys 
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residues in the 2Fe-2S creating a square plane to coordinate the cofactor (shown as red stick 
in Figure 10 7). The high conservation of the residues bound to both ligands probably 
facilitated the binding of both prosthetic groups FMN and Fe-S in the model to the structure, 
thereby catalysing the transformation of electrons from a donor (NADPH or NADH) to the 
active site (heme cofactor) of B1279. The existence of the active site represented by a typical 
P450 heme cofactor connected to the structure and the fact that this heme domain naturally 
fuses to the ferredoxin reductase containing two prosthetics groups (FMN and Fe-S) suggests 
that this protein may be catalytically active.    
The 3D model of the reductase domain of B1009 showed three prosthetics groups: a 
flavodoxin-like domain FMN, ferredoxin reductase-type FAD binding domain (FAD_FR) 
and nicotinamide-adenine-dinucleotide phosphate (NADP). These three ligands were shown 
as sticks in Figure 10-11and together formed a typical reductase structure (detailed analysis 
of the prosthetics groups of the reductase domain of B1009 is absence from this study).  
Both B2406 and B1743 successfully expressed using E. coli BL21(DE3) and SB AIM at 
30°C and the high yield obtained was efficiently purified by three chromatography steps 
(affinity, ion exchange and gel filtration) without any further optimisation. Optimisation of 
B1279 expression was attempted using different E. coli strains, inducer agents and expression 
temperatures. However, during the purification process, a large amount of B1279 was lost 
and it was diluted extensively, with recovery percentages of this protein of 14%, 52% and 
31% after affinity, ion exchange and gel filtration respectively. The recovery percentages for 
the protein expressed in E. coli BL21(DE3) were similar to those when E. coli C41(DE3) 
was used. Despite the many changes applied, unfortunately the recovery of B1279 remained 
low. The analysis of the results from the B1279 purification and application of a step to step 
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comparison with the B1743 purification (Table 11-1), indicated that the low recovery of 
protein was probably due to the protein nature and tendency to non-specifically bind to the 
purification column matrix and filtration membranes.      
The expression of B1009 in E. coli BL21(DE3) and E. coli C41(DE3) was very low and the 
numerous unsuccessful attempts to enhance its expression in these two strains, such as 
different expression temperatures, different inducers and various media gave the motivation 
to examine another E. coli strain. An enhancement was observed when B1009 was expressed 
in E. coli HMS174(DE3) by using AIM SB at 30°C. However, the expressed B1009 in E. 
coli HMS174(DE3) showed low solubility.  
The light absorbance scanning of B2405, B1743 and B1279 between 250-800 nm showed 
typical features of heme cofactors of P450, confirming the sequence analysis and 3D 
structure findings that these three proteins are new members of the P450 monooxygenases 
superfamily. With regard to potential substrates of B2406 and B1743, changes in the spectra 
of the lauric acid-B1743 and 3-phenoxytoluene -B1743 complexes were observed. B1279 
was excluded from the binding experiments because it was unlikely to observe any change 
in its spectra due to the low concentration after the purification process. Instead, B1279 
activity was investigated with all 11 substrates using NADPH and NADH as cofactors 
proteins, showed possible activity with indol, EPTC, malonic acid, adipic acid and 3-
phenoxytolouene as indicated by the increase in NADPH consumption rate in substrate-
enzyme solution in comparison to SF B1279 solution.   
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12 Conclusion and Future Prospects 
 
12.1 Cytochrome P450 BM-3  
Despite the fact that P450 BM-3 has been the subject of study for many years, only a few 
researchers have reported the effect of co-solvents on BM-3 activity. Previously, BM-3 
tolerance was investigated in traditional solvents which were classified as hazardous 
materials according to many classifications such as the one published by GSK in 2010 
(Henderson et al., 2011). In recent years, using alternative green solvents has earned the 
attention of both industrialists and academics due to their environmental advantages 
including waste reduction, hazard elimination and process economy improvement.      
In part II of the project, I used three green solvents, 1-butanol, 2-butanol and dimethyl 
carbonate, to dissolve one of the most common insoluble fatty acid substrates, lauric acid, 
for hydroxylation catalysed by P450 BM-3. The activity of the WT and the W5F5 variant 
were compared in the presence of these solvents. The W5F5 variant was chosen owing to its 
tolerance to many co-solvents (Wong et al., 2004). To the best of my knowledge, this is the 
first report of the P450 BM-3 tolerance against green solvents. The results from this part of 
the project (Part II) showed that dimethyl carbonate is a very good green replacement of the 
traditional hazardous solvents, as the relative activity of the P450 BM-3, both WT and W5F5, 
was 31% and 128% respectively at 5% (v/v) solvent.    
Both the wild type and its mutant W5F5 showed very low tolerance towards other green 
solvents tested, 1-butanol and 2-butanol. It is necessary to apply further steps in the future 
towards improving BM-3 resistance against these green solvents. This could be achieved by 
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applying one or more of protein stabilisation strategies such as isolation of stable biocatalysts, 
immobilisation, chemical modification, ionic liquid coating and genetic modification (see 
section 5.7 for more detail).  
12.2 Putative cytochrome P450s from Cupriavidus necator H16  
This part of the thesis presented a detailed analysis of four novel cytochrome P450s: H16_ 
B2406, H16_B1743, H16_B1279 and H16_B1009. All these proteins are natural 
cytochromes from Cupriavidus necator H16. This bacterium can grow heterotrophically and 
autotrophically and is an excellent platform for the production of degradable bioplastic and 
value-added compounds. Three of these four proteins, B2406, B1743 and B1279, were 
successfully expressed in E. coli and purified using three chromatograph steps. The optical 
analysation of these three proteins confirmed typical features of heme cofactors of 
cytochrome P450, with a Soret peak at 416 nm for B2406 and 418 nm for B1743 and B1279, 
as well as alpha/beta at 571/535, 569/537 and 567/533 for B2406, B1743 and B1279 
respectively.  
12.2.1 P450 B2406 and P450 B1743 
The sequence alignment of B2406 and B1743 with other P450s provided by the database and 
the predicted 3D structures of these proteins showed the heme cofactors buried deep in the 
heme domain structure. Also, these results confirmed that both of these proteins are missing 
any type of reductase modules rendering them catalytically inactive.  
With regard to potential substrates of B2406 and B1743, no binding of any the 11 substrates 
tested was demonstrated by B2406, while lauric acid and 3-phenoxytoluene showed small 
blue shifts of the Soret bands towards 390 nm (Type I) when mixed with B1743. The binding 
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between these two substrates and B1743 suggests that this protein could be catalytically 
active if fused in future to an appropriate redox partner to generate a new multi-domain 
construct. The molecular Lego approach was used previously and proved to be successful for 
the enhancement of catalytic properties of P450 BM-3 heme domain. Flavodoxin from 
Desulfovibrio vulgaris (FLD) and BM-3 heme domain from Bacillus megaterium (BMP) 
were fused genetically to produce a BMP–FLD fusion protein. The catalytic activity of the 
BMP–FLD fused enzyme was improved by six fold when it was used to hydroxylate p-
nitrophenol (Fantuzzi et al., 2006; Sadeghi et al., 2000). For future work, it is recommended 
to use genetic approach to produce catalytic active fused enzyme.  
12.2.2 P450 B1279 
The genetic analysis of the B1279 sequence, the undefined structure and substrate selectivity 
cytochrome, enabled the characterisation of the heme binding cofactor, 2Fe-2S centre and 
FMN. This analysis confirmed the hypothesis that the heme domain of this protein is 
naturally fused to a reductase module. Typically, in this system, electrons are driven from a 
cofactor redox NADPH or NADH to the heme cofactor by the iron-sulphur centre and 
flavoprotein (FMN).  
The functional analysis of B1279 showed its potential to be catalytically active towards five 
substrates; indol, EPTC, malonic acid, adipic acid and 3-phenoxytolouene according to the 
significant increase in the consumption rate of NADPH. However, in general, the activity 
was very low and that may be very well because B1279 was highly diluted during the 
purification steps due to its tendency to form unwanted bonds with the purification column 
matrices. According to Whitehouse and co-workers, there are two possible scenarios for the 
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loss of P450 activity in a dilute solution, it may be due to monomerisation of the enzyme 
domains or to the FMN depletion if the enzyme was incubated for an extended period in the 
dilute solution (Whitehouse et al., 2012). The phenomenon of weak activity was also 
indicated previously with another fused protein containing the same reductase system, 
(FMN-[2Fe-2S]), RhF from Rhodococcus sp. NCIMB9784. This protein catalysed the O-
dealkylation of 7-ethoxycoumarin. Although, the consumption of the NADPH and NADH 
were not measured in the project, Raobert and co-workers confirmed the low level of 
substrate turnover depended on the fluorescent properties of the product 7-hydroxycoumarin 
(Roberts et al., 2003).    
Purification resolution depends, not only on the nature of the experimental conditions such 
as pH, ionic strength and elution conditions, but also on functional groups on the column 
matrix, so higher efficiency purification columns may be required in furture studies. 
Resolution in terms of efficiency can be improved by decreasing the particle size of the 
matrix. For example, using the Mono Q™ ion exchange column instead of Super Q and 
Superdex Peptide gel filtration column as an alternative to Hiload 26/600 Superdex 200 pg 
may increase the purification resolution to significant levels due to the small particle sizes of 
these matrices. Nonetheless, it would be interesting in the future to investigate the activity of 
B1279 with other substrates usually metabolised by Cupriavidus necator H16, such as acetic 
acid, propionic acid, glycolate, lactate, levulinic acid and benzoate (Lu et al., 2016).  
Due to time limitations and technical issues, there are many analysations yet to be performed 
in the investigation of B1279 activity with indol, EPTC, malonic acid, adipic acid and 3-
Phenoxytoluene which will be the focus of further studies of this protein. In particular, the 
determination of kinetic constants (Km and Kcat) using Michaelis equation, the pyridine 
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hemochromogen assay to detect the concentration of heme and determine the extinction 
coefficient of the hemoprotein sample using Beer-Lambert’s law, flavin cofactor 
identification using HPLC, stopped-flow kinetics to determine cofactor concentration 
dependent enzyme reduction rates and protein concentration measurement by ferrous-CO 
complex formation (Luciakova, 2015; Warman et al., 2012).  
12.2.3 P450 B1009 
H16_B1009 was studied genetically and structurally for the first time in this project. The 
results proved that the structure of this protein consists of two domains, heme and reductase. 
The reductase domain in this protein comprises two main proteins, FAD and FMN, which 
help in the electron transformation from the redox partner to the heme cofactor (active site).   
The expression of B1009 in two E. coli strains; BL21(DE3) and C41(DE3) was very low. All 
attempts to improve B1009 expression in these strains like using different media, 
temperatures, inducer agents and expression time were unsuccessful. Fortunately, A 
significant improvement in protein expression was observed when E. coli HMS174(DE3) 
strain was used. However, B1009 showed low solubility when E. coli HMS174(DE3) was 
used.  therefore it would be interesting to investigate the improvement of protein solubility 
in the future by using one or more of the tradition techniques to increase protein solubility in 
E. coli such as cultivation at reduced temperatures, changing media compositions and fusing 
to affinity tags like maltose binding protein (MBP) and N-utilizing substance A (NusA) 
(Sørensen & Mortensen, 2005).   
In general, these findings indicate that our knowledge regarding cytochrome P450 enzymes 
suggests that general rules cannot be applied to all members of this superfamily or even to 
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all P450s from Cupriavidus necator H16. Every new P540 will open the door to new 
products, substrates and catalytic reactions as well as to unlimited biotechnological 
knowledge.    
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Appendices 
Appendix I: Sequences alignment  
 
B2406 heme domain:   
Heme domain sequence alignment between B2406 and crystal structure (PDB ID:5HDI.A.). 
The model was suggested as a best hit by SWISS MODEL and Phyre online tools. Residues 
that bound to the heme cofactor were highlighted in yellow. (|) indicating similar identity, (.) 
is for strongly similar residues and (:) to indicate weak similarity. The alignment was 
produced by using ClustalW online tool  
  
 
 
 
B2406           1 MKHHHHHHPMSDYDIPTTENLYFQGAHMPDTDIDPLSAVTHPDPYPYYRE   50 
                              ..|....|.:|             .|.:..||||.|.. 
5HDI            1 ------------MTIAKDANTFF-------------GAESVQDPYPLYER   25 
 
B2406          51 LAASQPFFRDDRLGLWVAAGPQEVADVLAHSDCRVRPP--AQPVPPALAG   98 
                  :.|:....|......:...|...|.:.:.      ||.  :..:...:.. 
5HDI           26 MRAAGSVHRIANSDFYAVCGWDAVNEAIG------RPEDFSSNLTATMTY   69 
 
B2406          99 TAAG--------ELFG--RLVRMNDGAAHAPLKALLMPMLAGIDPAAAAQ  138 
                  ||.|        .|.|  .::...|..|||..:.|::..|       ||: 
5HDI           70 TAEGTAKPFEMDPLGGPTHVLATADDPAHAVHRKLVLRHL-------AAK  112 
 
B2406         139 RATVLAA-VLDAGEASWA-AMSGECINRWLFT----LPVVTVADLLGLPV  182 
                  |..|:.. .:.|.:..|. .|...|| .|:..    ||::.||:|:|||  
5HDI          113 RIRVMEQFTVQAADRLWVDGMQDGCI-EWMGAMANRLPMMVVAELIGLP-  160 
 
B2406         183 ANEGSSAAEAAQRVA-AFAGAQ--SPLADAPAVRAGAEAAQWLGHWLADA  229 
                        ..:.||.|. .:|..|  ..|.:...:.|...|...|..::.:. 
5HDI          161 ------DPDIAQLVKWGYAATQLLEGLVENDQLVAAGVALMELSGYIFEQ  204 
 
B2406         230 ADGAGPLP------ALRQAARAAGIDAQAVAANIIGLLVQACEATAALAG  273 
                  .|.|...|      .|..|..:..:|.......::.|.....|:||||.| 
5HDI          205 FDRAAADPRDNLLGELATACASGELDTLTAQVMMVTLFAAGGESTAALLG  254 
 
B2406         274 NTLLRLG-RDTTQSGLP-----LDAVVARVAREDPPVQNTRRFLAADAQL  317 
                  :.:..|. |...|..:.     |.|.:....|.:||.:...|.:.....| 
5HDI          255 SAVWILATRPDIQQQVRANPELLGAFIEETLRYEPPFRGHYRHVRNATTL  304 
 
B2406         318 CGHAVKAGDAVLVLLAAASCSGAAASERPW-------------TFGHGRH  354 
                  .|..:.| |:.|:||..|:....|..|.|.             :||.|.| 
5HDI          305 DGTELPA-DSHLLLLWGAANRDPAQFEAPGEFRLDRAGGKGHISFGKGAH  353 
 
B2406         355 ACPGDRLAQALAAATVAALRARGADPAALAQAFRYRPSLNARIPHFL---  401 
                  .|.|..||: |.|..|..|..........|....:.||:..|....|    
5HDI          354 FCVGAALAR-LEARIVLRLLLDRTSVIEAADVGGWLPSILVRRIERLELA  402 
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B1743 heme domain:   
Heme domain sequence alignment between B1743 and crystal structure (PDB ID: 2UVN. 
A.). The model was suggested as a best hit by SWISS MODEL and Phyre online tools. 
Residues that bound to the heme cofactor were highlighted in yellow. (|) indicating similar 
identity, (.) is for strongly similar residues and (:) to indicate weak similarity. The alignment 
was produced by using ClustalW online tool. 
 
 
 
 
 
 
B1743           1 MKHHHHHHPMSDYDIPTTENLYFQGAHMTDTNQHALLHDGYDLLSDHYVQ     50 
                   .|||||                   |||....|..               
2UVN.           1 -MHHHHH-------------------HMTSVMSHEF--------------     16 
 
B1743          51 EAHALWRDIRSSGCPVAHSEKWGGSWLP-----TTYDDIHHVA--QNPA-     92 
                                .:|.:|.|...| |     ..:|.:|||.  |.|.  
2UVN.          17 --------------QLATAETWPNPW-PMYRALRDHDPVHHVVPPQRPEY     51 
 
B1743          93 --VFSSRAAEI-------------------AGEVPPQGSGLVLPPLTSDP    121 
                    ...||.|::                   .||:...|.....|.:..|| 
2UVN.          52 DYYVLSRHADVWSAARDHQTFSSAQGLTVNYGELEMIGLHDTPPMVMQDP    101 
 
B1743         122 PDHKIHRDLLEPYFTPARVAAIEPYAQSLARDLARRVAVKGEADLGEDYS    171 
                  |.|...|.|:...|||.:|..:||..:....:...::...|..|:..:.. 
2UVN.         102 PVHTEFRKLVSRGFTPRQVETVEPTVRKFVVERLEKLRANGGGDIVTELF    151 
 
B1743         172 KPFVLSLLTRFLDVPDDRQERFMDWAIRVLKYGPFDQELRKA--AFDEAF    219 
                  ||....::..:|.||::...:|..|...::.....|.....|  |..... 
2UVN.         152 KPLPSMVVAHYLGVPEEDWTQFDGWTQAIVAANAVDGATTGALDAVGSMM    201 
 
B1743         220 ADLEQLLKEREQDPGEDLVSHIALATI--DGKPISRKHRIGSLLLAVLAG    267 
                  |....|::.|..:|.:|.:||:..|.:  ||........:......|..| 
2UVN.         202 AYFTGLIERRRTEPADDAISHLVAAGVGADGDTAGTLSILAFTFTMVTGG    251 
 
B1743         268 ADTTWNALNASLNHLADHPADRATLINEP-GLLRTTAVEELLRFYAPL-S    315 
                  .||....|..|:..|...|..|..|:::| |:  ..|||||||..:|: . 
2UVN.         252 NDTVTGMLGGSMPLLHRRPDQRRLLLDDPEGI--PDAVEELLRLTSPVQG    299 
 
B1743         316 IARVTTEEVELKGRCIGAGERVILAYPAANRDPAVFENPDEVQLDRKR--    363 
                  :||.||.:|.:....|.||.||:|.|.:||||...: .||..:||..|   
2UVN.         300 LARTTTRDVTIGDTTIPAGRRVLLLYGSANRDERQY-GPDAAELDVTRCP    348 
 
B1743         364 NRHLTFGVGVHRCLGSHLARMEMRVAIEEWLKAIPNFERISGAVKWSAGN    413 
                  ...|||..|.|.|||:..|||:.|||:.|.|...|:||.....:.||.|: 
2UVN.         349 RNILTFSHGAHHCLGAAAARMQCRVALTELLARCPDFEVAESRIVWSGGS    398 
 
B1743         414 ARGPENVRIRVV    425 
                     ..           
2UVN.         399 YV----------    400 
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B1279 heme domain:   
Heme domain sequence alignment between B1279 and crystal structure (PDB ID: 6GII.A.). 
The model was suggested as a best hit by SWISS MODEL and Phyre online tools. Residues 
that bound to the heme cofactor were highlighted in yellow. (|) indicating similar identity, (.) 
is for strongly similar residues and (:) to indicate weak similarity. The alignment was 
produced by using ClustalW online tool  
 
 
 
 
 
 
B1279           1 --MKHHHHHH-----PMSDYDIPTTENLYF-QGAMANPSPSAARSGCPID     42 
                    ..||||||     |...:....|..... :|:|.......||..||:. 
6GII.           1 MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSMETELKETARGTCPVA     50 
 
B1279          43 HSALTAPNGCPVSHNAAQFDPFGDGYQQDPPEYVRWSREQEPVFYSPRLG     92 
                  |...::..||||...|..||||.|.|..||.::|||:|||.|:||:|:|. 
6GII.          51 HGGQSSVGGCPVHRLAEDFDPFQDAYMADPAQFVRWAREQVPIFYAPKLN    100 
 
B1279          93 YWVVTRYEDIKAIFRDNLTFSPSIALEKITPTGDEANAVLASYGYAMNRT    142 
                  |||||||:.||.||||.:|||||..|:.......|...||..||||.||| 
6GII.         101 YWVVTRYDTIKQIFRDPVTFSPSNVLQSFAQPSAEVRQVLERYGYAFNRT    150 
 
B1279         143 LVNEDEPAHMPRRRALMAPFTPAELAHHEPLVRRLAREYVDRFIDDGRAD    192 
                  |||||||.|:.|||.||.||....||.|||:||.|.|..|:||||.|||| 
6GII.         151 LVNEDEPMHLERRRVLMEPFASEHLAEHEPMVRELVRRAVNRFIDTGRAD    200 
 
B1279         193 LVDQMLWEVPLTVALHFLGVPEEDMDLLRQYSIAHTVNTWGRPKPEEQVA    242 
                  |||||:||||.|||||||||.::|.:.:|:::||||||.:|||.||||:| 
6GII.         201 LVDQMIWEVPFTVALHFLGVDDDDREKMRRFAIAHTVNAFGRPSPEEQLA    250 
 
B1279         243 VAHAVGNFWQLAGRILDKMREDPSGPGWMQYGLRKQKELPDVVTDSYLHS    292 
                  ||..||.|||..|.:|:|||....|||||:|.:|:||..||||||||||| 
6GII.         251 VAETVGQFWQFCGEVLEKMRRTADGPGWMRYSIRQQKLYPDVVTDSYLHS    300 
 
B1279         293 MMMAGIVAAHETTANASANAIKLLLQHPDAWREICDDPSLIPNAVEECLR    342 
                  ||.|.||||||||..|:.||:|.||:|...|||||.||||||.|.||||| 
6GII.         301 MMQAIIVAAHETTVFATTNALKTLLEHETVWREICADPSLIPAAAEECLR    350 
 
B1279         343 HNGSVAAWRRLVTRDAEVGGIRLPAGSKLLIVTSSANHDERHFADADLFD    392 
                  :||.||.|||..||:.||.|:|||.|:.:|:|.:|||||..||.|.:.|| 
6GII.         351 YNGPVAGWRRRTTREVEVEGVRLPVGANILMVVASANHDSAHFDDPEFFD    400 
 
B1279         393 IRRDNASEQLTFGYGSHQCMGKNLARMEMQVFLEELTRRLPHMRLAEQTF    442 
                  |.|.||||.|.||||:|||:|:||.|||||:.:|||:|||||||||||.| 
6GII.         401 IGRSNASEHLNFGYGAHQCLGRNLGRMEMQIMIEELSRRLPHMRLAEQRF    450 
 
B1279         443 TYVPNTSFRGPEHLLVEWDPAQNPERRDPALLEVHQPVRIGEPSAHTIAR    492 
                  .|:.|.|||.|.||.||||||||||||||                      
6GII.         451 DYLHNVSFRAPRHLWVEWDPAQNPERRDP---------------------    479 
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B1009 heme domain:   
Heme domain sequence alignment between B1009 and crystal structure (PDB ID: 1BU7.A.). 
The model was suggested by SWISS MODEL online tool. Residues that bound to the heme 
cofactor were highlighted in yellow. (|) indicating similar identity, (.) is for strongly similar 
residues and (:) to indicate weak similarity. The alignment was produced by using ClustalW 
online tool  
 
 
 
 
 
B1009         1 MKHHHHHHPMSDYDIPTTENLYFQGAHMPPPIELSSPDQASDAPHQAPAR       50 
                                                                        
1bu7.         1 --------------------------------------------------        0 
 
B1009         51 SMHAPIPEPIPRDPGWPLVGNLLQITPGALGQHLLARSRHHDGIFELNFA     100 
                     .|.| :|:...:..:.||..:......|.|:..:.....||:.... 
1bu7.          1 ----TIKE-MPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAP      45 
 
B1009         101 GRRVPFVTSVALASELCDAAQFRKYIGPPVSYLRGMAGDGLFTARSDEAN    150 
                  ||...:::|..|..|.||.::|.|.:...:.::|..|||||||:.:.|.| 
1bu7.          46 GRVTRYLSSQRLIKEACDESRFDKNLSQALKFVRDFAGDGLFTSWTHEKN     95 
 
B1009         151 WGKAHRILMPAFSQRAMKGYFDVMLRVANRLVDKWDQQGPDADIAVADDM    200 
                  |.|||.||:|:|||:|||||..:|:.:|.:||.||::...|..|.|.:|| 
1bu7.          96 WKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDM    145 
 
B1009         201 TRLTLDTIALSGFGYDFESFASTELHPFIEAMVGALEEAMSKLTRFALQD    250 
                  ||||||||.|.||.|.|.||...:.||||.:||.||:|||:||.|....| 
1bu7.         146 TRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDD    195 
 
B1009         251 RFMHAAHQKFDQDTRFMRDLVDDVIRRRRAGDAAERPGGTANDLLGLMLE    300 
                  .......::|.:|.:.|.||||.:|..|:|.      |..::|||..||. 
1bu7.         196 PAYDENKRQFQEDIKVMNDLVDKIIADRKAS------GEQSDDLLTHMLN    239 
 
B1009         301 ARDPDTDQRLDDENIRNQVITFLIAGHETTSGLLTFALYELLRNPGVMAQ    350 
                  .:||:|.:.|||||||.|:|||||||||||||||:||||.|::||.|:.: 
1bu7.         240 GKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQK    289 
 
B1009         351 AYAEVDAVLPGDAAPVYADLARLPVLDRVLKETLRLWPTAPAFAVAPFED    400 
                  |..|...||. |..|.|..:.:|..:..||.|.||||||||||::...|| 
1bu7.         290 AAEEAARVLV-DPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKED    338 
 
B1009         401 TLLGGRYLIRKDRRLSVVLTALHRDPKVWADPERFDIDRFLPEQ---EAK    447 
                  |:|||.|.:.|...|.|::..||||..:|.|    |::.|.||:   .:. 
1bu7.         339 TVLGGEYPLEKGDELMVLIPQLHRDKTIWGD----DVEEFRPERFENPSA    384 
 
B1009         448 LPRHAYMPFGNGERACIGRQFALTEAKLALALMLRNFQFTDAHDYQFRIK    497 
                  :|:||:.|||||:|||                                   
1bu7.         385 IPQHAFKPFGNGQRAC----------------------------------    400 
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B1009 heme domain:   
Heme domain sequence alignment between B1009 and crystal structure (PDB ID: 2ij2.A). 
The model was suggested as a best hit by Phyre2.2 online tool. Residues that bound to the 
heme cofactor were highlighted in yellow. (|) indicating similar identity, (.) is for strongly 
similar residues and (:) to indicate weak similarity. The alignment was produced by using 
ClustalW online tool  
 
 
 
 
 
B1009          1 MKHHHHHHPMSDYDIPTTENLYFQGAHMPPPIELSSPDQASDAPHQAPAR      50 
                                                                      
2IJ2.          1 --------------------------------------------------       0 
 
B1009          51 SMHAPIPEPIPRDPGWPLVGNLLQITPGALGQHLLARSRHHDGIFELNFA    100 
                      .|.| :|:...:..:.||..:......|.|:..:.....||:.... 
2IJ2.          1 -----TIKE-MPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAP     45 
 
B1009         101 GRRVPFVTSVALASELCDAAQFRKYIGPPVSYLRGMAGDGLFTARSDEAN    150 
                  ||...:::|..|..|.||.::|.|.:...:.::|..|||||||:.:.|.| 
2IJ2.          46 GRVTRYLSSQRLIKEACDESRFDKNLSQALKFVRDFAGDGLFTSWTHEKN     95 
 
B1009         151 WGKAHRILMPAFSQRAMKGYFDVMLRVANRLVDKWDQQGPDADIAVADDM    200 
                  |.|||.||:|:|||:|||||..:|:.:|.:||.||::...|..|.|.:|| 
2IJ2.          96 WKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDM    145 
 
B1009         201 TRLTLDTIALSGFGYDFESFASTELHPFIEAMVGALEEAMSKLTRFALQD    250 
                  ||||||||.|.||.|.|.||...:.||||.:||.||:|||:||.|....| 
2IJ2.         146 TRLTLDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDD    195 
 
B1009         251 RFMHAAHQKFDQDTRFMRDLVDDVIRRRRAGDAAERPGGTANDLLGLMLE    300 
                  .......::|.:|.:.|.||||.:|..|:|.      |..::|||..||. 
2IJ2.         196 PAYDENKRQFQEDIKVMNDLVDKIIADRKAS------GEQSDDLLTHMLN    239 
 
B1009         301 ARDPDTDQRLDDENIRNQVITFLIAGHETTSGLLTFALYELLRNPGVMAQ    350 
                  .:||:|.:.|||||||.|:|||||||||||||||:||||.|::||.|:.: 
2IJ2.         240 GKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQK    289 
 
B1009         351 AYAEVDAVLPGDAAPVYADLARLPVLDRVLKETLRLWPTAPAFAVAPFED    400 
                  |..|...||. |..|.|..:.:|..:..||.|.||||||||||::...|| 
2IJ2.         290 AAEEAARVLV-DPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKED    338 
 
B1009         401 TLLGGRYLIRKDRRLSVVLTALHRDPKVWADPERFDIDRFLPEQ---EAK    447 
                  |:|||.|.:.|...|.|::..||||..:|.|    |::.|.||:   .:. 
2IJ2.         339 TVLGGEYPLEKGDELMVLIPQLHRDKTIWGD----DVEEFRPERFENPSA    384 
 
B1009         448 LPRHAYMPFGNGERACIGRQFALTEAKLALALMLRNFQFTDAHDYQFRIK    497 
                  :|:||:.|||||:|||||:||||.||.|.|.:||::|.|.|..:|:..|| 
2IJ2.         385 IPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIK    434 
 
B1009         498 ETLTIKPDGFTVRARRRRPHERIAAAPLCTAQAPRAGPDVQG-           539 
                  ||||:||:||.|:|:.::       .||....:|......:.  
2IJ2.         435 ETLTLKPEGFVVKAKSKK-------IPLGGIPSPSTEQSAKKV           470 
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Appendix II: Models qualification evaluation performed by VERIFY 3D. The model 
considers accurate if 80% or more of protein’s residues showed average (3D-1D) ≥ 0.2 
 
B2406 heme domain: 
VERIFY 3D results of B2406 heme domain model built by SWISS MODEL using the crystal 
structure (PDB ID: 5hdi. 1. A.). more than 82.02% protein’s residues showed average (3D-
1D) ≥ 0.2 
  
B1743 heme domain: 
VERIFY 3D results of B1743 heme domain model built by SWISS MODEL using the 
crystal structure (PDB ID: 2uvn. 1. A.). more than 98.70% of protein’s residues showed 
average (3D-1D) ≥ 0.2 
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B1279 heme domain: 
VERIFY 3D results of B1279 heme domain model built by SWISS MODEL using the 
crystal structure (PDB ID: 6gii. 1. A.). more than 94.95% of protein’s residues showed 
average (3D-1D) ≥ 0.2 
 
B1279 reductase domain: 
VERIFY 3D results of B1279 reductase domain model built by Phyre2.2 using the crystal 
structure (PDB ID: 2pia. 1. A.). more than 94.21% of protein’s residues showed average 
(3D-1D) ≥ 0.2 
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B1009 heme domain: 
VERIFY 3D results of B1009 heme domain model built by SWISS MODEL using the 
crystal structure (PDB ID: 1bu7. 1. A.). more than 90.52% of protein’s residues showed 
average (3D-1D) ≥ 0.2 
 
B1009 heme domain: 
VERIFY 3D results of B1009 heme domain model built by Phyre2.2 using the crystal 
structure (PDB ID: 2ij2. 1. A.). more than 91.92% of protein’s residues showed average 
(3D-1D) ≥ 0.2 
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B1009 reductase domain: 
VERIFY 3D results of B1009 reductase domain model built by Phyree2.2 using the crystal 
structure (PDB ID: 1j9z. 1. A.). more than 93.29% of protein’s residues showed average 
(3D-1D) ≥ 0.2 
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Appendix III: List of amino acids Abbreviations 
Amino acid 3-letter 1-letter 
Side chain 
class 
Side chain 
polarity 
Side chain 
charge 
Alanine  Ala A aliphatic nonpolar neutral 
Arginine Arg R basic basic polar positive 
Asparagine  Asn N amide polar neutral 
Aspartic acid Asp D acid acidic polar negative 
Cysteine  Cys C sulfur-containing nonpolar neutral 
Glutamic acid  Glu E acid acidic polar negative 
Glutamine Gln Q amide polar neutral 
Glycine  Gly G aliphatic nonpolar neutral 
Histidine His H basic aromatic basic polar positive (10%) 
neutral (90%) 
Isoleucine  Ile I aliphatic nonpolar neutral 
Leucine  Leu L aliphatic nonpolar neutral 
Lysine  Lys K basic basic polar positive 
Methionine Met M sulfur-containing nonpolar neutral 
Phenylalanine  Phe F aromatic nonpolar neutral 
Proline Pro P cyclic nonpolar neutral 
Serine Ser S hydroxyl-
containing 
polar neutral 
Threonine  Thr T hydroxyl-
containing 
polar neutral 
Tryptophan  Trp W aromatic nonpolar neutral 
Tyrosine  Tyr Y aromatic polar neutral 
Valine  Val V aliphatic nonpolar neutral 
 
 
 
 
 
 
 
 
  
11 
 
Appendix IV: List of Publications 
Publications in preparation 
“Characterization and genetic analysis of putative cytochrome P450s from Cupriavidus 
necator H16”. Article.   
“Protein engineering for tolerance and stability improvement in non-conventional 
solvents”. Review. 
Book chapter 
Omar Ali, H., Alessa, A. H. A., Al-nuaemi, I. J., Wong, T. S. “Protein engineering for 
lignocellulose degradation.” Environmental Science and Engineering Volume 8 (2017). 1st 
ed. USA: Studium Press LLC. 
Oral Presentation 
Activity Evaluation of Cytochrome P450s, Postgraduate Research Conference, Jun  2017, 
Sheffield, UK. 
Poster Presentations 
Cytochrome P450 BM-3 tolerances in non-conventional green solvents, The First Iraqi 
Conference, October 2016, Sheffield, UK 
Cytochrome P450 BM-3 W5F5 expression and purification optimisation, Postgraduate 
Research Conference, January 2016, Sheffield, UK 
 
